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SUMMARY 
 
The five member Inhibitor of Growth (ING) gene family has been proposed to 
participate in the regulation of cell growth, DNA repair, inflammation, chromatin 
remodeling, and tumor suppression.  All ING proteins contain a PHD motif implicated in 
binding to methylated histones and are components of large chromatin remodeling 
complexes containing histone acetyltransferase (HAT) and histone deacetylase (HDAC) 
enzymes, suggesting a role for ING proteins in regulating gene transcription.  
Additionally, forced overexpression studies performed in vitro have indicated that several 
ING proteins can interact with the p53 tumor suppressor protein and/or the NF-κB 
protein complex.  Since these two proteins play well-established roles in numerous 
biological processes, several models have been proposed in the literature that ING 
proteins act as key regulators of cell growth and tumor suppression not only through their 
ability to modify gene transcription but also through their ability to alter p53 and NF-kB 
activity.  However, these models have yet to be substantiated by in vivo experimentation.   
 
Research described in this dissertation utilizes a genetic approach to analyze the 
functional role of two ING proteins, Ing1b and Ing4, in regulating cell growth, 
inflammation, and tumorigenesis. Loss of p37Ing1b increased proliferation and DNA 
damage-induced apoptosis irrespective of p53 status in primary cells and mice.  However, 
all other p53 responses were unperturbed.  Additionally, p37Ing1b suppressed the 
formation of spontaneous follicular B-cell lymphomas in mice.   
 
 
 
v 
 
Analysis of B-cells from these mice indicates that p37Ing1b inhibits the proliferation of B 
cells regardless of p53 status, and loss of p53 greatly accelerates the rate of B-cell 
lymphomagenesis in p37Ing1b-null mice, with double null mice presenting with aggressive 
diffuse large B-cell lymphomas (DLBL).  Marker gene analysis in p37Ing1b/p53 null 
tumors indicates that these mice develop both non-germinal center and germinal center B 
cell-like DLBL, and also documents upregulation of NF-κB activity in both B-cells and 
tumors.  Similarly, Ing4 -/- mice did not have altered p53 growth arrest or apoptosis, and 
did not develop spontaneous tumors.  However, Ing4 -/- cells displayed reduced 
proliferation, and Ing4 -/- mice and macrophages were hypersensitive to treatment with 
LPS and exhibited decreased IκB gene expression and increased NF-κB activity. These 
studies demonstrate that Ing proteins can function to suppress spontaneous tumorigenesis 
and/or inflammatory responses without altering p53 activity, and identifies NF-κB as a 
biologically-relevant in vivo target of Ing1 and Ing4 signaling. 
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CHAPTER I: 
INTRODUCTION 
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1.1 Forward 
ING1, the initial member of the Inhibitor of Growth (ING) gene family was first 
cloned in a subtractive hybridization screen to identify genes under-expressed in 
transformed versus normal human epithelium.  Subsequent database searches identified a 
total of five members of the ING family (ING1-ING5) conserved from yeast to humans.  
Little is known about the role of ING proteins in regulating cell growth.  Biochemical and 
molecular biological analysis has revealed that all ING members encode a PHD finger 
motif proposed to bind both methylated histones and phosphoinosital, and most ING 
proteins have also been found as components of large chromatin remodeling complexes 
that also include histone acetylase transferase (HAT) and histone deacetylase (HDAC) 
enzymes, suggesting a role for ING proteins in regulating gene transcription.  In addition, 
the results of forced overexpression studies performed in tissue culture have indicated 
that several of the ING proteins can interact with the p53 tumor suppressor protein and/or 
the nuclear factor-kappa B (NF-κB) protein complex.  As these ING-associated proteins 
play well-established roles in numerous cell processes, including DNA repair, cell growth 
and survival, inflammation, and tumor suppression, several models have been proposed 
in the literature that ING proteins act as key regulators of cell growth not only through 
their ability to modify gene transcription but also through their ability to alter p53 and 
NF-kB activity.  However, these models have yet to be substantiated by in vivo 
experimentation.   
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1.2 Suppression of Tumorigenesis 
Cancer is a complex genetic disease initiated by cells that have accumulated 
several mutations that ultimately bestow malignant characteristics.  With rare exceptions 
cancers arise from single somatic cells and their progeny.  As the neoplastic cells divide, 
they accumulate either genetic or epigenetic changes resulting in altered phenotypes that 
provide various selective advantages to the cell (172).  These advantages have been 
grouped by Hanahan and Weinberg into six general principles of a cancer cell phenotype: 
1) disregard for signals to stop proliferating, 2) disregard for signals to differentiate, 3) 
capacity for sustained proliferation, 4) evasion of apoptosis, 5) invasion/metastasis, and 
6) angiogenesis (82). Over the past several years evidence has been accumulating that a 
rare fraction of cells in the tumor, termed cancer stem cells, are the actual cells that have 
accumulated these six selective advantages.  In this model, expansion of the cancer stem 
cell gives rise to the bulk of the tumor and accounts for the clonal origin of cancer (171), 
although whether or not cancer stem cells actually exist or if a single stem cell would be 
sufficient to recapitulate the tumor after surgery or in a transplanted recipient remains a 
point of debate. 
 
The mutations that provide these selective advantages to a cancer cell (regardless 
of its “stemness”) can occur in numerous genes that encode a wide variety of proteins 
(111, 112).  Although these corresponding oncoproteins can differ greatly in their cellular 
functions, the genes encoding these proteins have been conventionally grouped into two 
classes: oncogenes and anti-oncogenes (or tumor suppressors).   
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Oncogenes typically encode proteins that promote cell growth or cell survival, and are 
usually overexpressed in cancer cells (due to promoter mutations or gene amplification) 
or, in some instances, the presence of an activating mutation upregulates the function of 
the encoded oncoprotein.  Conversely, proteins encoded by tumor suppressor genes 
typically inhibit cell growth.  These tumor suppressor proteins are usually lost in tumor 
cells due to deletion or mutation of the coding region of the tumor suppressor gene, or 
due to DNA methylation of CpG islands in the promoter regions of these genes (52).  
Two classes of tumor suppressor genes have been proposed: class I genes that are 
mutated or deleted in cancer and class II genes that are not mutated but rather alter 
cellular phenotype due to alterations in their level of gene expression (178). Regardless of 
class, it is clear from studies of human hereditary cancer syndromes such as familial 
melanoma, Li- Fraumeni syndrome, retinoblastoma, and others, that loss or mutation of 
tumor suppressor genes is an integral part of the genetic alterations needed to give rise to 
cancer. 
 
Tumor suppressor proteins have been found to regulate numerous cellular 
processes, including cell cycle arrest, cell senescence, DNA repair, signal transduction, 
and apoptosis.  Reflecting this wide variety of regulatory effects, tumor suppressors 
include proteins that are involved in transducing external growth signals into the cell, 
proteins that sense or respond to genetic or metabolic insult, kinases that regulate the 
function of other enzymes in the nucleus or cytoplasm, proteins that can alter the cellular 
location or cellular levels of other regulatory proteins, and transcription factors that alter 
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the expression of genes involved in cell growth or survival.  In addition, tumor 
suppressors include certain proteins that regulate chromatin remodeling and gene 
expression, including the Inhibitor of Growth (ING) protein family, a recently recognized 
group of histone binding proteins. 
 
1.3 Identification, Organization, and Expression of ING Genes 
The first member of the ING family of candidate tumor suppressor proteins was 
discovered through a subtractive hybridization assay between normal mammary 
epithelium and seven breast cancer cell lines (61).  Short complimentary DNA (cDNA) 
sequences of candidate genes identified by this screen were termed genetic suppressor 
elements (GSE).  The antisense DNA sequence of these GSE acted effectively as an 
oncogene in transfection experiments to promote cellular growth and transformation by 
interfering with the activation of tumor suppressors.  Conversely, transfection of the 
sense sequence of the GSE would block cellular growth and prevent transformation.  
Sequence analysis of a GSE from this screen and comparison to the human genome 
identified the ING1 gene as a putative tumor suppressor (61).  Searching the database of 
expressed sequence tags for genes that were similar to p33ING1b yielded four other 
members of the gene family: ING2, ING3, ING4, and ING5, with various ING members 
sharing between 32% to 76% DNA sequence homology.  Additionally, comparison to 
genomes of other organisms revealed that the ING family is conserved from yeast to 
humans (87).  Mice were shown to possess five ING genes (Ing1- Ing5), similar to 
humans, whereas three ING genes were identified in yeast (Yng1, Yng2, and PHO23). 
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Human and mouse ING genes are dispersed throughout their respective genomes, as seen 
in Figure 1.1.  Analysis of the genomic structure of the human ING genes revealed that 
most members undergo alternative splicing, with the exceptions of ING2 and ING5.  
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Figure 1.1:  Genomic organization of mouse and human ING family members.  Human 
ING genes are depicted on the top of each panel and are in grey.  Mouse Ing genes are on 
the bottom and in black.  Figure shows genomic structure of each gene and each 
alternatively spliced transcript with protein masses in kilodaltons.  Shaded region for 
each transcript shows protein coding region.  Currently, extensive studies of genomic 
organization have been conducted for human and mouse ING1 and for human ING2-5.  
Shown for mouse ING2-5 is the predicted genomic organization and alternative splice 
variants. 
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The number of isoforms encoded by the ING1, ING3, and ING4 gene differs between the 
two species.  Human ING1 was found to have five alternative splice variants, each 
differing at the N-terminus with a conserved PHD motif at the C-terminus (Fig 1), 
whereas mouse Ing1 produces three splice variants, p31Ing1a, p31Inglc, and p37Ing1b.  Both 
human and mouse ING1 splice variants occur through alternative splicing of one of 
several upstream exons into a common last exon of the gene.  In contrast, human ING4 
encodes four splice variants, but only one Ing4 transcript has been observed in mouse.  
The number of splice variants encoded by mouse Ing2, Ing3, and Ing5 genes is presently 
unknown. 
 
Several studies have examined the temporal and spatial pattern of human and 
mouse ING gene expression (79, 145, 152, 216, 222).  All ING genes appear to be 
ubiquitiously expressed in fetal and adult tissues, though the relative abundance of the 
expression levels of different ING genes differs between organs and developmental 
stages. 
 
1.4 Structural Features of ING Proteins 
All ING proteins contain a plant homeodomain (PHD) at the C-terminus, a 
nuclear localization signal, and a unique domain with an unknown function called the 
novel conserved region (Figure 1.2).  The PHD motif comprises approximately 60 amino 
acids and displays a C4HC3 signature that typically binds two Zn2+ ions (1, 14).  
 
 
 
 
9
Approximately 150 separate PHD domain-bearing proteins have been predicted from the 
human genome analysis (1).  Currently it is unknown how many PHD proteins actually 
occur in man or mouse.  PHD domains closely resemble a canonical RING domain but 
lack the RING E2 ubiquitin ligase activity (14).   
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Figure 1.2:  Domain structure of human ING proteins.  The domain composition and 
approximate location for each domain is shown for various ING proteins.  Also shown 
for ING1 are the two known phosphorylation sites at serine 126 and 199.  14-3-3 binds to 
phosphorylated serine 199 and facilitates translocation from the nucleus into the 
cytoplasm (68).  Serine 126 is phosphorylated by CDK1 under non-stressed conditions 
and by CHK1 under DNA-damaging conditions.  This site has also been reported to 
affect the half-life of ING1 and its ability to repress the expression of CyclinB1 (58).  
Each ING protein is predicted have three conserved regions, which are a PHD domain 
(Plant Homeodomain), NCR (Novel Conserved Region), and NLS (Nuclear Localization 
Sequence) (23).  The NLS for ING4 has been reported to be the putative region which 
binds to p53 (242).  A Luezine Zipper-Like (LZL) domain is present in ING2-5.  Little is 
known about this domain, but it was reported to affect the ability of ING2 to function in 
DNA repair and apoptosis (227).  ING1 also has a PBD (Partial Bromodomain) and a PIP 
(PCNA-Interacting Protein Motif) domain.  The PBD domain appears to bind to the 
SAP30 subunit of the mSin3A-HDAC complex (118, 202).  Both ING1 and ING2 have a 
PBR (Poly Basic Region) domain, which appears to be involved with phosphoinositide 
binding (73, 101).  The domain structure for mouse Ing proteins have not been defined. 
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However, PHD domains have been implicated in chromatin remodeling, as they are often 
present in proteins that are known components of larger chromatin remodeling complexes 
(14).  For example, PHD domains are present on the William-Beuren syndrome 
transcription factor (WSTF), a component of an ISWI and SWI/SNF based chromatin 
remodeling complexes (164), on CHD4 (Mi-2β) the dermatomyositis-specific 
autoantigen, a component of the NuRD histone deacetylase complexes (HDAC) (46), and 
on the autoimmune regulator protein AIRE1, predicted to have a role in transcription 
control (17).  Using an electophoretic mobility shift assay with the isolated PHD finger of 
p300, this motif was shown to possess direct nucleosome binding activity (173), and the 
PHD domain of both the p300 and ACF (another protein containing a PHD domain) can 
cooperate with an adjacent bromodomain to constitute a functional nucleosome-binding 
module.  Thus, the role of the PHD domain may be to consolidate or strengthen a 
separate chromatin-binding activity of either the same protein or of a closely associated 
protein, and it is interesting to note that a partial bromodomain is present in ING1 (23). 
Recently, the PHD finger of the ING proteins has been found to bind directly to 
methylated histones, specifically H3K4me2 and H3K4me3 (168, 194).  This report 
further underscores the link between PHD domains and nucleosome binding. 
 
Another domain common among all ING proteins is the nuclear localization 
signal (NLS), and some ING proteins appear to have multiple NLS.  To date, the role of 
the NLS has been studied extensively only in ING1 (81, 184), in which deletion of the 
NLS results in cytoplasmic accumulation of the protein.   
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Localization of ING proteins to the nucleus has been proposed to be critical to their 
function, as is evident by the observation of loss of nuclear ING1 staining in a number of 
cancers (70), and because deleting the entire NLS of ING4 resulted in a protein that could 
no longer bind p53 in co-transfection experiments (242).  Additionally, there are two 
copies of a nucleolar translocation signal (NTS) contained within the NLS of ING1, and 
translocation of ING1 to the nucleolus following exposure to UV light appears to be 
required for ING1-associated apoptosis following UV exposure (23).  It is currently 
unknown if other ING genes have a similar NTS or can be detected in the nucleolar 
compartment.  
 
Other protein domains found in select ING proteins include the leucine zipper-
like (LZL) region present in ING2-5 (203), though the functional role of this LZL it not 
yet understood.  The LZL consists of 4-5 conserved leucine or isoleucine residues spaced 
seven amino acids apart, which has the potential to form a hydrophobic face near the N-
terminus of the protein.  One report for the function of the LZL of ING2 suggested that 
this motif is required for nucleotide excision repair and induction of apoptosis (227), 
though these functions have yet to be substantiated by further experimentation. 
 
1.5 ING Proteins Participate in a Variety of Cellular Processes and Pathways 
A review of the current literature suggests that ING proteins regulate a wide 
variety of cellular processes, including cell growth, apoptosis, DNA repair, senescence, 
and angiogenesis.   
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Several lines of evidence have indicated that ING proteins can influence cell cycle 
progression and are involved in cell cycle checkpoints (23, 203).  The majority of these 
studies have been conducted using ING1, but the fewer studies involving ING2-5 have 
also identified similar roles for these proteins.  In addition to the above processes, 
suppression of ING proteins has been shown to increase cell spreading, migration, and 
relieve contact inhibition (61, 109, 110, 189, 216).  
 
The results of several cell transfection studies have suggested that most ING 
proteins are required for proper p53 function (23, 203).  However, more recent studies 
have also suggested that there are p53-independent functions for the ING proteins, 
including regulation of the NF-κB (63) and hypoxia inducible factor (HIF) pathways 
(159) (see below).  Additionally, ING proteins have been found to serve as subunits in 
chromatin remodeling complexes (48).  These findings suggest that ING proteins act in 
the nucleus to regulate transcription, which could account for their multiple proposed 
roles in several essential biological processes (12, 23, 33, 55, 193).  As dysregulation of 
any of these pathways might lead to neoplasia, ING proteins have also been proposed to 
act as tumor suppressors in human cancers. The following is a description of the most 
important and compelling findings for each individual ING protein: 
 
1.5.1 ING1 
ING1 in growth regulation: A putative role for ING genes in cell cycle regulation was 
initially suggested from experiments involving either overexpression or antisense 
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knockdown of ING1 (61, 62).  Overexpression of ING1 in human diploid fibroblasts 
resulted in a 50% increase in the number of cells found in the G0/G1 phase of the cell 
cycle (61), indicating that ING1 might have a role in the G1-S transition.  Conversely, 
antisense ING1 constructs in these cells resulted in abolition of this arrest and entry of the 
cells into S phase (61).  These findings were corroborated in H1299 cells by ectopically 
expressing p33ING1b, which resulted in a slight increase in the doubling time with fewer 
cells in G1, possibly due to a delay or block in S or G2/M (215).  Therefore, ING1 appears 
to be involved in both the G1/S and the G2/M cell cycle checkpoints.  ING1 has also been 
found to negatively regulate the expression of cyclin B1 (206), further supporting a 
possible involvement of ING1 in the G2/M cell cycle checkpoint.  Additionally, ING1 
expression was found to be inversely related to cyclin E expression (154).  However, this 
latter finding needs to be corroborated and its significance determined with further 
investigation. It was also determined that ING1 expression is cell cycle regulated, 
decreasing from G0 to G1, increasing in late G1 to become maximal during S phase, 
followed by a decrease in G2 (64).  As would be expected, ectopic expression of p33ING1b 
can enhance the cell cycle arrest induced by doxorubicin, a topoisomerase II inhibitor that 
results in double-stranded DNA breaks (215).  Doxorubicin was found to decrease the 
population doubling time and increase the number of cells in G2/M.  The enhancement of 
cell cycle arrest due to p33ING1b overexpression was found to be DNA damaging agent 
specific, with no enhanced cell cycle arrest observed with cisplatin or UV irradiation 
(215).   
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Antisense knockdown of ING1 was also found to promote the ability of anchorage 
independent growth in soft agar and increase foci formation, supporting a functional role 
for ING1 in preventing cell transformation (59, 61, 62, 206). 
 
ING1 in apoptosis: Expression of ING1 increases prior to apoptosis induced by serum 
starvation, and ectopic ING1 expression was found to cooperate with c-myc expression to 
induce apoptosis in both P19 cells and rodent fibroblasts (88).  Conversely, antisense 
knockdown of ING1 provided protection from apoptosis.  Taken together, these results 
suggest that ING1 also has a role in regulating cell death.  The ability of ING1 to induce 
apoptosis was found to depend upon an interaction with PCNA following UV irradiation 
(186) and to be cell age dependent, as only early passage fibroblasts were able to 
upregulate p33ING1b and undergo apoptosis following growth factor deprivation (220).  
This study also suggests possible ING1 isoform-specific functions in apoptosis, since 
ectopic expression of p33ING1b, but not p47ING1a, sensitized young, but not old, fibroblasts 
to UV and hydrogen peroxide-induced apoptosis (220).  Ectopic expression of p33ING1b 
also sensitized cells to apoptosis induced by the chemotherapeutic agents etoposide, 
taxol, and doxorubicin (184, 206, 220).  However, a more recent paper appears to 
contradict the previous reports that overexpression of ING1 can promote apoptosis, as 
down-regulation of ING1 in p53 deficient glioblastoma cells sensitized these cells to 
cisplatin-induced apoptosis (208).  Interestingly, a very recent report found that 
overexpression of p33ING1b could synergize with tumor necrosis factor alpha (TNFα) 
treatment to induce apoptosis (54).   
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This finding suggests an indirect role for p33ING1b in the NF-κB pathway, since NF-κB 
signaling protects cells from TNFα-induced apoptosis (217). 
 
ING1 in DNA repair: Regulation of nucleotide excision repair (NER) following UV 
exposure has also been linked to ING1.  Overexpression of p33ING1b can enhance 
nucleotide excision repair (NER) of exogenously added plasmid DNA in a host-cell-
reactivation assay (34).  An interaction between GADD45 and p33ING1b was also detected 
to support the proposed involvement of p33ING1b in NER.  Mutations in the PHD domain 
and a region found to interact with SAP30 (Sin3A Associated Protein 30), a component 
of Sin3A co-repressor complexes, abrogated enhancement by p33ING1b of NER in host 
cell reactivation assays and radioimmunoassay (24, 121).  Furthermore, the p33ING1b 
variant was not recruited to UV-induced DNA lesions, but enhanced NER in XPC-
proficient cells possibly due to its ability to bind XPA (115).  As XPC/hHR23B acts at 
the first step of the NER pathway by recognizing helix-distorting DNA lesions and XPA 
acts further downstream to stabilize the resulting open DNA structure (231), these 
observations suggest that p33ING1b has an essential role in the early steps of the NER 
pathway, possibly by facilitating access of the nucleotide excision repair machinery to 
chromatin. 
 
ING1 and p53 functions: The ING proteins have been implicated in the regulation of the 
p53 pathway by several reports (60, 145, 167, 199).   
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p53 is a tumor suppressor that responds to disruption of DNA integrity and/or 
perturbation of cell division in cells exposed to various forms of stress (8).  Following 
DNA damage, stress signals are transmitted to the p53 protein by a cascade of post-
translational modifications that activate the p53 transcription factor and initiate or 
upregulate a wide variety of genes involved in cell cycle arrest, senescence, DNA repair, 
and apoptosis (8).  These p53-responsive genes encode proteins that not only interact 
with other signal transduction pathways (Figure 1.3), but also serve to regulate the 
duration of the p53 response (84).  One well-characterized regulator of p53 is the E3 
ubiquitin ligase Mdm2.  p53 upregulates the expression of Mdm2, which subsequently 
regulates the stability of the p53 protein by placing ubiquitin moieties onto p53 to target 
p53 for 26S proteosomal degradation.  In addition, Mdm2 can also inhibit p53 activity by 
targeting p53 for export from the nucleus into the cytoplasm.  Regulation of p53 by 
Mdm2 is governed by the p19ARF tumor suppressor.  The levels of the p19ARF protein 
increase in response to the inappropriate expression of certain oncogenes, (190, 191), and 
p19ARF complexes with MDM2 and sequesters MDM2 into the nucleolus, thereby 
stabilizing p53 and facilitating activation of p53-dependent gene expression (192). 
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All ING genes except ING3 have been found to co-immunoprecipate with p53 
following ectopic co-expression of ING proteins and p53, and subsequent functional 
studies utilizing forced overexpression of ING genes in cultured cells have indicated that 
the ability of ING proteins to arrest cell proliferation and induce apoptosis is lacking in 
p53-deficient RKO-E6 cells, suggesting that ING proteins require functional p53 to 
inhibit cell growth (12, 23, 203).  
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Figure 1.3:  Proposed model of ING1 in the p53 pathway.  DNA damage such as 
oncogene overexpression or exposure to UV or γ-irradiation activates the ATM/ATR 
kinases, which can then activate CHK1/CHK2.  CHK2 can phosphorylate p53, increasing 
its stability by preventing the binding of MDM2 and allowing p53 to translocate into the 
nucleus (84).  Nuclear localized p53 can induce genes necessary for the cell to apoptose 
or enter a cell cycle arrest.  Oncogenic stress can also activate the ARF protein which can 
inhibit the ability of MDM2 to bind with p53 and target it for degradation (139).  ING 
proteins have been suggested to participate in at least two locations in the 
ARF/MDM2/p53 pathway.  1) All ING proteins except ING3 have been found to co-
immunoprecipate with p53 (23), 2) ARF has been suggested to interact with p33ING1b in 
vivo to alter the sub-cellular localization of p33ING1b from the nucleus to the nucleolus 
and the ability of exogenous p33ING1b to induce cell cycle arrest was impaired in ARF-
deficient mouse embryonic fibroblasts (71), and 3) ING1b and MDM2 compete for the 
same binding site on p53 (124).  In addition, ING1 has been proposed to be 
phosphorylated on serine 126 by CDK1 under non-stressed conditions and by CHK1 
under DNA-damaging conditions (58).  Phosphorylation of serine 126 has been suggested 
to alter the half-life of ING1 and its ability to repress the expression of CyclinB1 (58).  
Grey arrows designate proposed interactions and black arrows show well characterized 
interactions. 
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Conversely, expression of antisense ING1 constructs inhibited expression of a 
p21WAF1-CAT construct in cultured cell that were wildtype for functional p53 (59), 
suggesting that p53 requires the ING proteins to function as a transcriptional activator. 
 
Additional evidence linking ING proteins and p53 function was provided by 
experiments utilizing adenoviral-mediated gene transfer of p33ING1 and p53 into glioma 
cells.  Increased apoptosis was observed in U251 and U-373MG glioma cell lines only 
when both genes were co-introduced (198), and similar results have been obtained 
following co-transfection of a human esophageal carcinoma cell line (196).  Furthermore, 
expression of ING1 in transfected HepG2 (p53-wt) and Hep3B (p53-null) hepatocellular 
carcinoma cells repressed expression of the α-fetoprotein (AFP) gene in a p53-dependent 
manner (61).  AFP expression is normally inhibited by p53 (62), and repression of AFP 
by p53 was found to involve binding of ING1 to AT- motifs within the AFP promoter, 
with attendant acetylation of p53 (107).  However, these conclusions drawn from this 
data are open to interpretation, as the precise role of p53-acetylation on p53 
transactivation and transrepression remains a matter of some dispute (16).   
 
Recent findings have indicated that ING1 may also regulate several components 
of the Arf-Mdm2-p53 signaling axis (Fig 1.3).  The p33ING1b protein has been proposed to 
compete with Mdm2 for the same binding site on p53 as a means of increasing the 
stability and activity of p53 (124).   
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In addition, Arf has been suggested to interact with p33ING1b in vivo to alter the sub-
cellular localization of p33ING1b from the nucleus to the nucleolus (much like the effect of 
Arf on Mdm2), and the ability of exogenous p33ING1b to induce cell cycle arrest has been 
found to be was impaired in Arf-deficient mouse embryonic fibroblasts (71). 
 
p53-independent functions of ING1: There also appears to be p53-independent roles for 
the ING proteins (54, 67, 206, 208, 215, 226).  The results of microarray analysis of cells 
with p33ING1b knocked down by antisense constructs indicate that the cyclin B1 gene may 
be regulated by p33ING1b (206).  This study also reported that overexpression of p33ING1b 
in p53-deficient Saos2 cells caused a decrease in cyclinB1 message, revealing that 
regulation of cyclinB1 expression by ING1 was p53-independent.  Likewise, 
transcriptional regulation of HSP70 was also found to be regulated by p33ING1b in a p53-
independent manner (54).  Several p53-independent roles for p33ING1b in growth 
regulation and cell cycle arrest have been proposed based upon transfection studies 
utilizing cell lines lacking functional p53.  Overexpressing p33ING1b in H1299 lung 
carcinoma cells increased the doubling time of these p53-deficient cells by about 10% 
and enhanced a doxorubicin-induced G2/M DNA damage checkpoint (215).  
Additionally, siRNA knockdown of ING1 in LN229 glioblastoma cells caused these p53-
null cells to be more sensitive to cisplatin treatment and to transition faster through the G1 
phase of the cell cycle (208).  These findings suggest that ING1 can function to inhibit 
cell growth or cell death independent of p53, since overexpressing ING1 or knocking 
down ING1 in the absence of p53 would be otherwise expected to have no effect.   
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In addition, the transcriptional silencing effect of ING1 has been proposed to be p53-
independent, as ectopic expression of a Gal-p33ING1b fusion protein in p53-null, H1299 
cells repressed the expression of a co-transfected chloramphenicol acetyl-transferase 
(CAT) reporter gene that was placed under transcriptional control of a modified 
thymidine kinase promoter (67). 
 
ING1 and the NF-κB pathway: ING proteins have also been proposed to regulate NF-
κB activity.  NF-κB can be activated by a number of stimuli, including components of 
microbial pathogens such as lipopolysaccharide (LPS), and by inflammatory cytokines 
(146).  NF-κB is a dimeric transcription factor composed of the Rel protein family 
members c-Rel, RelA (p65), RelB, NF-κB1 (p50 and its precursor p105), and NF-κB2 
(p52 and its precursor p100) (141).  Typically, NF-κB exists as a hetero- or homodimer 
of two Rel members, the most common dimer combination being p65/p50.  This 
heterodimer pair generates an NF-κB complex that functions as a transcriptional 
activator. In contrast, NF-κB composed of homodimers of p50 or p52 can repress 
transcription from NF-κB-responsive promoters (141). 
 
Following activation of upstream cellular receptors, the NF-κB transcription 
complex positively regulates the expression of specific genes involved in the innate 
immune response (142).  One such example involves the Toll-like receptor.  Binding of 
cognate ligands to the Toll receptor recruits Myd88, an adaptor protein, and results in 
activation of the IRAK family of kinases (141, 142, 162).   
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Subsequent signaling steps serve to activate the downstream IkB kinases (IKK1 and 
IKK2), leading to phosphorylation and subsequent proteosomal degradation of the 
inhibitor IkB family of proteins (141) (Figure 1.4).  Destabilization of IkB proteins cause 
the NF-κB complex to translocate into the nucleus and activate gene transcription.  In 
addition, an alternative Myd88-independent signal transduction pathway exists which 
ultimately activates the IRF family of transcription factors (142, 162).  NF-κB has been 
suggested to play a role in tumorigenesis by acting as a tumor promoter (75, 104, 105).  
Although mutations in NF-κB are rarely observed in tumors, alterations in upstream NF-
kB regulators have been documented (eg. IκB loss of function in Hodgkin’s lymphoma) 
that lead to constitutive activation of NF-κB (175).  Because NF-κB regulates the 
expression of many genes proposed to govern apoptosis, angiogenesis, metastasis, 
proliferation, and tumor growth and survival (169), perturbation of NF-kB signaling has 
been strongly linked to tumorigenesis.  
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Figure 1.4:  Model of a role for ING1, ING2, and ING4 in the regulation of the NF-κB 
pathway.  External stimuli, such as lipopolysaccharide (LPS), cytokines, or TNFα, binds 
to specific receptors, in the case of LPS they are members of the Toll-like receptor 
family, and lead to activation of a signal transduction cascade.  This cascade activates the 
IκB kinases (IKK1 and IKK2) which can phosphorylate IκB proteins and release the NF-
κB complex.  The complex can then translocate into the nucleus to induce expression of 
genes for cytokines and pro-survival proteins (221).  A) ING4 was recently determined to 
directly interact with p65/RelA and negatively regulate the transactivation activity of the 
NF-κB complex (63).  Also depicted is the possible recruitment of the HBO1 histone 
acetyltransferase complex by ING4.  However, the exact role of the HBO1 complex in 
regulation of NF-κB activity is not fully understood (42).  B)  Recently, ING1 and ING2 
were found to induce the expression of the heat shock protein HSP70 (54).  HSP70 is 
able to bind to the IKK complex and inhibit its ability to phosphorylate and activate the 
NF-κB complex (174, 195).  Therefore, ING1 and ING2 may have an indirect role in the 
NF-κB pathway. 
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Recent microarray data has indicated that expression of the heat shock protein 
HSP70 is upregulated by p33ING1b expression (54).  Since HSP70 can inactivate the NF-
κB pathway by interacting with IKKγ and preventing degradation of IκB (135, 174, 195), 
these findings suggest a possible indirect role for p33ING1b in regulating the NF-kB 
signaling pathway. 
 
ING1 in chromatin remodeling and regulation of gene expression: In addition to 
possible roles in p53 and NF-kB signaling, p33ING1b (but not p24ING1c) was found to 
associate with a chromatin remodeling complex (see Table 1.1).  By fractionating HeLa 
nuclear extracts, the endogenous p33ING1b protein was found as a subunit of an 
approximate 1-2 MDa complex (202).  This complex also contained mSin3, SAP30, 
histone deacetylase 1 (HDAC1), RbAp48, and additional components of the mSin3A 
transcriptional co-repressor complex (202), and purified p33ING1b -containing complexes 
were found to be active in deactylating core histones in in vitro assays. Although 
Sin3/HDAC has been reported to act as a repressor, recent evidence suggests that it might 
act to positively regulate transcription as well (200).  Recently, p33ING1b and ING2 have 
been reported to recruit SIRT1 to the Sin3/HDAC complex (15).  As SIRT1 acts to 
negatively regulate the transcriptional repression activity of the Sin3/HDAC complex 
(14), this data suggests a possible role for ING proteins in transcriptional activation. 
Thus, p33ING1b and other ING proteins may function within the Sin3/HDAC complex to 
act as a global regulator of gene transcription.   
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Table 1.1:  The composition of each ING protein containing chromatin remodeling 
complex.  Also, provided are the function of each complex and methods used to 
characterize the assembly of the ING protein within each complex.  Abreviations used:  
IAP-MS, Immune affinity purified mass spectroscopy; Co-IP, co-immunoprecipitation. 
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In addition, the ING proteins might contribute to other functions that have been ascribed 
to the Sin3/HDAC complex, including nucleosome remodeling, DNA methylation, N-
acetylglucoseamine transferase activity, and histone methylation (200).  Interestingly, the 
Sin3/HDAC complex does not possess DNA-binding activity, and targeting of this 
complex to gene promoters likely occurs via interaction of Sin3/HDAC with DNA-
binding proteins (200). 
 
Different human ING1 isoforms have been found to associate with either HAT or 
HDAC activity.  Overexpression of p33ING1b can induce hyperacetylation of histone H3 
and histone H4 in vitro and in transfection assays, suggesting that ING proteins regulate 
HAT activity (218).  Conversely, overexpression of p47ING1a induces histone 
deacetylation, suggesting an association between ING proteins and HDAC activity (107, 
218).  These effects would obviously impact transcription by altering histone-DNA 
interactions in the promoter region of a gene or by altering the binding ability of other 
regulatory proteins. 
 
In addition, there is some evidence in the literature to suggest that ING1 might be 
involved in DNA methylation.  The DNA methyltransferase 1-associated protein 1 
(DMAP1) has been found to physically associate with p33ING1b during S-phase at sites of 
pericentric heterochromatin and correlate with methylated H3 lysine 9 (H3K9), histone 
deacetylation, and DNA methylation (233).   
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Additionally, the PHD domain of all human ING proteins was found to preferentially 
bind di- and tri-methylated H3K4 and repress gene transcription (122, 168, 194). 
 
Finally, the p33ING1b protein has also been found to associate with Alien in GST-
pull-down in vitro assays (53).  Alien is a transcriptional co-repressor involved in gene 
silencing mediated by select members of nuclear hormone receptors and E2F1 (53). 
 
1.5.2 ING2 
ING2 in cell growth regulation, apoptosis, and DNA repair: Links between ING2, cell 
cycle regulation, apoptosis, and NER have also been proposed.  Ectopic expression of 
ING2 in RKO cells inhibited colony formation and induced a G1 cell cycle arrest (144).  
Overexpression of ING2 was also found to induce replicative senescence whereas RNAi-
mediated downregulation of ING2 delayed the onset of replicative senescence (167).  A 
recent study contradicts this observation, RNAi knockdown was found to induce a p53-
independent senescence and overexpression of ING2 was found to induce a p53-
dependent senescence in hTERT-immortalized human fibroblasts (114).  These two 
studies suggest that ING2 has a role in senescence regulation; however, further work is 
needed to elucidate the mechanism of this regulation. 
 
 Consistent with a role for ING2 in cell proliferation, ING2 has recently been 
found to interact with SnoN and Smad2 to promote TGFβ dependent gene expression 
resulting in the inhibition of cell proliferation (182).   
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At present it is unknown if other ING family are potential regulators the TGFβ pathway.  
As TGFβ signaling is involved in cellular proliferation, cell survival, apoptosis, 
migration, invasion, and inflammation(140), this may be an important topic for future 
research.  ING2 may also have a role in etoposide-induced apoptosis (223) and 
overexpression of ING2 enhanced apoptosis after irradiation of transfected cells with 
ultraviolet light (227).  The BCL-2 protein was upregulated following UVB exposure of 
MMRU melanoma cells overexpressing ING2, which also promoted the translocation of 
BAX to the mitochondria followed by alterations in the mitochondrial membrane 
potential.  Additionally, ING2 was found to regulate Fas expression, thus suggesting a 
link between ING2 and both the mitochondrial/intrinsic and death-receptor/extrinsic 
apoptotic pathways (35). 
 
Truncation mutants of ING2 that lack the luecine zipper-like (LZL) domain did 
not display elevated apoptosis following UV exposure (227), suggesting that this ING2 
domain is required for apoptosis.  RNAi knockdown of ING2 was also found to abrogate 
the NER capacity of melanoma cells (223).  Similar to p33ING1b, ING2 may be involved 
in the initial steps of NER by inducing chromatin relaxation and the recruitment of XPA 
to the photo-lesions in DNA.  Interestingly, the NER ability of ING2 was found to 
require the LZL domain, a domain that is not present in p33ING1b (227).  
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Role of ING2 in the NF-κB pathway and in chromatin remodeling: Similar to 
p33ING1b, HSP70 expression can also be upregulated by ING2 and suggests that the ING 
proteins might indirectly regulate NF-κB activity (54).  ING2, like p33ING1b, was found to 
associate with the co-repressor Alien through an in vitro GST-pull-down assay (53), to 
co-purify with components of the mSin3 complex, and to associate with Brg1-based 
SWI/SNF chromatin remodeling complexes (Table 1.1) (48).  Furthermore, ING2 and 
p33ING1b could also interact in vitro and in vivo with the RBP1 protein, a component of 
the mSin3A complex, and recruit SIRT1 to the mSin3A/HDAC1 complex.   
The recruitment of SIRT1 to this complex was found to negatively regulate the 
transcriptional repression activity of the mSin3A complex (15). 
 
1.5.3 ING3 
ING3 in proliferation and apoptosis: ING3 has been linked to regulation of the cell 
cycle and apoptosis.  However, unlike other ING proteins, an involvement of ING3 in 
NER and replicative senescence has not been found.  Similar to ING1, ectopic expression 
of ING3 in RKO cells decreased colony formation, possibly by decreasing the number of 
cells in S phase (145, 199).  ING3 overexpression also induced Fas expression, increased 
the cleavage of Bid, caspases-8, -9, and -3 and promoted apoptosis in UV treated cells 
(226).  Similar to ING2, these findings suggest that ING3 may be involved in the death-
receptor/extrinsic pathway.  Unlike other ING proteins, ING3 does not appear to interact 
with p53 and is not thought to have a role in IR-induced cell death (145). 
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ING3 and chromatin remodeling: ING3 was found to be mainly, if not exclusively, a 
subunit of the NuA4/Tip60 HAT complex (Table 1.1) following biochemical purification 
of ING protein- containing complexes from HeLa cell nuclear extracts (50).  Tip60 is an 
important cofactor for p53, NF-κB, Myc, E2F1, and nuclear-receptor dependent 
transcriptional activation, and is involved in the cellular response to DNA damage, 
apoptosis, and metastasis suppression (7, 209).  Mice deficient for Tip60 die during 
embryogenesis prior to implantation (E4), and haplo-insufficiency for Tip60 results in 
accelerated lymphomagenesis in transgenic Eµ-Myc mice (72).   
These data suggest that ING3 might also function in these processes through its 
association with the NuA4/Tip60 HAT complex. 
 
1.5.4 ING4 
Cellular functions of ING4: Ectopic expression of ING4 in RKO cells was found to 
inhibit colony formation, likely due to a decrease in the percentage of cells in S phase 
(145, 199), and serum starvation-induced apoptosis following ING4 overexpression was 
increased and correlated with increased Bax expression levels (243).  Thus, similar to 
other ING proteins, ING4 has been proposed to regulate cell cycling and apoptosis.  
However, ING4 appears to differ from the other ING family members in several aspects: 
ING4 does not appear to have a role in NER, and ING4 has been proposed to alter 
angiogenesis and cell migration.  
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ING4 and angiogenesis and cell migration: A relationship between ING4 and 
angiogenesis was uncovered by studies utilizing implantation of the glioblastoma cell line 
U87MG into the cranial windows of nude mice. Tumor cells in which ING4 was knocked 
down by siRNA grew faster than control cells and yielded tumors with higher vascular 
volume fractions (63).  Additionally, a reduction of ING4 expression in multiple 
myeloma cells increased the expression of the pro-angiogenic molecules interleukin-8 
(IL-8) and osteopontin (OPN).  In addition to these in vitro observations, a correlation 
was noted between reduced expression of ING4 and increased mircovascular density in 
multiple myeloma patients (40). 
 
ING4 has also been linked to cell migration, cell spreading, and contact 
inhibition.  Ectopic expression of ING4 in several cell lines both decreased cell spreading 
and cell migration (216).  Subsequent mass spectroscopy analysis of extracts from RKO 
cells overexpressing a FLAG-ING4 construct indicated that ING4 interacts with liprin 
α1, G3BP2a, COP1β, CaBP1, and several ribosomal proteins (189).  ING4 was also 
found co-localized with Liprin α1 in the lamellipodia of cells.  Since Liprin α1 may play 
a role in focal adhesion disassembly (187), ING4 might exert an effect upon cell 
spreading and migration through its interactions with Liprin α1.  Interestingly, ING4 was 
also identified in a screen for genes that suppressed the loss of contact inhibition caused 
by MYCN overexpression (110).  The ability of ectopically expressed ING4 to suppress 
contact inhibition was further supported by reports of an attenuation of the ability of 
T47D breast cancer cells to grow in soft agar when ING4 was overexpressed (110). 
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Involvement of ING4 in the p53, NF-κB, and HIF-1α pathways: ING4 has also been 
suggested to bind to and regulate the functions of either p53, NF-κB, and/or HIF-1α.  
Forced overexpression and co-immunoprecipitation experiments performed in the 
glioblastoma cell line U87MG indicated that ING4 physically interacts with p65 (RelA), 
linking ING4 to the NF-κB pathway (63).  Further analysis of this interaction using gel 
mobility shift assays and siRNA knockdown of ING4 suggests that ING4 can increase 
the DNA-binding activity of RelA.  Additionally, knockdown of ING4 could stimulate 
expression of a NF-κB-dependent luciferase reporter plasmid in transfected cells.   
These results suggest that ING4 interacts directly with RelA to inhibit NF-κB 
transcriptional activity. 
 
Knockdown of ING4 by siRNA also led to elevation of the HIF-1α target genes 
NIP3 and AK3 under hypoxic conditions (159).  Nuclear levels of HIF-1α were 
unchanged in these experiments, suggesting that ING4 was suppressing HIF-regulated 
genes by altering HIF-1α activity, although no direct interaction between ING4 and HIF-
1α was observed.  Subsequent experiments revealed that ING4 might regulate HIF-1α 
activity by affecting the recruitment of chromatin remodeling enzymes (159).  
Additionally, in myeloma cells, ING4 has been proposed to suppress HIF-1α activity by 
interacting with HIF prolyl hydroxylase-2 (PHD2/HPH2) (40), an oxygen sensing protein 
that helps to target the HIF-1α protein for degradation (13).   
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Although suppression of ING4 increased vessel formation in RPMI-8226 cells under 
hypoxic conditions (40), no further corroborative studies have been published to 
substantiate ING4 regulation of HIF activity.   
 
ING4 and chromatin remodeling: ING4 has also been reported to exist as a component 
of a novel HBO1- HAT complex (Table 1.1) (48).  The HBO1 protein is the catalytic 
subunit of two different but related HAT complexes that specifically acetylate histone 
H4, and HBO1 has been linked to DNA replication, S-phase progression, and 
transcriptional regulation (7).  In addition, HBO1 has been suggested to act as a co-
repressor for the androgen receptor (7) and NF-κB (42).   
Furthermore, p53 has been found to interact with HBO1 and to down-regulate HBO1 
acytyltransferase activity (95). While these are intriguing findings, the ability of HBO1 to 
function as a regulator of transcription is controversial as the evidence is sparse and 
conflicting.  Therefore, a role for ING4 in regulating HBO1 complex formation or 
contributing to its function remains uncertain. 
 
1.5.5 ING5 
ING5 in regulation of transcription and cell growth: Biochemically, ING5 appears 
similar to ING4 in that it can interact with p53 and recruit p300 to induce p53 acetylation 
on lysine-382 (199).  Similar to ING4, ING5 was found as a member of HBO1-
containing HAT complex, and ING5 was also found as a subunit of a histone H3-specific, 
HAT complex that included MOZ/MORF leukemic proteins (Table 1.1) (48).  
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However, almost nothing is known about ING5 functions to date.  ING5 transfection 
studies have suggested that ING5 reduces colony-forming efficiency, the percentage of 
cells in S-phase, and induces apoptosis in a p53-dependent manner (199).  Additionally, 
ING5 could also induce expression of the cyclin-dependent kinase inhibitor p21 (199), a 
p53 target gene.  These results implicate ING5 in regulation of cell growth and p53 
activity, but further studies are needed in order to better characterize ING5 functions. 
 
1.6 Regulation of ING Gene Expression and Protein Function 
Little is known about the regulation of ING gene expression or ING protein 
functions.  Analysis of mouse and human ING1 expression has indicated that ING 
expression is not regulated by p53 (31, 239).  However, p53 was recently determined by 
chromatin immunoprecipitation (ChIP) and electrophoretic mobility shift (EMSA) assays 
to bind to two regions in the promoter of ING2 (114).  Studies have found that expression 
of ING2, but not of ING1 (144) or ING3 (145), can be induced by certain DNA 
damaging agents such as etoposide or neocarzinostatin, but not by other agents such as γ-
irradiation or doxorubicin.  A recent study determined that RUNX3 induces the 
expression of both ING1 and ING4 in MKN-1 human gastric carcinoma cell lines (143), 
but further information linking RUNX to ING gene expression is not available. 
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Subcellular localization is another mechanism utilized by cells to regulate protein 
activity.  Localization of p33ING1b has been proposed to be regulated by 14-3-3 family 
members, which can tether ING1 to the cytoplasm.  Binding between ING1 and 14-3-3 
appears to be dependent upon the phosphorylation status of serine 199 of ING1 (68).   
Localization of ING2 to the plasma membrane was also reported to occur by a PHD 
domain-phosphoinositide interaction (73).  However, clear binding preferences or 
consistently strong binding affinities between PHD containing proteins and specific 
phosphoinositides has not been observed by other groups (14), and further experiments 
will be needed to confirm these observations.   
 
Proteins can also be regulated by posttranslational modifications such as 
phosphorylation, acetylation, and ubiquitinylation.  The p33ING1b splice variant was 
indeed found to be phosphorylated on serine 126 by CDK1 under non-stressed 
conditions, and similarly by CHK1 under DNA-damaging conditions (58).  As CHK1 is 
normally activated by ATM/ATR kinases, these findings suggest that p33ING1b might be a 
downstream target of ATM/ATR- CHK1 signaling following UV damage.  In addition, 
phosphorylation of serine 126 was found to alter the half-life but not the subcellular 
localization of p33ING1b (58), and could alter the expression of cyclin B1 leading to 
altered cellular proliferation. 
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1.7 ING Genes as Tumor Suppressors 
The reported involvement of the ING proteins in numerous essential biological 
processes predicts that ING proteins have important implications in human disease.  
Although analysis of ING gene mutation status, expression levels, and protein 
localization in a variety of primary tumors and cell lines revealed that ING genes are 
infrequently mutated, they often display reduced gene expression or mislocalization of 
proteins in cancerous cells.  These findings place the ING genes in the category of type II 
tumor suppressors.  Additionally, some reports have found a correlation between 
decreased expression levels of ING genes and cancer progression or a correlation 
between ING gene expression levels and decreased survival rates for a number of cancer 
types (see below).  Various mechanisms have been proposed to inactivate ING gene 
functions in tumors, including mutations arising from gene rearrangements, loss of 
heterozygosity (LOH), and promoter CpG hypermethylation, and altered protein 
localization (23, 70, 149).  A summary of reports of ING gene mutations in cancers is 
compiled in Table 1.2. 
 
ING1 in human cancers: Several groups have looked at the expression and mutational 
status of ING genes in a variety of primary tumors and cell lines (see Table 1.2 for 
references).  ING1 expression appeared to be decreased in head and neck squamous cell 
carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), acute lymphoblastic 
lymphoma (ALL), breast cancer, transitional cell carcinoma of the bladder, 
heptatocarcinoma (HCC), ovarian cancer, cancers of the central nervous system,  
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non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer.  In 
support of a role for ING1 in tumor suppression, loss of heterozygosity (LOH) for ING1 
has been occasionally seen in colorectal cancers, pancreatic cancers, HNSCC, and in 
breast cancers.  
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Table 1.2:  Alterations in expression and the mutations found in human cancers for each 
ING gene.  The number of samples; either primary tumors or cell lines, analyzed are 
depicted.  Percentage is based on the number of samples harboring a mutation in an ING 
gene.  Also shown is the position in the ING protein of the mutation and the method used 
to determine the alternation in the ING gene. 
 
1: Associated with shortened survival times and advanced clinical stage.   
2: MSP determined expression due to DNA methylation.   
3: Better survival if nuclear staining for p33 is negative.   
 
Abreviations used: WB, western blot; IHC, Immunohistochemistry; ISH, In situ 
hybridization; qRT-PCR, quantitative real time polymerase chain reaction; SSCP, single 
stranded confirmation polymorphism PCR; and CGH-array, comparative genomic 
hybridization array; MSP, methylation-specific PCR; ESCC, esophageal squamous cell 
carcinoma; HNSCC, head and neck squamous cell carcinoma; ALL, acute lymphocytic 
lymphoma; TCC, transitional cell carcinoma; HCC, hepatocellular carcinoma. 
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Further evidence for a role for ING1 in tumor suppression was provided by reports 
showing that p33ING1b expression was greater in lower grade brain tumors than in high 
grade tumors, indicating a role for ING1 in malignant progression of astrocytomas (207).  
Another report on invasive carcinoma of the breast showed that reduced nuclear 
expression of p33ING1b correlated with larger, less differentiated and more malignant 
tumors that were estrogen receptor and progesterone receptor negative (148). 
Interestingly this study also found that most of these tumors had also lost functional p53. 
ING1 has also been proposed as a candidate tumor suppressor gene in mantle cell 
lymphoma (MCL), as expression of ING1 was decreased in 3 of 5-tested MCL cell lines 
(176, 183).  However, these findings have not been extended to primary tumor samples. 
 
Studies of primary ovarian tumors using methylation-specific PCR found that the 
p33ING1b promoter was methylated and silenced in almost a quarter of all cases (188).  
This was confirmed using bisulfite sequencing and statistically correlated with decreased 
mRNA expression.  Additionally, treatment of ovarian cancer cell lines with 5’-aza-2’-
deoxycytidine, a demethylating drug, caused a dosage dependent increase in ING1 
expression.  However, a different report utilizing cell lines and the COBRA method to 
detect promoter CpG methylation status found no evidence for ING1 promoter 
methylation in mantle cell lymphoma (176).  Further analysis of primary tumors, ING 
expression levels, and promoter methylation is needed to determine the relevance of 
promoter inactivation for loss of ING function in human cancer. 
 
 
 
 
 
42
In contrast, no differences in ING expression levels were observed in recent 
studies of myeloid leukemia (96), or of melanoma (204), contradicting an earlier report of 
increased p33ING1b expression in this cancer (21).  However, the link between mutations 
in ING1 and development of melanoma is strengthened by a report identifying ING1 
mutations in primary tumor samples.  Two p33ING1b PHD domain mutations (R102L and 
N260S) were detected in 20% of tested melanomas (204), and either of these alterations 
proved as detrimental as deletion of the entire PHD domain to the enhancement of 
nucleotide excision repair mediated by p33ING1b in host-cell-reactivation assays and 
radioimmunoassays.  Furthermore, those patients bearing an ING1 codon 102 or 260 
mutation had a reduced 5-year survival rate (50% versus 82%) (24).  These findings 
highlight the importance of the PHD domain in ING1 function and possibly in tumor 
suppression, as loss of NER activity would likely facilitate tumorigenesis.  In agreement 
with this proposal, other reports have indicated the presence of mutations within the PHD 
motif or the NLS of ING1 in melanoma, HNSCC, ESCC, breast cancer, pancreatic 
cancer, and in colon cancer (245). 
 
Surprisingly, increased expression of ING1 was also observed during a study of 
glioblastomas.  However, this overexpression resulted in the mislocalization (and 
presumed inactivation) of ING1 in these samples (219).  Supporting evidence was 
obtained in a recent study comparing normal oral mucosa to oral squamous cell 
carcinoma (OSCC) finding that p33ING1b was either lost or mislocalized to the cytoplasm 
in the tumor cells (241). 
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Other ING proteins in human cancer: Although a majority of the analysis of ING 
proteins in human cancer has centered on ING1, more recent work has begun to examine 
the links between ING2-ING5 in tumorigenesis (see Table 1.2).  Decreased ING2 
expression (but not ING2 mutation) has also been observed in lung cancer, melanoma, 
and in colon cancer (133, 156, 197).  ING2 may have a role in melanoma initiation, since 
reduction of nuclear ING2 expression has been reported in radial growth phase, vertical 
growth phase, and metastatic melanoma compared with dysplastic nevi (133).  However, 
the reduced expression was not associated with tumor stage, subtype, or 5 year survival 
rate (133).  In contrast, reduced ING2 expression was found to be associated with tumor 
progression and shortened survival time in hepatocellular carcinoma (240).  These 
epidemiological studies suggest that ING2 loss or reduction may be important for tumor 
initiation and/or progression (133, 240). 
 
Similar findings were also seen for ING3 in cutaneous melanoma, with reduced 
ING3 expression observed in malignant melanoma compared with dysplastic nevi (225).  
As with ING2, decreased nuclear ING3 was associated with poorer 5 year survival rates 
(225).  Survival rates were 93% for strong nuclear ING3 staining and dropped to 44% for 
patients with negative to moderate nuclear staining.  ING3 expression has also been 
associated with poor overall survival and tumor initiation in head and neck cancers (76), 
and a missense mutation in ING3 codon 20 has been observed in HNSCC (79).   
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ING4 also displays reduced expression levels in glioblastoma (63), HNSCC (77), 
and myeloma (40), and LOH of the ING4 locus has been observed in HNSCC (77) and 
breast cancer (110).  ING4 has also been associated with tumor progression in 
glioblastomas (63) and myeloma (40).  In both cases, decreased ING4 expression was 
associated with higher tumor grade and increased tumor angiogenesis.  In the case of 
myeloma it was also associated with increased expression of interleukin-8 and 
osteopontin (40).  Expression of ING4 was also found to be reduced in malignant 
melanoma compared to dysplastic nevi and was found to be an independent factor for the 
poor prognosis of these patients (125).   
 
Currently the only report linking ING5 to cancer used 16 microsatellite markers to 
report LOH on the long arm of chromosome 2 in samples from patients with oral cancer 
(27).  This report needs to be corroborated with further studies. 
 
In summary, a number of epidemiologic studies have implicated alterations in 
ING expression to the development of a variety of cancers.  However, LOH or specific 
point mutations within ING genes are more rarely observed, and ING mutation or loss is 
not proposed as the molecular basis of a familial cancer syndrome. Thus, although ING 
genes have been demonstrated in vitro and in cell culture assays to impact a number of 
processes that regulate cell cycling, cell transformation, and apoptosis, definitive 
evidence that ING proteins function in vivo to regulate cell growth or to suppress tumor 
formation is lacking. 
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1.8 Aims of this Dissertation 
Multiple lines of evidence generated from in vitro experiments that employ 
transformed cell lines and overexpression or antisense knockout of the ING genes 
indicate that ING proteins are involved in a variety important biological processes, many 
of which are known to be altered in cancer.  These findings have indicated that ING 
proteins function as tumor suppressors, and have further implicated ING proteins as key 
regulators of several different signaling pathways, including p53 and NF-kB.  These 
considerations warrant the development of genetically modified mice bearing alterations 
in ING genes to further explore the role of the ING proteins in development and in the 
regulation of normal and neoplastic cell growth.  Such mouse models might also prove 
useful in future preclinical analysis of diagnostic tests and to assess therapeutic options 
for treating cancer.  Therefore, the main aims of this dissertation were to generate and 
characterize mice deficient for either Ing1 or Ing4, to analyze the effects of Ing deletion 
on spontaneous tumorigenesis in these mice, and to explore the role of Ing1 and Ing4 
proteins in regulating the p53 and NF-kB signaling pathways. 
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CHAPTER II: 
DELETION OF p37Ing1b IN MICE REVEALS A p53-INDEPENDENT 
ROLE FOR Ing1 IN SUPPRESSION OF CELL PROLIFERATION, 
APOPTOSIS, AND TUMORIGENESIS. 
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Forward 
 ING proteins have been proposed to alter chromatin structure and gene 
transcription to regulate numerous aspects of cell physiology, including cell growth, 
senescence, stress-response, apoptosis, and transformation.  ING1, the founding member 
of the Inhibitor of Cell Growth family, encodes p37Ing1, a PHD protein that interacts with 
the p53 tumor suppressor protein and appears to be a critical cofactor in p53-mediated 
regulation of cell growth and apoptosis. In this study, we have generated and analyzed 
p37Ing1-deficient mice and primary cells in order to further explore the role of Ing1 in 
regulation of cell growth and p53 activity. The results demonstrate that endogenous 
levels of p37Ing1 inhibit the proliferation of p53-wildtype and p53-deficient fibroblasts, 
and that p53 functions are unperturbed in p37Ing1–deficient cells.  In addition, loss of 
p37Ing1 induces Bax expression and increases DNA damage-induced apoptosis in primary 
cells and mice irrespective of p53 status.  Finally, p37Ing1 suppresses the formation of 
spontaneous follicular B-cell lymphomas in mice. These results indicate that p53 does not 
require p37Ing1 in order to negatively regulate cell growth and offers genetic proof that 
Ing1 suppresses cell growth and tumorigenesis.  Furthermore, these data reveal that 
p37Ing1 can negatively regulate cell growth and apoptosis in a p53-independent manner. 
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Introduction 
ING1 was initially isolated in a screen to identify genes that were underexpressed 
in transformed versus normal human epithelium (62). Subsequently, ING1 was identified 
as a member of a 5-gene ING family that encode PHD-finger domain proteins conserved 
in yeast and vertebrates (22).   Forced overexpression of ING1 in normal human diploid 
fibroblast cells was found to inhibit cell growth by inducing a G1-phase cell cycle arrest.   
Conversely, downregulation of ING1 in cell lines by antisense RNA increased cell 
proliferation and cell transformation, as assayed by colony formation in soft agar (62, 
67), and inhibited Myc-induced apoptosis (89).  The ability of ING1 to inhibit cell growth 
and promote apoptosis in these various assays indicated that ING1 might function as a 
tumor suppressor. 
 
 The murine Ing1 gene produces several spliced isoforms of Ing1 mRNA that 
generate two distinct Ing1 proteins (238).  The larger 37Kd protein (p37Ing1) contains all 
of the residues present in the smaller 31Kd (p31Ing1) protein, as well as additional 
sequences at the amino terminus that interact with the p53 tumor suppressor protein 
(238). Both mouse p37Ing1 and the human ortholog p33 ING1 have been shown to co-
immunoprecipitate with p53 in transfected cells (60, 238). Furthermore, p33 ING1 has been 
reported to stabilize p53 levels in transfected cells by binding with p53 and blocking 
Mdm2-p53 interactions and by inhibiting hSir2 deacetylation of p53 (60, 106, 123).   
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Functional data linking Ing1 with regulation of p53 activity was provided by transfection 
studies in which forced overexpression of ING1 in cell lines was found to both increase 
cell sensitivity to double strand DNA breaks in a p53-dependent manner (32), and induce 
the expression of certain p53 target genes such as p21 following DNA damage (106).  In 
addition, the ability of exogenous p53 to inhibit cell growth in Balb/c 3T3 cells appears to 
be compromised in cells partially depleted for ING1 by antisense RNA (60). 
 
 These cell-based studies suggest that the negative effects of Ing1 on cell growth 
are mediated through p53.  Furthermore, mutation of ING1 has also been detected in 
human primary tumors and in tumor derived cell lines, further underscoring the 
possibility that ING1 functions as a tumor suppressor (22, 150).  In support of this model, 
mice deleted for Ing1 via gene targeting experiments in ES cells were recently found to 
be smaller in size, have reduced viability following whole body irradiation, and display a 
slight increase in the rate of spontaneous tumor formation relative to wildtype mice, 
particularly in lymphomagenesis (108). However, these Ing1-deficient mouse primary 
fibroblasts displayed little or no differences in replicative lifespan or in sensitivity to 
various forms of genotoxic stress.   Thus, the link between Ing1, p53 activity, and tumor 
suppression remains unclear.  
 
 In order to determine if Ing1 regulates p53 functions in cell growth and in 
tumorigenesis, we generated p37Ing1 -deficient mice by utilizing mouse ES cells bearing a 
gene trap mutation that specifically ablates p37Ing1.   
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Analysis of p37Ing1 deficient mice and mouse embryonic fibroblasts (MEFs) revealed that 
loss of p37Ing1 increased the growth rate of MEFs, providing direct genetic evidence in 
primary cells that the endogenous level of Ing1 negatively regulate cell proliferation.  
However, deletion of p37Ing1 also increased the proliferation of p53-deficient MEFs, 
demonstrating a p53-independent role for p37Ing1 in control of cell growth.  Furthermore, 
loss of p37Ing1 failed to alter numerous other cell characteristics normally governed by 
p53, including the rate of primary cell immortalization, oncogene-induced cell 
senescence, or cell growth arrest following DNA damage by known inducers of p53 
activity. In addition, p37Ing1 deletion did not affect the p53-induced embryonic lethality of 
Mdm2-null mice. These data indicate that p53 remains fully functional in cells lacking 
p37Ing1, indicating that p37Ing1 downregulates cell growth in a p53-independent manner.    
 
Although loss of p37Ing1 did not alter the levels of the pro-apoptotic, p53 response 
gene Puma, p37Ing1 deletion was found to significantly increase Bax gene expression and 
promote apoptosis following DNA damage in thymocytes irrespective of p53 status, 
demonstrating that p37Ing1 also has a p53-independent, pro-survival role in apoptosis.   
While DNA damage-induced apoptosis was upregulated in p37Ing1-deficient primary 
cells, mice lacking p37Ing1 developed spontaneous follicular B cell lymphomas, indicating 
that p37Ing1 functions as a tumor suppressor in vivo.  
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Results 
Generation of p37Ing1-deficient mice 
 A mouse embryonic stem (ES) cell line bearing a retroviral promoter trap inserted 
into one allele of the Ing1 gene was used in standard blastocyst injection experiments to 
generate chimeric mice (237).  DNA sequence analysis of the gene-trapped locus 
revealed that the retrovirus inserted into exon C, the third exon of Ing1 (238) thereby 
interrupting coding of the longer, Ing1b transcript that encodes p37Ing1 (Figure 2.1A).  
Several high-degree chimeric mice were bred with C57Bl/6 mice to generate agouti 
offspring, and genomic DNA was harvested from tail biopsies and analyzed by Southern 
blot hybridization (Figure 2.1B) and PCR (Figure 2.1C) to identify mice that inherited the 
Ing1-targeted allele.  Heterozygous F1 generation mice were intercrossed to obtain mice 
homozygous for the mutant Ing1 allele, which were recovered with normal Mendellian 
frequency.  Similar to a recent report of mice mutated at the Ing1 locus (108), 
homozygous mutant mice weighed approximately 15% less at weaning but were 
otherwise indistinguishable from the Ing1-heterozygous and wildtype littermates.  
Western analysis of Ing1 proteins harvested from the spleen and thymus of wildtype and 
homozygous mutant mice revealed that the homozygous mutant mice retained expression 
of the p31Ing1 protein in the presence (4 Gy whole body)  or absence of DNA damage, but 
displayed loss of p37Ing1 protein (Figure 2.1D).  Thus, retroviral insertion into the Ing1 
locus in the ES cells resulted in a p37Ing1–specific knockout allele. 
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Figure 2.1: Generation of p37Ing1b-deficient mice. A) Schematic of the gene-trapped 
locus showing the gene-trap inserted into exon C.  The trap interrupts the Ing1b message 
isoform and corresponding p37 protein, but encodes the shorter Ing1c isoform and p31 
protein.  B) PCR genotyping of the ES cells and mouse tail biopsies showing the presence 
of the gene-trap.  A 650bp fragment is generated from wildtype Ing1 using primers 1 and 
2 and a 700bp fragment is generated from the targeted Ing1 allele using primers 3 and 4. 
C) A Southern blot strategy using a Bgl II digest and a probe to the common exon was 
used to confirm germ-line transmission of the gene-trap.  The wild-type fragment is ∼8kb 
and the mutant fragment is ∼10kb in length. A non-specific (NS) band corresponding to 
an Ing1 pseudogene present in 129-strain mouse DNA is also observed.  D) To confirm 
that the longer p37Ing1 form was specifically deleted, a western blot was performed using 
an Ing1 antibody that recognizes sequences encoded in the common exon.  The presence 
of the shorter form (p31) and the absence of the longer form (p37) were observed.  
Tubulin was used as a loading control.  Abbreviations used: wt (W), heterozygous (H), 
null (N), kilodalton (KD), and Tar refers to the targeted ES cells. 
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Negative regulation of cell growth by p37Ing1
 We generated primary fibroblasts from wildtype, p37Ing1 heterozygous, and 
p37Ing1 homozygous-deficient embryos to to characterize and compare the growth rates of 
these cells with p53-null MEFs (Figure 2.2A). The results indicate that the proliferation 
rate of p37Ing1-heterozygous MEFs is similar to wildtype MEFs. However, p37Ing1-null 
MEFs proliferate significantly faster than wildtype MEFs, though not as fast as MEFs 
lacking p53.  Although p37Ing1-null MEFs displayed wildtype plating efficiencies under 
normal conditions, these cells showed increased survival and growth relative to wildtype 
MEFs when plated at low density (Figure 2.2B), similar to results obtained with p53-null 
MEFs (86). In order to determine if the downregulation of cell proliferation by p37Ing1 is 
mediated through p53, we bred the p37Ing1 deficient mice with p53-null mice (47) and 
generated p37Ing1/p53- null MEFS.  Analysis of the growth rate of these double-null cells 
revealed that deletion of p37Ing1 enhanced the growth of p53-deficient primary fibroblasts 
(Figure 2.2C), indicating that the increased proliferation rate of p37Ing1-null MEFs was 
not due to alteration of p53 activity in these cells. 
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Figure 2.2: Growth regulation by p37Ing1.  A) Proliferation of p37Ing1- deficient cells. 
Two independent MEF cell lines of p37Ing1-wildtype, p37Ing1-heterozygous, p37Ing1-null, 
or p53-null genotypes were plated in triplicate in 60mm plates and the growth analyzed 
over the course of 7 days.  Statistical analysis between Wt and p37Ing1-heterozygous 
curves shows no significant difference (p<1), but there is statistical difference between 
the Wt and p37Ing1-null curves (p<0.005).  B) Growth of p37Ing1- deficient cells at low 
density. Two lines of either wildtype, p37Ing1-heterozygous, or homozygous genotype 
were seeded at 104 cells per 10cm plate and incubated for 8-12 days before being stained 
with crystal violet.  C) Growth inhibition by p37Ing1 is independent of p53 status.  Three 
MEF cell lines deficient for p53 or for p53 and p37Ing1 were plated in triplicate in 6-well 
plates and counted over a 7-day period.  Wildtype MEFs were also similarly plated as a 
control.  A statistical difference exists between the proliferation rate of p53-null and 
p53/p37Ing1-double null MEFs (p<0.0005).  
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Immortalization of p37Ing1 null MEFs 
 Spontaneous immortalization of MEFs is dependent, in part, on p53 functions. To 
analyze further the role of p37Ing1in cell growth, we performed a modified 3T3 (3T9) cell 
immortalization assay.  MEFs were generated from wildtype, p37Ing1-null, or p53-null 
embryos and passed continuously in culture following a standard protocol (86). In 
agreement with our previous reports (99, 205), p53-null MEFs displayed a rapid rate of 
cell growth throughout the course of the assay relative to wildtype MEFs (Figure 2.3). In 
contrast, p37Ing1 deficient MEFs continued to divide more slowly than p53-null MEFs, 
and never exhibited robust induction of cell growth. Thus, unlike deletion of p53, loss of 
p37Ing1 does not alter the immortalization rate of primary cultured cells. 
 
 
 
 
Figure 2.3:  Immortalization of p37Ing1- deficient cells.  A 3T9 assay was performed 
using two independent MEF cell lines of p37Ing1-wildtype, p37Ing1-null, or p53-null 
MEFs.  
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Ras-induced cell senescence in p37Ing1 deficient MEFs 
 Oncogene-induced stress induces a p53-dependent, replicative senescent 
phenotype in MEFs (57).  To determine if forced expression of an activated ras oncogene 
induces senescence in p37Ing1-deficient fibroblasts, MEFs that were either wildtype, 
p37Ing1-null, or p53-null MEFs were infected with pBABE retrovirus (vector) or with 
pBABE bearing an activated H-ras gene (vector + ras).  After puromycin selection for 72 
hours, the transduced cells were plated at equal densities and scored for cell growth at 
day 6 post-infection.  Vector alone (no ras) had little effect of the growth of MEFs 
regardless of genotype (Figure 2.4). As expected, exogenous ras suppressed the growth 
of wildtype MEFs whereas the growth of p53-null MEFs was not affected by activated 
Ras expression.  Similar to wildtype MEFs, the growth of p37Ing1-null MEFs was 
suppressed following oncogene transduction.  These data indicate that p53-mediated cell 
senescence induced by inappropriate oncogene expression in MEFs is unaffected by the 
presence or absence of p37Ing1.  
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Figure 2.4:  Ras-induced senescence in p37Ing1- deficient cells is unchanged. Triplicate 
experiments of multiple lines each of wild-type, p37Ing1-null, or p53-null MEFs were 
transduced with recombinant virus with or without H-ras, and cells were plated at equal 
densities and counted.  Graph represents the ratio of cell number after 6 days in culture 
versus the cell number at initial plating. 
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Response of p37Ing1 deficient MEFs to DNA damage 
 Induction of double-stranded DNA breaks in MEFs by treatment with ionizing 
radiation (IR) or doxorubicin induces stabilization of p53 and subsequent inhibition of 
cell growth.  In order to determine if loss of p37Ing1 alters the ability of p53 to arrest cells 
following DNA damage, wildtype, p37Ing1-null, or p53-null MEFs were synchronized in 
their cycling and mock-treated or treated with either 8Gy IR or 0.3 ug/ml doxorubicin. 
The results of this experiment (Figure 2.5) are expressed as the ratio of treated cells in S 
phase to untreated cells in S phase.  As expected, wildtype MEFs treated with either IR or 
doxorubicin had a large reduction in the numbers of cells present in the S phase of the 
cell cycle, whereas p53-null MEFs displayed far less cell growth inhibition following 
treatment with IR or doxorubicin.  However, MEFs lacking p37Ing1 were 
indistinguishable from wildtype MEFs in their response to these DNA damaging agents, 
indicating that the ability of p53 to induce cell growth arrest in response to DNA double-
strand breaks is unaltered in p37Ing1 -null MEFs.  In addition, wildtype, p37Ing1-null, or 
p53-null MEFs were treated with 60 Joules/m2 UVC and assayed for a damage-induced 
reduction in S phase.  Although UVC treatment strongly inhibits cell growth in wildtype 
MEFs, this effect requires functional JNK signaling and is not p53-dependent in MEFs 
(6, 212). Similar to wildtype and p53-deficient MEFS, cells lacking p37Ing1 were also 
growth-inhibited by UVC treatment. 
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Figure 2.5:  Cell cycle arrest is normal in p37Ing1-deficient MEFs.  Absence of p37Ing1 
does not alter cell cycle arrest due to DNA damaging agents.  Three lines each of wt, 
p37Ing1-null, or p53-null MEFs were plated in duplicate and synchronized in their growth 
prior to mock-treatment or treatment with doxorubicin, IR, or UVC.  Cells were stained 
with BrdU and PI, and analyzed by FACS.  Results are expressed as a ratio of treated 
cells in S-phase versus untreated cells in S-phase.   
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Deletion of p37Ing1does not alter p53-induced lethality in Mdm2-null mice 
 Mdm2 is a well-established regulator of p53 activity and p53 stability in cells (10, 
113), and mice deleted for Mdm2 display an early embryonic lethal phenotype that is 
rescued by deletion of p53 (98).  Recently, the amino terminus of p33ING1, the human 
orthologue of p37Ing1, has been found to complex with the p19-ARF tumor suppressor 
(119).  In cells, p19-ARF regulates p53 activity by binding with Mdm2 and inhibiting 
Mdm2-ubiquitination of p53 (132).  Interaction of p19-ARF and p33ING1 suggests that 
Ing1 may play a role in p19-Mdm2-p53 signaling, and Ing1 has been previously proposed 
to alter p53 stability possibly by interfering with Mdm2-p53 interactions (123). 
 
In order to explore whether deletion of p37Ing1 alters p53 activity and Mdm2-p53 
signaling during development, we bred p37Ing1-null mice with mice bearing a mutated 
Mdm2 allele (98).  Intercrosses of the resulting Mdm2+/-, p37Ing1-null mice were 
performed, and DNA isolated from the offspring (n= 40) of these matings were 
genotyped to determine Mdm2 status. This experiment failed to generate any Mdm2-null 
mice (expected n= 10), indicating that the embryonic lethality induced by p53 in the 
absence of Mdm2 was not dependent upon p37Ing1 function.  This result is in keeping 
with our finding that p37Ing1-null MEFs are not compromised in p53-mediated cell 
growth arrest following DNA damage.  
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Anti-apoptotic role of p37Ing1 in DNA damage response 
 MEFs transduced with adenovirus E1A undergo p53-induced apoptosis following 
treatment with doxorubicin (6).  To determine if p53 apoptosis was compromised in 
p37Ing1-null cells, MEFs that were wildtype, p53-null or p37Ing1-null were infected with a 
recombinant retrovirus encoding both the adenovirus E1A gene and a puromycin 
resistance gene.  Following a two-day selection in puromycin, E1A-transduced MEFs 
were recovered, plated in triplicate at equal cell density, and mock-treated or treated with 
0.25 μg/ml doxorubicin for 24 hours.  Cell viability was scored by trypan blue exclusion 
(Figure 2.6A).  As expected, wildtype MEFs displayed reduced cell viability upon 
treatment with doxorubicin (35.3 + 4% viable cells), whereas p53-null MEFs were much 
less susceptible to treatment with this DNA damaging agent (64.7 + 4% cell viability). 
Surprisingly, p37Ing1-null MEFs showed far greater sensitivity to doxorubicin-induced 
death (9.7 + 1% viable cells) than wildtype cells (Figure 2.6A).  To confirm that cell 
death was due to apoptosis, the experiment was repeated and the percentage of cells 
undergoing apoptosis was determined by FACS analysis of the sub-G1 DNA content for 
each genotype (Figure 2.6B).  As before, p53-null MEFs were compromised in their 
ability to undergo apoptosis relative to wildtype MEFs, whereas p37Ing1-null MEFs were 
highly sensitive to the effects of doxorubicin with most of the p37Ing1-null MEFs 
undergoing apoptosis.   
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Figure 2.6:  Apoptosis is elevated in p37Ing1-deficient MEFs transduced with E1A.  A) 
Trypan blue exclusion of wt, p37Ing1b null, and p53 null E1A-transduced MEFs treated 
with doxorubicin.  Graph shows and average and standard deviation of three independent 
experiments.  B) Triplicate experiments of multiple lines of E1A-transduced MEFs were 
mock-treated or treated with doxorubicin for 24 hours.  Cell viability was determined by 
staining with propidium iodine (PI) before being analyzed by FACS.  Graphs show a 
representative result and sub-G1 content (mean plus standard deviation) derived from 3 
separate experiments.  
 
 
 
 
 
 
63
 In order to further explore aberrant apoptosis in p37Ing1-null mice, we isolated 
thymocytes from 6 week-old wildtype, p53-null or p37Ing1-null mice.  The total number 
of thymocytes recovered from the thymii of p37Ing1–null mice was reduced 2-fold relative 
to the cell numbers recovered from wildtype mice, whereas no differences were observed 
in cellularity of the spleen or peripheral lymph nodes in these mice (data not shown).  
However, wildtype, p53-null and p37Ing1-null thymocytes displayed similar kinetics of 
cell death when plated in culture (Figure 2.7), suggesting that the spontaneous, non-
DNA-damage induced thymocyte death that occurs under these culture conditions is 
independent of either p53 or p37Ing1 status.  
 
 
 
Figure 2.7:  Apoptosis is increased in p37Ing1-deficient thymocytes.  Spontaneous 
apoptosis is unchanged in p37Ing1-deficient thymocytes.  Thymocytes were isolated from 
two wildtype, p37Ing1-null, or p53-null mice, plated in triplicate, and cultured for 4 days 
ex vivo.  Cells were harvested at 24-hour intervals, fixed in 70% ethanol, and stained with 
PI and analyzed by FACS. 
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 Mouse immature thymocytes (CD4/8 double positive T cells) will undergo p53-
dependent apoptosis in response to ionizing radiation (38, 131).  To determine if DNA-
damage induced cell death is upregulated in thymocytes lacking p37Ing1, three 4-5 week 
old mice that were either wildtype, p53-null, p37Ing1-null, or both p53 and p37Ing1-null 
were whole-body treated with 10Gy ionizing radiation and thymocytes were recovered at 
8 hours post-treatment from these mice and from age-matched, non-treated mice.  FACS 
analysis of thymocyte populations stained with CD4 and CD8 antibodies revealed that 
45.5 + 3.1% of the wildtype CD4+/8+ double positive (DP) cells survived IR treatment, 
whereas only 31.4 + 2.1% of the non-damaged levels of p37Ing1-null DP T cells were 
recovered after IR treatment.  As expected, far more p53-null DP T cells survived IR 
damage (78.5 + 1.4%). However, deletion of p37Ing1 also significantly reduced the 
survival of p53-null DP T cells (56.3 + 0.3%).  These data suggest that p37Ing1 plays a 
pro-survival role in thymocytes following DNA damage irrespective of p53 status.  To 
confirm that p37Ing1 deletion alters thymocyte apoptosis, thymocytes were harvested from 
wildtype, p53-null, p37Ing1-null, or both p53/p37Ing1-double null mice that were either 
untreated or treated with 2.5Gy of ionizing radiation. Cells were collected four hours 
after treatment or mock treatment and analyzed by PI staining and FACS to measure sub-
G1 DNA content (Figure 2.8).  In agreement with the findings of the previous E1A-MEF 
experiments, deletion of p37Ing1 led to more DNA damage induced apoptosis in wildtype 
thymoctes.  
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Furthermore, although deletion of p53 correlated with reduced thymocyte apoptosis 
following IR damage, loss of p37Ing1 also resulted in increased apoptosis following DNA 
damage in p53-null cells, indicating that p37Ing1 has a p53-independent, anti-apoptotic 
role in thymocytes. 
 
 
 
Figure 2.8:  Apoptosis is altered in p37Ing1-deficient thymocytes.  Thymocytes were 
isolated from wildtype, p37Ing1-null, p53-null, or p53/p37Ing1-double null mice and either 
mock-treated or irradiated with 2.5 Gy of IR, fixed in 70% ethanol after 4 hours, and 
stained with PI for FACS.  Graph shows the average of three separate experiments with 
standard deviations (error bars) for each genotype.  Statistical analysis between wt and 
p37Ing1-null or p53-null and p53/p37Ing1-double null thymocytes showed that the 
difference in apoptosis is statistically significant (p<0.005 in both cases).   
 
 To determine if increased apoptosis in p37Ing1-null thymocytes reflected 
upregulated expression of the pro-apoptotic, p53-target gene Puma, an important 
regulator of DNA damage induced apoptosis in lymphocytes and in MEFs (29), the levels 
of Puma RNA transcripts were measured by quantitative PCR before and after DNA 
damage.  
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Total RNA was harvested at 4 hours post-treatment from the thymus, spleen, liver, and 
brain of mock-treated or IR-treated (10 Gy) mice that were either wildtype, p53-null, 
p37Ing1-null, or p53/p37Ing1-double null, and real-time PCR analysis was performed to 
determine the expression levels. As expected, Puma expression was increased in the 
thymus of wildtype mice in response to DNA damage, but not in mice lacking functional 
p53 (Figure 2.9A). However, there was no significant difference in the levels of Puma 
induction in thymus of wildtype mice and p37Ing1-null mice, or in p53-null mice in the 
presence or absence of p37Ing1. 
 
 Bax is also a critical inducer of apoptosis in T cells and in other cell types, but is 
not thought to be an important transcriptional target of p53 in the mouse (36, 37).   In 
keeping with this model, Bax mRNA levels were only slightly upregulated in wildtype 
thymus, spleen and liver following DNA damage, and were unchanged or slightly 
decreased following IR treatment in p53-null samples.   In contrast, Bax mRNA levels 
were induced after DNA damage approximately 8-10 fold in both p37Ing1 null thymus and 
in p37Ing1/p53-double null thymus (Figure 2.9B).  Induction of Bax expression following 
DNA damage was also elevated 4-6 fold in the spleen, liver, and brain of p37Ing1–null 
mice, and approximately 2 fold in these tissues in p37Ing1–null mice lacking p53.  In 
addition, levels of Bcl-2 RNA, an anti-apoptotic gene, were not significantly altered in 
these tissues by the presence or absence of either p37Ing1 or p53 (data not shown). 
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 These data suggest that loss of p37Ing1 does not promote thymocyte apoptosis by 
altering p53-transactivation of Puma following DNA damage.  Instead, loss of p37Ing1 
leads to upregulated Bax gene expression following DNA damage of thymocytes 
irrespective of p53 status.  
 
 
 
Figure 2.9:  Quantitative real-time PCR for Puma and Bax was done using p37Ing1-
deficient tissues.  A) and B) Quantitative real-time PCR was performed with primers to 
Puma (A) or Bax (B) on tissues harvested from mice that were either mock-treated or 
whole-body treated with 10Gy of IR and harvested 4 hours later.  Graphs show the 
average values (relative fold induction) and standard deviations (error bars) of three mice 
for each genotype.  The difference in Bax expression between wt and p37Ing1-null for 
thymus and spleen is statistically significant (p<0.05), but not for brain and liver 
(p≥0.05).  Statistical analysis of the difference in Bax expression between p53-null and 
p53/p37Ing1-double null tissues indicates a significant difference for thymus, spleen, and 
brain (p<0.05), but not liver (p≥0.05). 
 
Tumorigenesis in p37Ing1-deficient mice 
 In order to determine if mice specifically deleted for p37Ing1 are tumor prone, we 
generated cohorts of wildtype mice, p37Ing1- heterozygous (p37Ing1 +/-) mice, and p37Ing1-
null (p37Ing1 -/-) mice and monitored these mice for the development of spontaneous 
tumors.   
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Approximately 40% of the p37Ing1 +/- mice and half of the p37Ing1 -/- mice formed tumors 
by 22 months of age, whereas spontaneous tumorigenesis was not observed in the 
wildtype (C57Bl/6 x 129-SV hybrid) mice during this time (Figure 2.10A).  All of the 
tumors arose in the spleen or peripheral lymph nodes in these mice and were classified as 
follicular B cell lymphomas.  Staining of tumor tissues with antibody against B220 and 
CD3 confirmed that these tumors originated in the B cell compartment (Figure 2.10B) 
and not in T cells.  Thus, although deletion of p37Ing1 does not alter p53 growth control 
and greatly upregulates apoptosis in response to DNA damage, p37Ing1 clearly functions 
as a tumor suppressor in B cells in mice. 
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Figure 2.10:  Tumorigenesis in mice deficient for p37Ing1.  A) Kaplan-Meier survival 
curves of cohorts of wildtype, p37Ing1-heterozygous, or p37Ing1- null mice.  Mice that were 
either moribund or reached 22 months of age were sacrificed for necropsy and fixed in 
10% phosphate-buffered formalin.  The rate of tumor incidence between wt and either 
p37Ing1-heterozygous or p37Ing1- null mice is statistically significant (p<0.005 or p<0.05, 
respectively).  B) Tumors arising in mice were paraffin embedded and stained for 
hematoxylin and eosin (H&E) for pathological analysis.  Tumor sections were also 
stained with either B220 or CD3 antibodies to determine tissue of tumor origin. 
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Discussion 
 ING family members are highly-conserved, plant homeodomain (PHD)-
containing proteins that are linked to chromatin remodeling and transcriptional regulation 
through their association with histone acetyl transferase (HAT) and histone deacetylase 
(HDAC) complexes (22, 49, 56, 153).  Previous studies have implicated Ing1 (or human 
ING1) as an important regulator of numerous aspects of mammalian cell physiology, 
including cell growth, apoptosis, senescence, and tumorigenesis (22). The Ing1 gene 
encodes for three alternatively spliced isoforms of Ing1 message: Ing1a and Ing1c encode 
a p31kDa protein and Ing1b encodes for a 37kDa protein in mice (p33 kDa in human). 
Forced Ing1b overexpression or antisense RNA knockdown experiments in cultured cells 
have indicated that p37Ing1 (or p33ING) and p53 co-immunoprecipitate with one another 
and can function in a synergistic manner to inhibit cell growth or promote apoptosis 
following DNA damage (60, 106, 238). Furthermore, some ING proteins, including 
p33ING, have been proposed to regulate cellular p53 levels by modifying p53 interactions 
with components of the p19-Mdm2-p53 signaling pathway (22, 123). In addition to 
altering p53 activity, transfection experiments have also suggested possible p53-
independent roles for ING1b in regulation of cell proliferation and apoptosis (69, 89, 
214). 
 
 In this study, we generated p37Ing1-deficient mice and primary cells in order to 
examine the role of this p53-binding protein in the regulation of cell growth, cell death, 
and tumorigenesis.   
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Specific deletion of p37Ing1 in MEFs increases the rate of cell proliferation and growth at 
low plating densities, confirming that physiological levels of an ING protein can function 
to inhibit cell growth in primary cells.  However, this regulation does not appear to 
involve p53, as deletion of p37Ing1 also increases the proliferation of MEFs lacking p53.  
The increase in proliferation seen in the p37Ing1 null cells could be due to the observed 
inverse relationship between p37Ing1 and cyclin B1 expression (206), but this possibility 
needs to be validated.  Furthermore, p37Ing1-deficient MEFs fail to exhibit perturbation of 
other cell growth parameters governed by p53, including spontaneous cell 
immortalization, oncogene-induced senescence, or cell cycle arrest following DNA 
damage.  In addition, deletion of p37Ing1 failed to rescue the p53-dependent embryonic 
lethality seen in Mdm2-null mice, offering further support that loss of p37Ing1 does not 
appear to compromise p53 activities in cells or in mice. 
 
 Human ING1b (p33ING1) has been proposed previously to play a pro-apoptotic 
role in fibroblasts (89, 185). In contrast, analysis of apoptosis in p37Ing1-deficient MEFs 
indicates that physiologic levels of p37Ing1 strongly inhibit apoptosis in these cells 
following DNA damage.  To confirm a pro-survival role for p37Ing1 following DNA 
damage, we analyzed IR-induced apoptosis in primary thymocytes and in thymus tissue 
in vivo. As expected, apoptosis was decreased in cells lacking p53 following DNA 
damage.  However, apoptosis was increased in thymocytes both in vitro and in vivo in 
p37Ing1-deficient cells, in keeping with our previous results in primary fibroblasts.  
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Notably, apoptosis was dramatically increased in thymocytes isolated from both p37Ing1-
deficient mice and from p37Ing1/p53 -double null mice following DNA damage.   
Thus, in contrast to the pro-apoptotic role of p53 in these cells, p37Ing1 plays an anti-
apoptotic role in thymocytes following DNA damage that is clearly p53-independent. 
 
 Puma is a p53 transcriptional target validated in vivo as important regulator of 
apoptosis following DNA damage (29). In thymocytes, p53-mediated apoptosis is 
governed primarily through Puma activation, since mice deleted for either Puma or p53 
are equally deficient in IR-induced thymocyte apoptosis.  However, Puma expression was 
equally upregulated in wildtype and p37Ing1–null thymocytes following DNA damage, 
further supporting a p53-independent role for p37Ing1 in suppression of apoptosis.   
 
Bax, another critical regulator of mitochondrial-associated apoptosis, functions by 
altering permeabilization of the mitochondrial outer membrane. Deletion of p37Ing1 
dramatically increased upregulation of Bax expression in vivo in both wildtype and p53-
null thymocytes following DNA damage.  Loss of p37Ing1 also upregulated Bax levels to 
a lesser extent in spleen, liver, and brain tissue. Increased levels of Bax induction in 
p37Ing1-deficient mice following DNA damage occurred independent of p53 status in all 
tissues, confirming a p53-independent role for p37Ing1 in suppressing Bax expression 
following DNA damage. 
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 The results of our study indicate that p37Ing1 suppresses cell proliferation in the 
presence or absence of p53, and does not alter p53-mediated cell growth arrest following 
DNA damage.  In addition, p37Ing1 negatively regulates Bax levels in vivo and functions 
as a pro-survival molecule following DNA damage in thymocytes regardless of p53 
status.  These data suggest that p37Ing1 might also suppress tumor formation in a p53-
independent manner.  Interestingly, all of the tumors that arose in the p37Ing1 deficient 
colonies were classified as follicular B cell lymphoma.  This tumor type is rarely 
observed in p53-null mice (47), which present mainly with thymic lymphomas and 
osteosarcomas, offering further support that p53 and p37Ing1 may suppress tumorigenesis 
through different mechanistic pathways.  Furthermore, while there is a significant 
acceleration of tumorigenesis in mice haploinsufficient or deleted for p31Ing1, the onset of 
tumors in p31Ing1 heterozygous or homozygous null mice is similar, suggesting that any 
reduction in p31Ing1 levels might promote spontaneous tumor formation.  This would be 
consistent with observations from human cancers, where ING gene expression is often 
reduced but not completely absent (70). 
 
 Recently, mice lacking both p37Ing1 and p31Ing1 have been analyzed (11). The 
p37Ing1/p31Ing1 -deficient mice undergo normal development, but have reduced body size 
and present with spontaneous tumors later in life.  In addition, MEFs derived from 
p37Ing1/p31Ing1 -deficient mice display little or no changes in cell cycling after treatment 
with taxol or other DNA damaging agents.  
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As these characteristics are also observed in p37Ing1-deficient mice, it is possible that loss 
of p37Ing1 is the underlying cause of the defects observed in the p37Ing1/p31Ing1 -deficient 
mice and cells.  However, in addition to B cell lymphomas, histiocytic sarcomas and 
myeloid leukemias were also observed in p37Ing1/p31Ing1 -deficient mice, suggesting that 
the p31Ing1 protein may also have unique tumor suppressing properties.  Interestingly, 
expression of p31Ing1 appears slightly elevated in mice lacking the p37Ing1 isoform. 
Therefore, it is also possible that upregulation of p31Ing1 may contribute in some way to 
the increased proliferation and DNA damage induced apoptosis observed in p37Ing1 -
ablated cells and mice.  However, any contribution of increased p31Ing1 levels to the 
phenotype of p37Ing1-deficient mice and cells must also be p53-independent. 
 
 The results of this study demonstrate a p53-independent role for p37Ing1 in 
negative regulation of cell proliferation and apoptosis and highlights a role for p37Ing1 in 
suppression of B-cell lymphomagenesis. Furthermore, the data indicate that loss of 
p37Ing1 correlates with increased Bax expression in thymocytes following DNA damage.  
Although upregulation of Bax has been found to also increase cell proliferation in some 
settings (18, 66), it is possible that the increased apoptosis observed in p37Ing1 null thymii 
might prevent tumor formation in this tissue.  Further work will be needed to better 
characterize the role of Bax in p37Ing1 regulation of cell proliferation, apoptosis, and B 
cells lymphomagenesis. 
 
 
 
 
 
 
75
Materials and Methods 
Generation of p37Ing1b–deficient mice:  
 Mouse (129 strain) ES cells (Omnibank no. OST206270, Lexicon Genetics) 
containing a retroviral promoter gene trap inserted into one allele of Ing1 were used to 
generate chimeric mice, which were bred to generate p37Ing1-heterozygous mice and 
subsequent p37Ing1-homozygous mice.  Mice were genotyped by PCR analysis of 
genomic DNA using the following primer sequences: wildtype allele- ING1g6673SN: 5’- 
TCCCCCGTGGAATGTCCTTATC–3’, ING1g7259ASN: 5’- 
CTGCCAACAGTAGTTCTGAGCAAG –3’; targeted allele- ING1gLTR: 5’-
AAATGGCGTTACTTAAGCTAGCTTGC –3’, INGg1874ASN 5' - 
CTTGTGGAGAAAAATGCC - 3'.  A Southern blot strategy using a Bgl II digest of 
genomic DNA and a probe to the p31/p37Ing1- common exon was used to confirm the 
PCR genotyping results.  Ing1b null mice were crossed to Mdm2 +/- or p53-null mice 
and genotyped as described previously (47, 98) .  All mice were maintained and used in 
accordance with both federal guidelines and the University of Massachusetts Animal 
Care and Use Committee. 
 
Cell culture and proliferation assay. 
 Mouse embryonic fibroblasts (MEFs) were generated from E13.5 day embryos as 
described previously (210).  All subsequent studies were conducted using low passage 
embryonic fibroblasts (pass 2-pass 4), maintained in a 370C, 5% CO2 incubator in  
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Dulbecco’s modified Eagles medium (DMEM) supplemented with 10% fetal bovine 
serum, penicillin, and streptomycin (MEF media).  To determine the rates of cell 
proliferation, multiple lines of wildtype, p53-null, p37Ing1 -heterozygous, p37Ing1-null, or 
p37Ing1/p53-double null MEFs were seeded at 2 x 105 cells per 60mm plate or 1 x 105 
cells per well of a 6-well plate.  Triplicate plates of each line were harvested and counted 
every 24 hours using a Z1 Coulter Particle Counter (Beckman Couture, Miami, FL).   
Duplicate gelatinized 10 cm plates with 10,000 cells per plate were seeded in MEF media 
for each genotype to assay for cell survival and growth at low plating density. At 8-12 
days post-plating, the cells were fixed with methanol and stained with 0.1% crystal violet 
to visualize colony formation.  
  
Cell immortalization assay: 
 A 3T9 assay was performed as described (86) to examine the rate of spontaneous 
immortalization of wildtype, p37Ing1-null, or p53-null MEFs.  Briefly, 3x106 cells were 
plated into MEF media on 10cm plates every three days.  A total of 3 plates (9x106 cells) 
were maintained for two separate lines of fibroblasts for each genotype. Triplicate plates 
for each line were trypsinized prior to counting and replating at a density of 3x106 cells 
per 10cm plate every three days. 
 
Cell senescence assay: 
 MEFs were transduced with a recombinant Ras retrovirus  as described previously 
(57) and plated at 2 x 105 cells per 60 mm plate.   
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Triplicate wells of each of two lines of cells per genotype were harvested and counted 
every 48 hours following initial plating using a Z1 Coulter Particle Counter (Beckman 
Couture, Miami, FL).  Data was expressed as a ratio of the cell number after six days in 
culture versus the cell number at initial plating. 
 
 
Cell growth arrest studies: 
 MEFs from three independent lines of each genotype were seeded onto 10cm 
plates at a density of 8x105 cells per plate in 0.1% fetal bovine serum for three days.  
Cells were then fed with media supplemented with 10% serum for 4 hours, and the 
cultures left untreated or exposed either to 8 Grays γ-radiation in a cesium irradiator, to 
300 ng/ml doxorubicin (Sigma-Aldrich, St. Louis, MO), or to 60 Joules/cm2 UVC in a 
UV-crosslinker (Stratagene, Cedar Creek, TX).  At 15 hours post-treatment, the MEFs 
were pulse labeled with 60uM bromodeoxyuridine (BrdU) for 3 hours, harvested by 
trypsinization into phosphate-buffered saline (PBS), and fixed in 70% ethanol overnight 
at 4oC.  Flow cytometric analysis of DNA synthesis and total DNA content was 
performed by the UMMS FACS Core using an anti-BrdU antibody, propidium iodide 
(PI) staining, and Flowjo software.  Data is presented as a ratio of percentage of cells in S 
phase for treated versus untreated cells.  
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Apoptosis studies: 
 MEFs transduced with a recombinant retrovirus encoding the Adenovirus E1A 
gene (17) were plated at 106 cells per 10cm plate and treated with 0.3ug/mL of 
doxorubicin for 24 hours.  Adherent and non-adherent cells were collected by 
trypsinization and assayed either for trypan blue exclusion or for PI staining by FACS 
analysis. Wildtype, p37Ing1-heterozygous, p37Ing1-null, or p53-null mice that were 4-6 
weeks old were whole-body irradiated with 10Gy of ionizing radiation (IR), and thymii 
harvested at 12 hours post-IR.  Thymii were ground between frosted glass slides to make 
single cell suspensions, and cells were assayed for viability by trypan blue exclusion.  
Approximately 106 thymocytes were stained with CD4-phycocyanin (BD Pharmingen, 
diluted 1/250) and CD8-allophycocyanin (BD Pharmingen, diluted 1/100) for 30 minutes 
prior to FACS analysis.  For spontaneous apoptosis experiments, single cell suspensions 
of thymocytes were plated in RPMI media with 5% fetal calf serum at 106 cells per 60 
mm plate and incubated at 37oC, 5% CO2 for 96 hours.  Plates were harvested, fixed in 
70% ethanol, PI-stained, and analyzed by FACS.  Ex vivo thymocyte apoptosis 
experiments were performed by plating 106 thymocytes onto 60mm plates in RPMI 
media with 5% fetal calf serum and either mock-treating or irradiating the plates with 2.5 
Gy of IR.  After 4 hours, cells were harvested, stained with PI, and FACS analyzed. 
 
Quantitative real-time RT-PCR (QRT-PCR): 
 Relative levels of mRNA expression were analyzed by QRT-PCR as described 
previously (136).    
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cDNA was first generated from RNA extracted from whole mouse tissue using Invitrogen 
Superscript first-strand synthesis system for RT-PCR.  The following primer sequences 
(shown 5’ to 3’) were used in the PCR reactions: Bcl-2: 
CTCGTCGCTACCGTCGTGACTTCG and GTGGCCCAGGTATGCACCCAG, Puma: 
CCTGGAGGGTCATGTACAATCT and TGCTACATGGTGCAGAAAAAGT, and 
Bax: CTGAGCTGACCTTGG and GACTCCAGCCACAAA.  All samples were 
normalized to EF1α levels present in each tissue as described previously (136). 
 
Tumor Assays: 
 A tumor cohort was established for p37Ing1-heterozygous and p37Ing1-homozygous 
null mice and aged for 22 months. Moribund mice or those that reached 22 months of age 
were sacrificed for necropsy, and select tissues harvested for DNA, RNA, and protein.  
A portion of each tissue was fixed in 10% phosphate-buffered formalin, paraffin 
embedded, and stained with eosin and hematoxylin by the UMMS Histology Core. 
Tumors were classified by morphology and by immunostaining using antibodies against 
surface antigens B220 (BD Pharmingen, diluted 1/50) or CD-3 (DAKO, diluted 1/400). 
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CHAPTER III: 
P37ING1B REGULATES B CELL PROLIFERATION AND 
COOPERATES WITH P53 TO SUPPRESS DIFFUSE LARGE B 
CELL LYMPHOMAGENESIS. 
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Foreword 
The Inhibitor of Growth (ING) gene family encodes structurally related proteins 
that alter chromatin to regulate gene expression and cell growth. The initial member, 
ING1, has also been proposed to function as a tumor suppressor in human cancer based 
upon its ability to suppress cell growth and transformation in vitro. Mouse Ing1 produces 
two proteins (p31 and p37) from differentially spliced transcripts. We have recently 
generated p37Ing1b-null mice and observed spontaneous follicular B cell 
lymphomagenesis in this model to demonstrate that ING proteins can function in vivo as 
tumor suppressors.  In this present report, we examine the role of p37Ing1b in the 
regulation of B cell growth and explore the relationship between p37Ing1b and p53-
mediated tumor suppression.  Our results indicate that p37Ing1b inhibits the proliferation of 
B cells and follicular B cells regardless of p53 status, and loss of p53 greatly accelerates 
the rate of B-cell lymphomagenesis in p37Ing1b-null mice. However, in contrast to the 
highly penetrant follicular B-cell lymphomas observed in p37Ing1b-null mice, mice lacking 
both p37Ing1b and p53 typically present with aggressive diffuse large B-cell lymphomas 
(DLBL). Analysis of marker gene expression in p37Ing1b/p53 null tumors indicates that 
the double-null mice develop both non-germinal center and germinal center B cell-like 
DLBL, and also documents upregulation of NF-κB activity in p37Ing1b/p53-null B cells 
and B cell tumors. These results confirm that p53 mutation is an important mechanistic 
step in the formation of diffuse large B-cell lymphomas and reveals a p53-independent 
role for Ing1b in suppressing B cell tumorigenesis. 
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Introduction 
Follicular B-cell lymphoma (FL) and diffuse large B-cell lymphoma (DLBL) 
account for approximately half of all malignant, non-Hodgkin lymphomas in adults (90, 
128, 147).  Patients with FL typically display microscopic accumulations (follicles) of 
CD45R/B220+ B-cells in lymph nodes.  The median survival time for FL patients is 8 to 
10 years with a variable disease course that is usually protracted with multiple relapses 
after treatment (90, 91).  Eventually, the tumor becomes resistant to chemotherapy and 
can undergo transformation to a more aggressive phase that is often fatal to the patient.  
In contrast, diffuse large B-cell lymphoma (DLBL) is a more aggressive type of 
lymphoma, but with a more varied clinical course (2, 93).  Patients with DLBL display 
large, CD45R/B220+ lymphocytes in their tumor masses and a relatively high frequency 
of widespread organ involvement.  DLBL can arise either de novo from mature germinal 
center B-cells or via transformation from a less aggressive B cell lymphoma, such as FL 
(5).  Although the disease responds initially to chemotherapy, a durable remission occurs 
in fewer than half of treated DLBL patients. 
 
Several groups have used either cDNA microarrays or immunohistochemistry to 
divide DLBL into three subgroups with prognostic significance; germinal center B-cell 
like (GCB), activated B-cell-like (ABC), or type 3 expression profile (4, 138).  The 
expression of CD10, BCL-6, and IRF-4 (MUM1) are used to differentiate the GCB from 
ABC subtypes.  Germinal center B-cell-like DLBL usually expresses CD10, but can also 
have a CD10-, BCL-6+, IRF-4- signature (83).   
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This subgroup has the best prognosis with 60% of patients surviving for 5 years or more 
(130).  Activated B-cell-like DLBL can have several different expression signatures, such 
as CD10-, BCL-6-, or CD10-, BCL-6+, IRF-4+.  ABC-DLBL has a less favorable 
prognosis with only about 35% of patients survivng to 5 years (130).  The third subgroup 
of DLBL encompasses those cases that do not express genes characteristic of either the 
ABC or GCB types.  It also has a poor prognosis similar to ABC-DLBL, but is less well 
studied (45). 
 
Despite the morphologic heterogeneity of human B cell lymphomas, a number of 
common genetic alterations have been observed. The most prevalent is a t(14;18) 
translocation seen in human FL, which results in BCL-2 overexpression and protection of 
cells from apoptosis.  Since the t(14:18) translocation is also detected in healthy human 
B-cells, Bcl-2 overexpression is thought to be necessary but not sufficient to induce FL.  
Furthermore, mice harboring an Eµ promoter-Bcl-2 transgene fail to develop spontaneous 
lymphoma (11), and overexpression of BCL-2 is not observed in all human FL.  These 
data suggest that an alternative pro-survival mechanism may exist in these tumors.  In 
support of this finding, overexpression of MCL-1 is also detected in human B cell 
lymphomas (137).  MCL-1 is an antiapoptotic BCL-2 family member required for 
survival of both T and B-cells (157), and MCL-1 transgenic mice develop widely 
disseminated B-cell lymphomas displaying a variety of histological subtypes, including 
FL and DLBL (244).   
 
 
 
 
84
In addition, BCL-6, a critical regulator of the germinal center (GC) response wherein B-
cells undergo antigen-driven somatic hypermutation in order to generate high affinity 
antibodies, is another pro-survival BCL-2 family member often dysregulated in B cell 
lymphoma. Chromosomal translocations involving BCL-6 have been observed in 15-40% 
of human DLBL and 5-10% of FL cases (179), and transgenic mice expressing 
exogenous Bcl-6 in B-cells developed a GC B cell-like subtype of DLBL (26).  
Collectively, these findings support a role for overexpression of various BCL-2 family 
members in the pathogenesis of B cell lymphomas. 
 
 Mutations in the p53 tumor suppressor gene have been observed in many types of 
human lymphomas, and often correlate with a poor patient prognosis.  Furthermore, 
mutations in p53 have been proposed to play a role in the transformation of FL to a more 
aggressive DLBL (94, 129, 181).  However, recent work suggests that p53 may have a 
limited role in the transformation of FL to DLBL (43), and mice either deficient for p53 
or bearing a transgene encoding the p53-inhibitor Mdm2 do not develop FL or DLBL.  
Rather, these mouse models develop CD4+/CD8+ T cell lymphomas, B220+ marginal 
zone B cell lymphomas, or mixed lineage T cell and B cell lymphomas (85, 97, 224, 
228). Thus, the precise role of p53 in suppressing the formation or transformation of FL 
and DLBL is unclear. 
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 Recently, studies of Ing1-mutated mice have revealed a role for ING proteins in 
suppressing B cell lymphomagenesis (39, 108).  ING1, a member of the Inhibitor of 
Growth gene family, has been proposed to regulate a number of biological processes, 
including nucleotide excision repair, chromatin remodeling, proliferation, apoptosis, and 
senescence.  In addition, ING1 has been proposed to function as a tumor suppressor by 
regulating p53 activity (23, 70, 149, 203).  Mouse Ing1 encodes two different proteins 
(p31 and p37) from differentially spliced transcripts (239).  Approximately 20% of mice 
lacking both p31 and p37 Ing1 proteins developed a B220+, B cell lymphoma by 23 
months of age (108). A small percentage of these tumors were bi-phenotypic, expressed 
both B220 and CD3 surface antigens, and were classified as follicular center B-cell 
lymphomas.  We have previously generated mice deficient solely for p37Ing1b, the most 
prevalent isoform of Ing1. These mice developed spontaneous follicular B220+ 
lymphomas between one and two years of age, and analysis of the growth and response 
of p37Ing1b deficient mouse embryonic fibroblasts (MEF) and thymocytes to DNA 
damaging agents revealed that p37Ing1b inhibited MEF proliferation and suppressed 
thymocyte apoptosis in a p53-independent manner (39).  In this present study, we 
examine the role of Ing1b in B-cell growth and apoptosis, and explore the relationship 
between p37Ing1b and p53 in tumor suppression.  Our data indicate that p37Ing1b inhibits 
follicular (FO) B cell proliferation regardless of p53 status and that p37Ing1b and p53 co-
operate to suppress the formation of non-germinal center and germinal center B cell-like 
DLBL. In addition, we find that NF-κB activity is upregulated in the absence of p37Ing1b, 
supporting a role for mouse Ing1b in regulating NF-κB signaling.   
 
 
 
 
86
These results reveal a p53-independent role for Ing1b in suppressing B cell 
lymphomagenesis and demonstrate that p53 deletion facilitates the formation of DLBL in 
a mouse model of FL. 
 
Results 
Mice deficient for p37Ing1b have an expanded follicular (FO) B-cell compartment. 
 To characterize the B cell compartment in p37Ing1b-deficient mice, single-cell 
suspensions were prepared from spleens isolated from 6 month old, asymptomatic mice 
and FACS analysis was performed.  CD45R/B220, a B-cell marker, staining revealed a 
subtle expansion of splenic B cell lymphocytes in p37Ing1b null mice compared to age-
matched wildtype (wt) mice (51.4% versus 36% in wt), with a majority of the B220+ 
cells also staining positive for both IgM and CD23, a marker of follicular (FO) cells (Fig 
3.1).  These data suggest that loss of p37Ing1b leads to an increase in the number of mature 
follicular B cells in adult mice, consistent with a role for p37Ing1b in regulating the growth 
of these cells.  Spleens harvested from mice deleted for both p37Ing1b and p53 revealed a 
similar expansion of these mature B cells (data not shown). 
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Figure 3.1:  Follicular (FO) B-cells in p37Ing1 deficient mice are increased.  FACS 
analysis of spleen cells from a healthy 8-month old wild-type control mouse and matched 
ING1 KO mouse.  FSC is forward scatter (proportional to cell size). The middle and right 
plots depict all live spleen cells within the lymph scatter gate, whereas the left plots 
displays data from CD23+ B cells.   
 
Proliferation, but not apoptosis, is altered in p37Ing1b and p37/p53 deficient B-cells. 
 In order to further investigate the role of p37Ing1b in B-cell growth, we isolated 
either total CD45R/B220+ B-cells or follicular (IgDhi) B-cells from the spleens of adult 
wt, p37Ing1b-null, p53-null, and p37/p53-double null mice by FACS sorting using either 
anti-B220 or IgD-PE antibodies.  Since anti-IgM F(ab’)2 antibodies activate B-cells by 
cross-linking of the B-cell receptor complex (BCR) to initiate cell proliferation and death, 
we treated either total B-cells or FO B-cells with increasing amounts of anti-IgM 
antibody for 16 hours and measured cell proliferation via [3H] thymidine incorporation 
(Fig 3.2A).   
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Both total B-cells (Fig 3.2A, left panel) and FO B-cells (Fig 3.2A, right panel) isolated 
from p37Ing1b-deficient mice displayed increased proliferation relative to their wt 
counterparts.  Although deletion of p53 also increased the proliferative response of FO B-
cells, co-deletion of both p37 Ing1b and p53 further increased the proliferation of the IgDhi, 
FO B-cells in response to BCR activation.  As FO B-cells from p37/p53-double null mice 
displayed even greater proliferation than observed in either p37-null or p53-null cells, 
these data indicate that p37Ing1b does not require functional p53 to inhibit FO B cell 
growth. Rather, the p37 and p53 tumor suppressors co-operate in negatively regulating 
the proliferation of these cells. 
 
 To confirm that the increased numbers of FO B cells observed both in vivo in p37 
Ing1b–null mice and in the in vitro proliferation assays were due to increased cell 
proliferation and not a reflection of altered cell death, we examined apoptosis in p37 Ing1b–
null cells.  FO B-cells were isolated from the spleens of adult wt, p37Ing1b-null, p53-null, 
and p37/p53-double null mice and grown in prolonged culture or treated with increasing 
amounts of anti-IgM. Sub-G1 content following staining of the IgDhi cells with 
propidium iodide was used to identify the percentage of apoptotic cells in each 
population (Fig 3.2B). Although prolonged culture in vitro or activation of BCR by anti-
IgM treatment increased apoptosis in FO B cells, the presence or absence of p37 Ing1b did 
not alter the apoptotic response of the FO B-cells.   
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In addition, there was no difference in the apoptotic response of wt, p37 Ing1b-null, p53-
null, or p37/p53-double null FO B-cells to treatment with either 2.5 Gy ionizing radiation 
or with 100nM dexamethasone (data not shown).  Thus, neither p37Ing1b nor p53 plays a 
role in regulating apoptosis in FO B-cells in response to these stimuli.  These findings 
contrast with the increased apoptosis we observed previously in p37Ing1b-null thymocytes 
(39), and confirm that the increase in FO B-cell numbers observed in adult p37 Ing1b-null 
mice is likely due to increased proliferation of these cells. 
 
 
 
Figure 3.2:  Analysis of follicular (FO) B-cells in p37 and p37/p53deficient mice.  A) 
[3H] thymidine uptake assay of wt, p37, p53, and p37/p53deficient purified B-cells.  
Assay was done in triplicate and repeated twice.  B-cells were treated with the indicated 
amount of anti-IgM and harvested 24 hours for [3H] thymidine uptake assay.  B) 
Apoptosis assay on purified FO B-cells from wt, p37, p53, and p37/p53 deficient mice.  
Plots show percent of sub-G1.  Assay was done in triplicate and repeated twice. 
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p37/p53 double null mice primarily develop aggressive B-cell lymphomas. 
 The increase in FO B cell proliferation when co-deleted for p37Ing1b and p53 
suggests that p37Ing1b and p53 may cooperate to suppress B cell tumorigenesis.  To test 
this hypothesis, we collected cohorts of wt mice, p37 Ing1b-null mice, p53-null mice, and 
p37/p53 double-null mice and compared the rate of spontaneous tumor formation (Figure 
3.3) and the spectrum of tumor types in these mice (Table 3.1).  The p37 Ing1b-null mice 
presented with FL between one and two years of age, in agreement with our previous 
report (39).  Three quarters of the p37 Ing1b-null cohort developed spontaneous cancer, 
whereas wt mice did not develop tumors during this time.  Tumors arising in p37 Ing1b-
null mice were predominantly localized to the lymph or spleen, with little or no 
involvement of peripheral tissues.  As expected, all p53-null mice succumbed to 
spontaneous tumorigenesis within 10 months of age, with 75% of the tumors classified as 
lymphomas and the remainder a mix of sarcomas and carcinomas.   
 
As previously reported, two-thirds of the p53-null lymphomas formed in the thymus and 
were composed of CD4+CD8+ T cells, whereas the remaining third of the lymphomas 
formed in the spleen and were classified as marginal zone B cell lymphomas or as 
polymorphic tumors containing both B cells and T cells (47, 85, 97, 98, 228).  Similarly, 
p53-null mice co-deleted for p37 rapidly formed spontaneous tumors by 45 weeks of age 
(Fig 3.3).  However, all of the p37/p53-double null mice presented with lymphoma, with 
three quarters (17/23) of the p37/p53-null mice displaying enlarged spleens, discolored 
and enlarged livers, and lymph node involvement.   
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Microscopic analysis of hematoxylin and eosin stained tumor samples isolated from 
p37/p53-double-null mice revealed evidence of a lymphoblastic lymphoma involving 
spleen, liver, and/or mesenteric lymph node. In contrast to tumorigenesis in p53-null 
mice, only a small subset (6/23) of lymphomas arising in p37/p53-double null mice 
formed in the thymus. 
 
 
Figure 3.3:  Kaplan-Meier survival curve showing tumor formation in p37/p53 deficient 
mice.  Cohorts of mice that were either wt (n=50), p53 (n=32), p37 (n=19), or p37/53 
(n=23) null were monitored for 20 months.  
 
 
 
 
 
Table 3.1: Comparison of the tumor spectrums of p53, p37Ing1b, and p37/p53 null mice.  
Both (B and T-cell) refers to mice that had two or more tumors which were classified as 
being of both B-cell and T-cell origin.  Abbreviations used: MZL; marginal zone B-cell 
Lymphoma, FL; follicular lymphoma, DLBL; diffuse large B-cell lymphoma.   
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The non-thymic p37/p53–null tumors were characterized by a uniform population 
of large, malignant lymphocytes with round, vesicular nuclei with frequent membrane 
indentations, occasional centrally placed nucleoli, and scanty cytoplasm.  Lymphoblasts 
completely effaced lymph node architecture, diffusely involved the splenic white pulp, 
and infiltrated periportal and sinusoidal regions in the liver.  Immunohistochemistry 
performed on select sections of paraffin embedded tumors isolated from p37 Ing1b mice 
and from p37/p53-double null mice using antibodies against CD45R/B220 and CD3 
antigens confirmed that the predominant tumor type was a CD45R/B220+ lymphoma 
(Fig 3.4A). Additionally, histopathology suggests that the tumor cells frequently present 
in the different associated lymphatic tissues of p37/p53-double null mice all originate 
from a common tumor, suggesting that deletion of both tumor suppressor genes results in 
the formation of an aggressive B cell tumor. 
 
 Although deletion of p53 greatly accelerated tumorigenesis in p37 Ing1b–null mice 
(p<0.05), co-deletion of p37 Ing1b and p53 appeared to also delay slightly tumor onset in 
p53-null mice (Fig 3.3), though the difference in the tumor curves was subtle (p<0.1).  
This may reflect the reduced incidence in p37/p53-double null mice of the highly 
aggressive thymic lymphomas typically seen in p53-null mice.  Furthermore, the cellular 
characteristics of the thymic lymphomas arising in the p37/p53-double null mice 
appeared different from those arising in p53-null mice.  FACS analysis of thymii isolated 
from p53-null and p37/p53-double null mice revealed that the CD4+CD8+ population 
was somewhat larger in p37/p53-double null mice relative to p53-null mice (Fig 3.4B).  
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Analysis of a thymic tumor originating in p37/p53-double null mice revealed an 
expansion of the non- CD4+CD8+ compartments.  In contrast, FACS analysis of p53-null 
thymic tumors indicated that these tumors originated in CD4+/8+ double positive T-cell 
compartment, in agreement with earlier studies (97). 
 
 
 
Figure 3.4:  Analysis of tumors and from p37/p53 deficient mice.  A) Representative 
hemotoxylin and eosin or B220 stained tumor sections from p37 or p37/p53null mice.  
The p37/p53 null spleen, liver, and lymph node sections are from one mouse.  All 
pictures were taken at 20x magnification.  B) FACS plot of CD4 and CD8 stained thymic 
tumors from p53 or p37/p53 null mice.   
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 We previously reported that thymocytes lacking p37 Ing1b display upregulated 
levels of pro-apoptotic Bax expression and possess an increased susceptibility to cell 
death induced by various stimuli (39). To confirm that the p37 Ing1b null CD4+CD8+ cells 
co-deleted for p53 also have increased Bax expression, we isolated total RNA from 
CD4+CD8+ thymocytes harvested from p37/p53-double null mice and performed qPCR 
to measure Bax transcripts. A modest increase in Bax mRNA (1.26 ± 0.02) was observed 
relative to wt CD4+CD8+ Bax transcript levels (Fig 3.5).  The increase in Bax expression 
in p37/p53-double null CD4+CD8+ cells correlates with the decrease incidence of 
CD4+CD8+ thymic lymphomagenesis observed in the double null mice and may account 
for the overall slight delay in the rate of tumorigenesis in p53-null mice co-deleted for 
p37 Ing1b. 
 
Figure 3.5:  Bax qRT-PCR of DP sorted T-cells from non-cancerous wt or p37/p53 null 
mice.  Experiment was done in triplicate.  Shown is a representative gel picture with 
quantified values above (* indicates statistically significant difference P≤0.05).   
 
DLBL in p37/p53 double null mice 
 FACS analysis was performed on the B-cell compartments of two tumor-bearing 
mice to further characterize the tumor phenotype of the p37/p53-double null mice (Fig 
3.6).   
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Several distinct splenic B cell populations were readily observed in non-tumor bearing 
mice, including FO B cells (IgD++ IgMlo CD23+), immature T1 (IgDlo IgM++ CD23-) and 
T2 (IgDlo IgM++ CD23+ CD24++ AA4.1++) B cells.  However, the splenic B cells of tumor-
bearing p37/p53-double null mice were almost exclusively composed of follicular B cells 
(IgD++ IgMlo CD23+ CD24lo AA4.1-).   In addition, the forward scatter distribution of this 
FO B population is shifted (Fig 3.6A), indicating that the majority of the FO B cells are 
larger, blast stage cells rather than resting cells.  The phenotype of FO B cells in p37/p53 
tumorigenic mice was distinguished by elevated levels of IgM and CD23 staining, and 
reduced amounts of CD24 staining relative to levels observed in WT FO B cells.  Similar 
results were obtained in a repeat of this experiment (data not shown). The difference in 
the staining patterns of the p37Ing1b-null tumor cells and p37/p53-double null tumor cells, 
coupled with the widespread organ involvement and larger size of the tumor cells arising 
in p37/p53-double null mice, classifies these CD45R/B220+ tumors as DLBL rather than 
FL. 
 
To determine if there was increased expression of pro-survival genes in 
lymphomas arising in the double null mice as had been previously observed in human FL 
and DLBL (11, 44, 130), real-time PCR was performed on total RNA isolated from the 
spleens and tumors of various mice.  Mcl-1 expression appeared unaltered in wt, p37Ing1b-
null, and in p53-null cells, but was slightly upregulated in p37/p53 double-null spleens 
(Fig 3.6B).  However, Mcl-1 expression levels were greatly increased in tumors arising in 
p37/p53-double null mice.  
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In contrast, Bcl-2 was not elevated in splenic tissues or in tumors, regardless of the 
genotype of the mice.  Reduced expression of Bcl-XL has also been seen in non-
Hodgkin’s lymphomas (234); however we did not determine expression of Bcl-XL in 
these tumor samples. 
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Figure 3.6:  Characterization of the tumors in p37/p53 deficient mice.  A) FACS analysis 
of spleen cells from a healthy wild-type control mouse (WT) and spleen cells from two 
p37/p53 null mice with tumors (D1, D2).  In the middle column, the larger bold numbers 
report the geometric mean fluorescence intensity values for IgM (y-axis) and CD23 (x-
axis) for the IgM+CD23+CD24+/-AA4.1- population.  This experiment was repeated with 
similar results.  B) Expression levels of Bcl-2 and Mcl-1 assayed by real-time RT-PCR in 
spleens from wt, p53, p37, and p37/p53 null mice or p37/p53 null splenic tumors.  Real-
time PCR of normal spleens was done in triplicate and the tumor samples are from three 
independent mouse tumors.  Shown is average and standard deviations (error bars). 
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Approximately one-third of all NHL display translocations involving BCL-6, a 
transcriptional repressor required for the formation of germinal center (GC) B cells. 
Overexpression of BCL-6 has been proposed to block the terminal differentiation of GC 
B cells by inhibiting the expression of the B lymphocyte maturation protein 1 (Blimp1), 
resulting in prolonged exposure of the GC B cells to the mutagenic effects of the somatic 
hypermutation machinery (166).  In addition, Bcl-6 has been proposed to suppress DNA 
damage-induced apoptosis caused by the hypermutation apparatus by suppressing p53 
expression (170).  Thus, Bcl-6 expression serves as a marker for DLBL that are derived 
from GC-like B cells.  To determine if Bcl-6 expression was upregulated in DLBL in 
p37/p53-double null mice, representative tissue sections were fixed, sectioned, and 
stained for Bcl-6 (Figure 3.7A). Bcl-6 was not detected in wt splenic tissue, or in a B cell 
lymphoma arising in the spleen of a p53-null mouse (Figure 3.7A, top panels). In 
contrast, varying levels of Bcl-6 expression could be detected in some but not all tumor 
tissues harvested from p37/p53-double null mice (Figure 3.7A, bottom panels).  To 
confirm upregulation of Bcl-6 expression in a subset of p37/p53-tumors, total RNA was 
harvested from thirteen p37/p53-double null DLBL and assayed for Bcl-6 transcript 
levels by qPCR. In addition, the expression levels of the CD10 surface marker, Irf-4 
transcription factor, and the NF-κB subunit Rela (p65) were also assayed by qPCR 
(Figure 3.7B).  Irf-4 is a transcription co-factor expressed in plasma cells that silences 
BCL-6 expression and the GC transcriptional program, and is critical for GC to plasma 
cell differentiation (20).  Bcl-6 was upregulated in 6 of 13-tested DLBL that arose in 
p37/p53-double null mice, marking these tumors as GC B cell-like DLBL.   
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CD10, another marker for GC B cells (9), was elevated in two other tumors, indicating 
that 8 of the 13 tumors were GC subtypes of DLBL.  The remaining 5 DLBL tumors did 
not display elevated levels of CD10, Bcl-6 or Irf-4.  Lack of CD10, Bcl-6, or Irf-4 
upregulation in the remaining 5 DLBL indicates that these are non-GC B cell-like tumors. 
 
 
 
 
 
Figure 3.7:  p37/p53 deficient mice develop predominately GC B-cell DLBL and have 
elevated RelA expression.  A) Representative Bcl-6 stained p37/p53 spleen and lymph 
node (LN) tumors.  Wt and p53 null spleen sections stained with Bcl-6 are shown as 
controls.  All pictures were taken at 20x magnification.  B) Table showing classification 
of 13 independent p37/p53 null B-cell tumors based on expression of CD10, Irf-4, and 
Bc1-6 by real-time PCR.  Values are averages of relative fold induction over normal 
p37/53 null spleens of three independent experiments for each tumor.  Standard 
deviations were within 10% of the mean value for each sample. 
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NF-κB activity is often increased in human lymphomas due to chromosomal 
translocations, mutation of NF-κB inhibitors such as IκB, or through other, less well-
characterized processes (92, 100).  Furthermore, NF-κB activation is also observed in 
subtypes of non-GC DLBL such as in peripheral (or activated) B cell-like DLBL. 
Recently, ING1 has been proposed to inhibit NF-κB signaling in human fibroblasts by 
upregulating HSP70 expression (54).  To examine NF-κB activity in cells deleted for 
p37Ing1b, qPCR was performed on total RNA isolated from the 13 DLBL samples.  
Analysis of RelA expression levels in the DLBL revealed that the RelA (p65) subunit 
mRNA expression was elevated in nearly all of the tumors (Fig 3.7B- right column) 
relative to RelA expression in wt splenic tissue.  To determine if NF-κB activity is 
upregulated in p37/p53-double null cells, FO B cells were isolated from the spleens of wt, 
p37Ing1b-null, p53-null, or p37/p53 double-null mice, and cell proliferation was measured 
in response to treatment of the cells with LPS, an established inducer of NF-κB activity 
(Fig 3.8A). Although deletion of p53 or p37Ing1b did not result in a greater proliferative 
response of FO B cells to LPS, co-deletion of p53 and p37Ing1b did result in increased 
proliferation of FO B cells to varying dosages of LPS.  To confirm that the increase in 
RelA expression observed in the DLBL samples correlated with increased NF-κB activity 
in the tumors, qPCR was used to measure expression of the Interleukin 6 gene (IL-6), a 
classic target gene upregulated by NF-κB signaling (Figure 3.8B).   
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Increased IL-6 transcript levels were observed in the spleens of p37-null mice, regardless 
of p53 status, and very large increases (100-600 fold) in IL-6 expression levels were 
observed in p37/p53 double-null tumors, regardless of their classification as GC B cell-
like DLBL (tumor #5 and #7) or as non-GC DLBL (tumor #9 and #11).  These results 
confirm that loss of p37Ing1b upregulates NF-κB activity in p37/p53 double-null mice and 
in tumors, supporting a role for Ing1b in inhibiting NF-κB signaling in suppression of 
DLBL. 
 
 
 
Figure 3.8:  p37/p53 deficient mice have elevated NF-κB activity.  A) [3H] thymidine 
uptake assay of wt, p37, p53, and p37/p53 deficient purified B-cells.  Assay was done in 
triplicate and repeated twice.  B-cells were treated with the indicated amount of LPS and 
harvested 24 hours for [3H] thymidine uptake assay.  B) Expression of IL-6 in wt, p37 
null, p37/p53 null spleens, and representative p37/p53 null GCB (n=2) and non-GC-
DLBL (n=2) tumors by real-time PCR.  Shown are average and standard deviations of 
real-time PCR performed in triplicate. 
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Discussion 
We have previously described the generation of mice deleted for the p37Ing1b 
isoform of Ing1 (39).  Loss of p37Ing1b increased the proliferation of mouse embryonic 
fibroblasts (MEFs) regardless of p53-status, and the p53-mediated response of cells to 
DNA damage or to overexpression of oncogenic Ras was unaltered in p37Ing1b deficient 
MEFs.  In addition, deletion of p37Ing1b upregulated Bax gene expression in the presence 
or absence of functional p53, and increased the apoptotic response of thymocytes to DNA 
damage. A majority of p37Ing1b-deficient mice spontaneously developed enlarged spleens 
between one and two years of age.  Histopathology revealed a CD45R/B220+ CD3- 
lymphocytic hypercellularity in spleens isolated from p37Ing1b-deficient mice, and all of 
the tumors arising in p37Ing1b-null mice were classified as FL (39).  Although our results 
indicated that p37Ing1b can inhibit cell growth and cell death in a p53-independent manner, 
in MEFs and in thymocytes, respectively, it was unclear from these data if p37Ing1b alters 
p53 functions to regulate tumorigenesis.  In this present study, we crossed p37Ing1b mice 
with p53-null mice to generate p37/p53-double null mice and explored the relationship 
between p37Ing1b and p53 tumor suppression. Deletion of p53 greatly accelerated the rate 
of tumor formation in p37Ing1b-null mice, an unexpected finding if p37Ing1b and p53 were 
functionally redundant, or if p37Ing1b suppressed tumorigenesis by signaling through p53.  
Thus, co-operation observed between the two tumor suppressors in preventing B cell 
lymphomagenesis indicates that p37Ing1b does not suppress tumors by activating p53.  Co-
operation between p37Ing1b and p53 in tumor suppression is also in agreement with the 
increased rate of cell proliferation in FO B cells when co-deleted for p37Ing1b and p53. 
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 Interestingly, there was a reduction in the incidence of thymic lymphomas in the 
p37/p53-double null mice relative to the high incidence CD4+CD8+ thymomas in p53-
null mice.  This reduction correlates with an increase in pro-apoptotic Bax expression 
observed in CD4+CD8+ T cells isolated from p37/p53-double null mice, in keeping with 
our previous finding of a dramatic increase in Bax mRNA in total thymus when treated 
with γ-irradiation (39). The reduced incidence of thymic lymphoma, typically an 
aggressive cancer resulting in rapid morbidity and mortality in p53-null mice, may 
account for the slight delay in the lethality of the p37/p53-double null mice. We also 
observed a slight decrease in expression of Mcl-1 in thymii from p37/p53null mice (data 
not shown).  The elevation of Mcl-1 in p37/p53null spleens and reduction of Mcl-1 in T-
cells might also explain the shift from a predominately T-cell lymphoma in p53-null mice 
to a more B-cell lymphoma in p37/p53null mice. 
 
 Approximately half of the tested DLBL were found to have elevated Bcl-6 
expression levels and/or increased CD10 expression, indicating a GC B cell-like subtype 
of DLBL.  In addition, nearly all of the tumors displayed elevated RelA expression and, 
in some cases, increased NF-κB activity.  It is yet unclear how Ing1b is regulating the 
expression of Bcl-6, CD10, or RelA in DLBL, or the expression of Mcl-1 and Bax in T 
cells.  Further experimentation is needed to determine if this effect is indirect or is a 
direct effect of altered factor binding at the promoters of these genes. 
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 A few studies have examined the expression of ING1 in human primary 
hematopoetic malignancies and found no mutation of ING1 or alterations in ING1 
expression in myeloid leukemias (108, 155, 176, 183).  However, down-regulation of 
ING1 expression has been reported in human mantle cell lymphomas in both primary 
tumors and cell lines (176, 183).  In addition, expression of Ing1 appears to be 
downregulated in gene expression profiling data performed on human DLBL samples, 
though the reduction in ING1 expression was not enough to highlight ING1 as a 
prognostic indicator for the disease in these studies (4, 138). However, the results of our 
analysis of Ing1b-deficient mice indicate that loss of p37Ing1b induces the highly penetrant 
formation of spontaneous FL and DLBL in mice, especially in mice co-deleted for p53.  
Thus, the role of Ing1b in suppressing human B cell lymphomas, especially DLBL, 
should be evaluated further. 
 
Materials and Methods 
Mice and tumor assay 
The generation of p37Ing1b–null mice and p37/p53-double null mice was described 
previously (39).  The p37Ing1b–null mice were backcrossed to C57Bl/6 strain for 6 
generations, and cohorts of these mice and of p37/p53-double null mice, wildtype mice, 
and p53-null mice (47) all on a C57Bl/6 inbred background were collected and aged in 
order to perform a tumor assay.  Mice displaying obvious tumors or signs of reduced 
vitality were euthanized and tissues were harvested for FACS analysis or fixed in 10% 
formalin for immunohistochemistry.   
 
 
 
 
105
Samples were also flash frozen in liquid nitrogen for use in qRT-PCR analysis.  Formalin 
fixed, paraffin embedded sections were stained with either hemotxylin and eosin or with 
an antibody to CD45R/B220 (BD Pharmingen; 1:50)  or to Bcl-6 (Santa Cuz; 1:50) 
before being analyzed by microscopy.  All mice were maintained and used in accordance 
with both federal guidelines and those established by the Institutional Animal Care and 
Use Committee at the University of Massachusetts Medical School. 
 
Cell sorting 
Single cell suspensions of spleens harvested from p37/p53 double null mice at 6-8 
weeks of age were stained with CD45R/B220-PE (eBiosciences; 1:200) or IgD-PE 
(eBiosciences; 1:200) and FACS sorted.  Resulting purity of either total B-cell (B220+) 
or follicular B-cell (IgDHi) populations were greater than 95%.  B-cells were maintained 
in RPMI1640 supplemented with 5% FCS, 2 mM L-glutanine, 100 ug/ml streptomycin, 
100 U/ml penicillin, and 50 uM 2-mercaptoethanol (GIBCO-BRL) and cultured at 37°C 
and 10% CO2.  Double positive (DP) thymocytes were sorted using CD4-PE (BD 
Pharmingen; 1:250) and CD8-APC (BD Pharmingen; 1:100) antibodies and sorted by 
FACS.  RNA from sorted DP T-cells was purified using Trizol reagent from Invitrogen 
(Carisbad, CA) according to the manufacturer’s instructions, and cDNA was generated 
using a first-strand cDNA synthesis kit from Invitrogen (Carisbad, CA). 
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Analysis of B-cell subsets 
Spleens were processed to single-cell suspension by pressing between frosted 
glass slides, and filtered through nylon mesh.  Red blood cells were lysed using brief 
hypotonic shock and the remaining cells were resuspended in biotin-, flavin-, and phenol-
red deficient RPMI 1640 (Invitrogen, Carlsbad, CA) staining media containing 10 mM 
Hepes, pH 7.2, 0.02% sodium azide, 1 mM EDTA, 3% newborn calf serum, and treated 
10 min on ice with 2.4G2 Fc block (BD Biosciences, San Jose, CA).  Cells were 
incubated for 20 min on ice with primary antibodies, washed and biotin-stained cells 
were incubated with streptavidin (SA)- pacific blue (Molecular Probes/Invitrogen) for 15 
min on ice. After 2 washes, cells were resuspended in 1 mg/ml propidium-iodide to 
exclude dead cells.  Primary antibodies included antibodies specific for: CD24 (clone 30-
F1) FITC or PE, CD45R/B220 (RA3-6B2) APC, IgM (II/41) biotin or FITC, IgD (11-26) 
PE, CD93/AA4.1 APC, CD23 (B3B4) biotin.  All reagents except when noted were from 
BD Biosciences, San Jose, CA; eBiosciences, San Diego, CA; Southern Biotechnology 
Associates, Inc. Birmingham, AL; or CALTAG Laboratories/Invitrogen, Burlingame, 
CA.  Flow cytometry was performed on a 3-laser 12-color LSR II (BD Biosciences, San 
Jose CA) and analyzed with FlowJo software (Tree Star, Ashland, OR). 
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Proliferation and apoptosis assays 
Incorporation of [3H] thymidine was used as a measure of proliferation as 
described previously (127).  In brief, sorted 2 × 105 B-cells were plated into wells of a 
96-well plate with 200 μl of RPMI medium.  Following 24 hr of culture, cells were 
pulsed with [3H] thymidine (1 μCi per well) for 16 hr prior to harvest.  Incorporated 
radioactivity was quantified with a Liquid Scintillation and Luminescence Counter 
(Perkin Elmer Wallace Inc.).  Apoptosis assays were described previously (51).  In brief, 
B-cells were plated as before and then treated with either increasing amounts of anti-IgM 
F(ab’)2  (Jackson Immunoresearch, West Grove PA), 250 rads γ-irradiation, 100 nM 
dexamethasone (Sigma, St. Louis MO), or allowed to die by neglect.  After 24 hours 
following IR or 100 nM dexamethasone treatment or 16 hours after IgM treatment, cells 
were collected, stained for propidium iodide, and analyzed by FACS. 
 
qRT-PCR 
Quantitative RT-PCR was done as previously described (41).  The following 
primers were used: Mcl-1: AGTCAGCACAGCTTTCCTGTCAGA and 
TGCCAATCCAAGAATGCCAATCCC; Bcl-2: CTCGTCGCTACCGTCGTGACTTCG 
and GTGGCCCAGGTATGCACCCAG; Bcl-6: GCAACGAATGTGACTGCCGTTTCT 
and TTTCTCACCCGTGTGGACAGTCTT; CD10: 
TTCTGTGGCCAGACTGATTCGTCA and GCAGCATTGGGTCATTTCGGTCTT; 
Irf4: GAGCTGCAAGTGTTTGCTCACCAT and 
ACAGTTGTCTGGCTAGCAGAGGTT;  
 
 
 
 
108
RelA (p65): TGTGTTGATAGCTCCTGCTTCGGT and 
ATCAAGGTGTACAGGAATCCGCGT; Il-6: AGTCACAGAAGGAGTGGCTAAGGA 
and TCTGACCACAGTGAGGAATGTCCA; and 
Ef1α;AGCTTCTCTGACTACCCTCCACTT and GACCGTTCTTCCACCACTGATT.   
All primers were amplified using 62OC for an annealing temperature and 24 cycles to 
keep the products in the linear range.  PCR products were run on a 2% agarose gel with 
SYBR green to visualize the bands. 
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CHAPTER IV: 
ING4 SUPPRESSES NF-κB SIGNALING AND INNATE IMMUNITY 
IN MICE. 
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Foreword 
ING4 is a member of the Inhibitor of Growth (ING) candidate tumor suppressor 
gene family.  ING proteins serve as subunits of chromatin remodeling complexes, and 
have been proposed to participate in a number of biological processes, including DNA 
repair, apoptosis, cell cycle regulation, and tumor suppression.  Recently, overexpression 
experiments in transformed cell lines found an interaction between ING4, the p53 tumor 
suppressor, and p300, which resulted in the increased acetylation of p53.  Additionally, 
ING4 was found to bind to p65/RelA, a component of the NF-κB complex, and cause a 
reduction in the activation of a canonical NF-κB -responsive promoter.  In this study, we 
have generated Ing4-/- mice to explore the in vivo role of Ing4 in cell growth and tumor 
suppression.  Surprisingly, deletion of Ing4 did not alter p53-mediated growth arrest or 
apoptosis, and Ing4-/- mice failed to develop spontaneous tumors.  However, Ing4-
deficient cells displayed reduced proliferation, and mice and macrophages deleted for 
Ing4 were hypersensitive to treatment with LPS and exhibited decreased IκB gene 
expression and increased nuclear p65/RelA and NF-κB activity.  In addition, Ing4-
deficient mice displayed an increased inflammatory response in vivo.  These results 
reveal that Ing4 suppresses NF-κB function and innate immunity in mice by promoting 
the expression of the p65/RelA inhibitory IκB genes. 
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Introduction 
ING4 is a member of the Inhibitor of Growth (ING) family, which is comprised 
of five evolutionarily conserved proteins (ING1-ING5) that are characterized by a 
conserved carboxy-terminal plant homeodomain (PHD)–like zinc finger (23).  These 
nuclear proteins are proposed to play roles in numerous biological functions by 
interacting with different acetylation and deacetylation complexes involved in chromatin 
remodeling and gene expression (48, 203).  ING4 was identified through its homology to 
ING1, the initial and best characterized member of the ING family. Similar to ING1, cell 
transfection studies have revealed that ING4 negatively regulates cell proliferation (126, 
199, 216, 243). Biochemical analysis has indicated that ING4 interacts with methylated 
histone H3 (160, 161, 194) and with the HBO1-JADE-hEAF6 histone acetyltransferase 
(HAT) complex (48).  This complex is responsible for most of the nucleosomal histone 
H4 acetylation that occurs in eukaryotes, and HBO1-ING4 complex formation is required 
for cells to progress properly through the DNA synthesis (S) phase of the cell cycle (7, 
95).  In addition to regulating cell proliferation, ING4 has been found to suppress the loss 
of cell contact inhibition induced by MYC or MYCN (110), to suppress cell spreading 
and migration by interacting with Liprin α1 (189), and to regulate the cellular response to 
hypoxia by interacting with hypoxia inducible factor (HIF) prolyl hydroxylase and 
repressing HIF activation (40, 158, 159).  Collectively, these findings underscore the 
possibility that ING4 functions as a tumor suppressor, and several reports have 
implicated ING4 in the development and progression of various types of human cancers.   
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Reduction of ING4 message correlates with tumor grade in glioblastoma and multiple 
myeloma (40, 63), and decreased ING4 expression correlates with decreased overall 
survival of patients with malignant melanoma (19). Loss of ING4 heterozygosity has also 
been observed in breast cancers and in head and neck squamous cell carcinoma 
(HNSCC), offering further support for a role for ING4 in tumor suppression (77, 110).  
 
Although the precise molecular basis for ING4 tumor suppression is unclear, 
several lines of evidence indicate that ING4 alters the tumorigenic potential of cells by 
altering the activity of the p53 tumor suppressor, a function that has been similarly 
proposed for other ING proteins (199, 203). Forced overexpression studies have indicated 
that ING4 can bind both to p53 and to the acetyltransferase p300 to facilitate p300-
mediated acetylation of p53 (199).  Furthermore, ectopic expression of ING4 in RKO 
cells caused diminished colony forming efficiency, a decrease in S-phase, and induction 
of apoptosis in a p53-dependent manner (199), and forced overexpression of ING4 in 
HepG2 cells decreased their rate of growth, increased the expression of the p53 target 
genes p21 and BAX, and increased apoptosis following exposure of these cells to DNA 
damaging agents or to serum starvation (243).  However, these transfection data were 
obtained using transformed cell lines engineered to either express ING4 or have reduced 
levels of ING4 (siRNA-knockdown of ING4), and alteration of p53 activity by ING4 has 
not been examined in vivo.  
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ING4 has also been proposed to regulate tumorigenesis by modulating NF-κB 
signaling.  Forced overexpression and co-immunoprecipitation experiments performed in 
the U87MG glioblastoma cell line have revealed that ING4 can physically interact with 
RelA, the large subunit of nuclear factor NF-κB (63).  Inhibition of ING4 by antisense 
RNA promoted tumor vascularization in transplanted SCID mice and downregulated the 
expression of several NF-κB target genes involved in angiogenesis, including 
interleukins IL-6 and IL-8, colony stimulating factor (CSF-3), and the prostaglandin-
endoperoxide synthase (Cox-2) gene.  Further analysis of ING4-p65 (RelA) interactions 
using gel mobility shift assays and reporter gene assays indicated that ING4-p65 binding 
decreased activation of a canonical NF-κB -responsive promoter. These findings indicate 
that ING4 may suppress tumorigenesis by complexing with RelA and inhibiting NF-κB -
mediated cell survival and angiogenesis. 
 
In this study, we have generated and characterized Ing4-deficient mice in order to 
determine if physiologic levels of ING4 regulate cell growth and development, and to 
further explore a role for ING4 in tumor suppression.  Mouse embryonic fibroblasts 
(MEFs) deficient for Ing4 proliferate slower than wildtype (wt) MEFs, indicating that 
Ing4 is required for proper growth control in primary cells.  However, p53 functions 
appear to be unaltered by deletion of Ing4, indicating that the p53 pathway is not 
compromised in Ing4-null mice. In keeping with this observation, Ing4 deficient mice 
failed to develop spontaneous tumors. 
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NF-κB signaling contributes to multiple biological processes, including 
tumorigenesis, angiogenesis, apoptosis, and the innate and adaptive immune response.  
To examine the ability of Ing4 to regulate NF-κB activity in vivo, we examined the innate 
immune response of Ing4-/- mice. Ing4-null mice are extremely sensitive to LPS 
treatment, and analysis of Ing4-null peritoneal macrophages revealed that Ing4 
suppresses NF-κB promoter binding and NF-κB activitation of cytokine gene expression. 
Upregulation of NFκB activity in Ing4-null mice was due to decreased expression of IκB 
genes, and Ing4-null mice display a greatly elevated inflammatory response in colorectal 
tissue, similar to that observed in IκBNS-deficient mice (117).  These results establish 
that physiologic levels of Ing4 can regulate NF-κB activity in vivo by altering IκB 
expression, and highlights a new role for Ing4 in regulating inflammation and innate 
immunity in mice. 
 
Results 
Generation of Ing4-deficient mice. 
To examine the physiological role of Ing4 in the mouse, we first determined the 
expression pattern of Ing4 in a panel of wt C57Bl/6 mouse tissues by real-time 
quantitative RT-PCR.  Ing4 transcript is ubiquitiously expressed in the adult mouse, with 
the highest expression levels observed in muscle (Figure 4.1A). In contrast to the 
multiple spliced isoforms of ING4 present in humans, only one Ing4 transcripts has been 
observed in mice (203, 216, 222).  
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Ing4-deficient mice were generated using an Ing4-gene trapped embryonic stem (ES) cell 
clone that was determined to harbor a retroviral insertion within intron 1 of the Ing4 gene 
(Figure 4.1B).  This clone was used in a standard blastocyst microinjection experiment to 
generate several high degree chimeric mice, and germ-line transmission of the modified 
Ing4 allele was obtained by breeding the chimeric mice to wt C57Bl/6 mice (Figure 
4.1C).  
 
 
 
 
Figure 4.1:  Generation of Ing4-deficient mice.  A) Real-time quantitative PCR analysis 
of Ing4 expression in a panel of wt C57Bl/6 mouse tissues.  B) Schematic of the 
genetrapped locus showing insertion within the first intron.  The trap produces a complete 
knockout by preventing expression of the downstream exons. C) PCR genotyping of the 
mouse tail biopsies showing the presence of the gene trap. A 650-bp fragment is 
generated from Wt Ing4 from primers 1 and 2 and a 400-bp fragment is generated from 
the targeted Ing4 allele from primers 2 and 3.  Abbreviations are: Wt (W), heterozygous 
(H), and null (N).  D) RT-PCR using primers 4 and 5 on mouse embryonic fibroblasts 
(MEFs) showing that the genetrap causes a complete knockout of the Ing4 gene as 
expected.  Last lane of gel shows that the Ing4-/- MEFs express an exon 1 to βGeo fusion 
transcript (primers not shown in B).  Bottom band is primer dimer. 
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Intercrosses of Ing4-heterozygous, F1 generation mice (C57Bl/6 x 129S9) were 
performed to generate Ing4-homozygous mice.  Ing4-heterozygous and Ing4-
homozygous mice were recovered in the expected Mendelian ratios from these crosses 
and appeared phenotypically indistinguishable from their wt littermates.  In addition, 
mouse embryonic fibroblasts (MEFs) were generated from embryos recovered at 
embryonic day 13.5 (E13.5) of gestation from female partners of Ing4-heterozygous 
intercrosses.  RT-PCR was performed on RNA isolated from Ing4-homozygous MEFs 
using PCR primers spanning exons 4 to 8 (primers 4 and 5) of the Ing4 gene or using 
primers contained within exon 8 (primers 6 and 7) of the Ing4 gene (Figure 4.1B).  In 
contrast to wt MEFs, no PCR products were obtained using these primers sets and RNA 
isolated from the Ing4-null MEFs (Figure 4.1D). These data confirm that the retroviral 
insertion in Ing4 locus generates an Ing4 message-minus allele, and that mice 
homozygous for the modified Ing4 allele fail to generate Ing4 message and are Ing4-null 
mice (Ing4-/-). Thus, Ing4 is not required in mice for proper embryonic development. 
 
 Fluorescence-activated cell sorting (FACS) analysis was performed on cells 
recovered from wt and Ing4-/- mice.  An initial experiment revealed that splenic T and B 
cells lacking Ing4 displayed a very slight decrease in CD4+ and CD4+CD8+ T-cell 
populations, but were indistinguishable from wt mice in the formation of mature 
B220+CD19+ B-cells, in contrast to what we had observed previously in Ing1-null mice 
(data not shown). 
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Regulation of cell growth by Ing4. 
A standard proliferation assay was performed to assess the growth rate of Ing4-/- 
MEFs and Ing4+/- MEFs (Figure 4.2A).  Ing4+/- cells proliferated slightly slower than wt 
cells, and Ing4-/- cells were much reduced in their ability to proliferate in culture.  FACS 
analysis of synchronized wt MEFs and Ing4-/- MEFs revealed a 50% reduction in S 
phase in MEFs lacking Ing4 following serum stimulation (Figure 4.2B). These results are 
in keeping with a previous report that Ing4 is required for progression of cells through the 
S phase of the cell cycle (48, 199), and reveal that physiologic levels of Ing4 do not 
inhibit cell growth, in contrast to what we observed previously for Ing1 (39). 
 
 A number of studies have reported an association between Ing4 and p53 (199, 
242, 243).  To explore a possible role for Ing4 in regulating p53 activity, we performed 
several well-established assays for p53 function in MEFs.  Ing4-/- MEFs failed to form 
colonies when plated at low density (Figure 4.2C).  Although these results are the 
opposite of what we and others have observed using p53-null MEFs (86), they are 
consistent with the results of our Ing4-/- MEF proliferation assays. 
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Figure 4.2:  Growth regulation by Ing4.  A) Proliferation of Ing4-/- cells. Two MEF cell 
lines for either Ing4 wildtype, heterozygous, or homozygous cells were plated in triplicate 
and the growth analyzed over the course of 7 days.   B) Wt or Ing4-/- MEFs were serum 
starved for 3 days, following which serum was added back in order to synchronize the 
cells which were then harvested, fixed, and sent for FACS analysis.  Experiment was 
repeated three times using three independent lines of cells.  Shown are representative 
propidium iodide (PI) plots.  C) Growth of Ing4-/- cells at low density. Two lines of 
wildtype, Ing4 null, or p53 null MEFs were seeded at 104 cells per 10cm plates and 
incubated for 8-12 days before being stained with crystal violet. 
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Ing4 is not required for p53 response to DNA damage in primary cells. 
 Ionizing radiation (IR) or doxorubicin treatment of MEFs induces DNA double 
strand breaks and a p53-mediated cell cycle arrest.  Treatment of growth-synchronized wt 
and Ing4-/- MEFs with either 8 Gy IR or with 0.3 µg/mL doxorubicin (Dox) resulted in a 
large reduction of the percentage of cells in S phase as determined by FACS analysis 
(Figure 4.3A).  In contrast, p53-null MEFs were compromised in their ability to undergo 
a DNA damage induced growth arrest. These data indicate that the ability p53 to induce 
cell growth arrest is not compromised in Ing4 deficient MEFs. 
 
To confirm that p53 activity is unaltered in Ing4-null cells, we treated cells with 
doxorubicin for various lengths of time and examined the expression of p21 and Mdm2; 
two well-established p53-responsive genes.  Quantitative (real-time) PCR was performed, 
and the results of this experiment (Figures 4.3B and 4.3C) were expressed as relative fold 
induction of p21 and Mdm2 gene expression.  As expected, wt cells displayed increased 
expression of both genes following DNA damage, whereas p53 null MEFs were 
compromised in their ability to induce the expression of these p53 target genes.  
However, no difference was observed in the ability MEFs containing or lacking Ing4 to 
induce the expression of these p53-target genes following DNA damage, again indicating 
that p53 activity is unaltered in Ing4-null cells. 
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Double positive (CD4+CD8+) thymocytes undergo p53-dependent apoptosis 
following IR exposure (38, 131).  To determine if Ing4 alters p53 apoptosis in these cells, 
we treated wt, p53-null, and Ing4 null thymocytes with varying doses of IR.  Thymocytes 
were collected and stained for annexin V at 4 hours post-IR, and the fraction of surviving 
cells was plotted versus dose of IR.  Following treatment with 5Gy of IR, 20% of wt 
thymocytes and 20% of Ing4-null cells survived, whereas 40% of p53-null thymocytes 
remained viable (Figure 4.3D).  This data indicates that loss of Ing4 does not alter p53-
mediated apoptosis in thymocytes.  These results, coupled with the MEFs analysis, 
indicate that Ing4 is not required for proper p53 function. 
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Figure 4.3: Classical p53 responses are not altered in Ing4-/- cells.  A) Absence of Ing4 
does not alter cell cycle arrest due to DNA damaging agents.  Three lines of wt, Ing4-
homozygous, or p53-null MEFs were duplicate plated and synchronized in their growth 
prior to mock-treatment or treatment with doxorubicin or IR.  Cells were stained with 
BrdU and PI, and analyzed by FACS.  Results are expressed as a ratio of treated cells in 
S-phase versus untreated cells in S-phase.  Quantitative real-time RT-PCR was performed 
using primers to B) p21 or C) Mdm2 on RNA from MEFs treated with 0.3 µg/mL of 
doxorubicin and harvested at the indicated time.  Graphs show the average and standard 
deviation from three independent lines.  D) Thymocytes were isolated from wildtype, 
Ing4 null, or p53-null mice and either mock-treated or irradiated, then stained with 
annexin V and PI.  Graph shows the average percent survival (annexin V-/PI-) and 
standard deviation.  Each time point was done in triplicate and shown is representative of 
two independent experiments. 
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Mice deficient for Ing4 do not develop spontaneous tumors 
A number of studies have linked ING4 loss with the development of cancer in 
humans (63, 70, 77).  Additionally, the connection between ING4 and p53 (199) would 
suggest a possible tumor suppressive function for ING4.  To determine if Ing4 deletion 
could induce the formation of spontaneous tumors in mice, we established cohorts of wt 
mice (n=50) and Ing4-/- mice (n=45) and aged them for 24 months.  No tumors were 
observed in either population over the course of the study.  Upon necropsy at 24 months, 
several Ing4 null mice presented with slightly enlarged spleens (data not shown), but this 
was determined to be extramedullary hematopoiesis and not cancer.  Therefore, unlike 
deletion of p53 (47) or Ing1 (39, 108), deletion of Ing4 does not induce formation of 
spontaneous tumors in mice, indicating that p53-mediated suppression of spontaneous 
tumorigenesis does not require functional Ing4. 
 
Suppression of innate immunity by Ing4. 
 A recent report indicates that ING4 directly binds to RelA (p65) and acts as a 
repressor of NF-κB responsive genes in glioblastoma cells (63).  To determine if NF-κB 
activity was altered in mice lacking Ing4, we examined the sensitivity of Ing4-deficient 
mice to lipopolysaccharide (LPS) challenge, which is known to activate NF-κB signaling 
via the TLR4 receptor. Twelve wt or Ing4-/- mice were intraperitonealy (i.p.) injected 
with either 0.25mg (Figure 4.4A) or 0.75mg LPS and monitored over the course of one 
week (Figure 4.4B).  Ing4-/- mice were more susceptible than wt mice to LPS at either 
dose.   
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Nearly half (5/12) of the Ing4-/- mice exhibited morbidity at the low dose, whereas only 
1/12 of the wt mice died by 6 days post-injection. An even greater difference in the 
response of the mice to LPS was seen at the higher dose.  All 12 of the Ing4-/- mice died 
within 24 hours of LPS injection, whereas only a third (4/12) of the wt mice died at 24 
hours, and one-third of the LPS treated wt mice were normal throughout the study period.  
These results indicate that Ing4-deficient mice are hypersensitive to LPS.  
 
 
 
 
Figure 4.4:  Ing4 -/- mice are hypersensitive when treated with LPS.  Age matched wt 
(n=12) or Ing4 -/- (n=12) mice were injected with either 0.25mg (A) or 0.75mg (B) LPS 
and monitored for morbidity over the course of one week.  Graphs show Kaplan-Meier 
survival analysis and at both doses there was a significant difference between wt and 
Ing4-/- survival (p ≤ 0.005).   
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 We examined cytokine levels in the serum, spleen, liver, and lung of mice after 
LPS treatment to determine if NF-κB activity was elevated.  Wt mice (n=8) and Ing4-/- 
mice (n=8) were either mock injected or injected i.p. with 0.5mg LPS, and serum and 
organs were collected at 6 hours post-injection.  ELISAs were conducted to determine the 
levels of Il-6, Rantes, and Mcp-1 in these samples, as the expression of these cytokines 
are activated in response to LPS, either directly through MyD88-dependent NF-κB 
signaling, or through MyD88-independent upregulation of the IRF-3 transcription factor, 
or through a combination of both pathways (162). 
 
 Significant elevation of Il-6 was seen in the serum (Figure 4.5A), spleen (Figure 
4.5B), and liver (Figure 4.5C) of Ing4-/-mice relative to wt levels following LPS 
injection. Rantes was also elevated in serum and in spleen of Ing4-/-mice compared to wt 
controls, and Mcp-1 was increased in liver (Figure 4.5C) and in lung (data not shown) in 
the Ing4-/- mice.  The increase in cytokine levels observed in the Ing4-/- mice after LPS 
treatment suggests that NF-κB activity is upregulated in these mice. 
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Figure 4.5:  Ing4 null mice show elevated cytokine levels in the serum and organs 
following treatment with LPS.  ELISAs for Il-6, Mcp-1, or Rantes were performed on 
serum (A), spleen (B), or liver (C) samples.  Either wt (n=8) or Ing4 null (n=8) mice 
were injected with 0.5mg LPS and serum and organs were collected at 0 or 6 hrs after 
injection.  Graphs show geometric mean with standard error.  P-values are *p ≤ 0.05 and 
**p ≤ 0.02. 
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Ing4 null macrophages display elevated expression of NF-κB -responsive genes. 
 Macrophages respond to bacterial infection by secreting pro-inflammatory 
cytokines and chemokines (235) and are essential components of innate immunity.  E. 
coli and certain bacterial components such as LPS are known to activate NF-κB signaling 
in macrophages by binding to Toll-like receptors on these cells.  In order to further 
examine the hypersensitivity of Ing4-/- mice to LPS, we generated thioglycolate-ellicited 
peritoneal macrophages by injecting wt or Ing4-/- mice with 4% thioglycolate and 
collecting peritoneal exudate cells by lavage at 4 days post-induction.  Macrophages were 
plated at a density of 106 cells per well in a 24 well plate and either mock treated or 
treated with either LPS or heat-attenuated E. coli. Macrophage supernatants were 
collected 24 hours after treatment, and used in ELISA assays to determine the levels of Il-
6 and Mcp-1.  Similar to what was observed in vivo, Il-6 expression was elevated in Ing4-
/- macrophages relative to wt macrophages after exposure of cells to either LPS or to heat 
killed bacteria.  We also detected a slight, but significant, difference in the levels of Mcp-
1 in cells lacking Ing4 following LPS or E. coli exposure (Figures 4.6A and 4.6B). 
 
Quantitative real-time PCR (qPCR) was performed on RNA isolated from 
macrophages that were either mock-treated or treated with 1µg/ml LPS for 1, 2, or 6 
hours to document the expression levels of various cytokines known to be activated by 
NF-κB signaling.  Expression of Il-6 and Ip-10 was at least 4-fold higher in Ing4-/- cells 
than in wt cells (Figure 4.6C).  
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In addition, IFN-β expression levels were dramatically higher in Ing4-/- cells at 1 or 2 
hours after LPS treatment, but returned to wt levels after 6 hours (Figure 4.6C). This data 
indicate that Ing4 negatively regulates the expression of NF-κB-responsive genes 
following exposure of macrophages to LPS. 
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Figure 4.6:  Ing4 null thioglycolate-elicited peritoneal macrophages also show elevated 
cytokine levels.  Macrophages from 4-5 wt or Ing4 null mice were pooled, plated at a 
density of 106 cells per well of a 24-well plate and either mock treated or treated with 
increasing amounts of LPS (A) or heat killed (HK) E. coli (B).  ELISAs for Il-6 and Mcp-
1 were performed on the supernatants 24 hours after treatment.  MOI: multiplicity of 
infection.  C) Expression of Il-6, Ip-10, and Ifnβ in macrophages following treatment 
with LPS. Macrophages from 4-5 wt or Ing4 null mice were pooled, plated at a density of 
106 per 10cm plate, and treated with 1µg/mL LPS, and then RNA was harvested at the 
indicated times.  The qRT-PCR was done in triplicate.  All graphs show average with 
standard deviations.  
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Ing4 inhibits nuclear NF-κB levels and activity. 
In order to explore the molecular basis of altered NF-κB activity in Ing4-/- cells, 
we examined the p65/RelA levels in the nuclear compartment of macrophages.  Ing4-/- 
macrophages and wt macrophages were untreated (0 minutes) or treated with 1µg/mL 
LPS and harvested at 30 or 60 minutes post-treatment.  Nuclear extracts were prepared 
and analyzed via western blot for total p65/RelA (Figure 4.7).  A clear elevation over wt 
levels was observed in nuclear p65/RelA levels in macrophages lacking Ing4 following 
treatment with LPS.   
 
 
Figure 4.7:  Higher nuclear p65/RelA levels in Ing4 null macrophages.  A) Nuclear 
extracts from wt or Ing4 null macrophages treated with 1µg/mL of LPS were used in 
western blots to determine the amount of p65/RelA at each time point.  TFIIB was used 
as a loading control.  Wt and Ing4-/- panels were from the same gel. 
 
Electrophoresis mobility shift assays (EMSA) were performed with these nuclear extracts 
using a canonical RelA/p65-DNA sequence motif (163).  The results revealed increased 
p65 binding in untreated Ing4-/- macrophage nuclear extracts relative to untreated wt 
extracts (Figure 4.8).  In addition, Ing4-/- macrophages showed an increase in p65/RelA 
promoter binding at 30 or 60 minutes after LPS treatment relative to wt cells.  
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However, this difference in RelA/p65 promoter binding was lost at 6 hours post-
treatment.  An antibody to p65 was added to the nuclear fractions prior to the EMSA and 
resulted in the disappearance of the higher p65 band at 1 hour after LPS treatment, 
indicating that the observed binding in the EMSA assay was p65-specific (Figure 5B; 1 + 
Ab lanes). 
 
 
Figure 4.8: EMSA of nuclear extracts from Ing4 null and wt thioglycolate-elicited 
macrophages.  Macrophages were prepared as before, treated with 1µg/mL of LPS, and 
harvested at the indicated time points.  Nuclear extracts were prepared and subjected to 
the EMSA protocol.  An antibody to p65/RelA was also added to the 1 hour samples in 
order to determine if the observed binding was specific for p65/RelA.  The first lane is a 
negative control (-); reaction mixture without nuclear extract, and the second lane is a 
positive control (+); reaction mixture with HeLa cell nuclear extract. 
 
To confirm the increased RelA/p65 binding in the nuclear compartment of Ing4-/- 
macrophages, we performed chromatin immunoprecipitation (ChIP) experiments to 
examine recruitment of RelA/p65 to the endogenous Il-6 promoter.  Ing4-/- or wt 
macrophages were either mock-treated or treated with LPS for 1 hour or 3 hours.  
Immunoprecipitation of crosslinked DNA was performed using either a p65/RelA 
antibody or an antibody to acetylated histone H4, and a qPCR to Il-6 promoter sequences 
was performed.   
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In agreement with our in vitro EMSA results, greater recruitment of p65/RelA to the Il-6 
promoter was observed in the Ing4-/- macrophages at 0 hours and at 1 hour (Figure 4.9).  
After 3 hours of LPS treatment, less difference was seen in the amount of p65/RelA 
recruitment to the Il-6 promoter.  This recruitment was specific, as we did not observe 
binding in ChIPs that employed an antibody to IgG.  Furthermore, the large difference 
seen in p65/RelA binding to the Il-6 promoter correlated with increased levels of 
acetylated histone H4 at the Il-6 promoter, suggesting that binding of NF-κB to the Il-6 
promoter is inducing transcriptional activation of the Il-6 gene.  These data are in 
agreement with our qPCR results indicating upregulation of Il-6 expression in Ing4-/- 
cells (Figure 4.6C), and further indicates that histone H4 can be acetylated even in the 
absence of Ing4.  Human ING4 was recently found as a component of the HBO1 HAT 
complex, which is responsible for the majority of global H4 acetylation (48). 
 
 
 
 
Figure 4.9: Elevated binding of p65/RelA to the Il-6 promoter was seen in Ing4 null 
macrophages.  Chromatin immunoprecipitation (ChIP) experiments were performed 
according to the manufacturer’s instructions (USB Cleveland OH).  Antibodies to either 
p65/RelA or acetylated-H4 were used to immunoprecipate the chromatin bound protein.  
Anti-IgG antibodies were used as a control for specificity.  Real-time quantitative PCR 
using SYBR green was done in triplicate.  Shown are a representative gel picture of the 
PCR products and a graph quantifying the results which are displayed as the average ± 
standard deviation.   
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To confirm that mouse Ing4 can suppress NF-κB activity, we transfected HEK-293T 
cells with a luciferase reporter gene placed under transcriptional control of an NF-κB 
promoter (Figure 4.10). In agreement with previously published transfection data (63), 
co-transfection of Ing4 expression vector suppressed luciferase activity in this 
experiment, confirming that Ing4 inhibits RelA/p65 transactivation of NF-κB regulated 
gene expression. 
 
 
 
Figure 4.10: Overexpression of Ing4 inhibited the expression of luciferase from a NF-κB 
reporter.  HEK293T cells were transfected with plasmids containing the Renilla 
luciferase gene, an NF-κB luciferase reporter construct, and the RelA cDNA.  Half the 
transfected HEK293T cells were also transfected with a plasmid containing the Ing4 
cDNA.  One day after transfection, cells were treated with 1µg/mL of LPS for 6 hours 
before being harvested to perform either a luciferase assay or qRT-PCR.  Graphs show 
the average and standard deviation of three independent experiments. 
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Ing4 upregulates IκB expression. 
Our results indicate that nuclear p65 levels and DNA binding activity was 
increased in both LPS-stimulated and non-stimulated Ing4-/- macrophages (Figures 4.8 
through 4.9).  Since nuclear levels of p65/RelA and NF-κB promoter activation are 
tightly regulated by IκB proteins (65, 165), we examined if IκB levels were altered in the 
presence or absence of Ing4.  
 
Interestingly, we observed increased levels of p65/RelA protein and decreased 
levels of IκBα protein in untreated whole cell extracts of Ing4-/- macrophages (Figure 
4.11A).  To confirm this observation, western blots for IκBα were performed using 
cytoplasmic fractions isolated from LPS-treated wt and Ing4-/- macrophages.  In wt cells, 
the level of IκBα is greatly reduced 15 minutes after LPS treatment, and begins to 
recover by 60 minutes post-treatment (Figure 4.11B).  Although Ing4-/- cells also display 
reduced IκBα levels 15 minutes after LPS treatment, the kinetics of IκBα re-synthesis 
appear delayed relative to wt cells, and IκBα levels remain lower in Ing4-/- cells that in 
wt cells even after 24 hours.  To determine if the reduced amount of IκBα protein in 
these cells is reflecting a decrease in the expression of IκB genes, we performed qPCR on 
RNA isolated from LPS-treated wt and Ing4-/- macrophages (Figure 4.11C).  These 
results indicate that expression levels of IκBα,  IκBβ, and IκBNS are lower in Ing4-/- 
cells compared to the expression of these genes in wt cells.  
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Figure 4.11:  Absence of Ing4 caused a decrease in IκB transcript levels.  A) Whole cell 
extracts from wt and Ing4 null macrophages were run on a 10% SDS-PAGE gel and 
probed with antibodies to p65/RelA or IκBα.  Tubulin was used as a loading control.  B) 
Wt or Ing4-/- macrophages were either mock treated or treated with 1µg/mL of LPS for 
the indicated times.  Following treatment, cytoplasmic fractions were run on a 10% SDS-
PAGE gel and probed using an antibody to IκBα.  PI-3-kinase was used as a loading 
control.  C) Quantitative real-time RT-PCR using primers to IκBα, IκBβ, IκBNS was 
performed on RNA from wt or Ing4 null macrophages treated with LPS (1µg/mL) for the 
indicated time points.  All samples were done in triplicate and shown are averages and 
standard deviations. 
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IκB genes are known targets of p65/RelA activation and form part of a negative 
feedback loop proposed to regulate RelA activity in the cell (141).  Thus, inhibition of 
NF-κB activity by binding of Ing4 to RelA might be expected to inhibit the expression of 
the IκB genes.  However, the expression of the IκB genes is upregulated by Ing4. 
Therefore, either Ing4 binding to RelA can have opposing effects of different RelA-
responsive promoters, or Ing4 negatively regulates p65/RelA activity by positively 
regulating the expression of IκB inhibitors.  To further validate this finding, we 
transfected an Ing4 expression vector into HEK-293T cells and measured the level of 
IκBα expression by qPCR.  IκBα expression was elevated in both mock and LPS-treated 
cells overexpressing Ing4 (Figure 4.12).  These results confirm that Ing4 upregulates the 
expression of this NF-κB inhibitor. 
 
 
 
Figure 4.12: Overexpression of Ing4 enhances the expression of IκBα.  HEK293T cells 
were transfected with plasmids containing cDNA for p65/RelA and Ing4.  One day after 
transfection, cells were treated with 1µg/mL of LPS for 6 hours before being harvested to 
for RNA in order to perform qRT-PCR.  Graphs show the average and standard deviation 
of three independent experiments. 
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Ing4-/- mice are hypersensitive to inflammation 
 Our data indicates that Ing4 acts as a negative regulator of NF-κB function by 
upregulating the expression of IκB genes.  Previous studies (75, 117) of genetically 
engineered mice deficient for IκB genes such as IκBNS have revealed that these mice 
have an exaggerated inflammatory response in the colon following oral administration of 
dextran sodium sulphate (DSS) (117).  To determine if our Ing4-/- model is likewise 
hypersensitive to inflammation, we treated eight (6-8 week old) Ing4-/- mice and eight 
(6-8 week old) control wt mice with a single dose regimen of DSS (5 days on DSS in the 
drinking water followed by 10 days of untreated water).  After DSS treatment, Ing4-null 
mice lost more body weight than the wt controls (Figure 4.13).  Several factors can 
contribute to loss of body weight; one is the inflammatory response, which can cause loss 
of fluids or prevent nutrient absorption by the intestines. 
 
 
 
Figure 4.13:  Ing4 null mice show a greater drop in body weight following treatment 
with dextran sodium sulfate (DSS).  6-8 week old Ing4 null (n=8) and wt (n=8) mice 
were given 4% DSS in their drinking water for 5 days followed by 10 days of normal 
water.  The mice were weighed initially and then every day after the exposure to DSS.  
The graph shows the average plus standard deviation of the percent change in weight of 
each group of 8 mice at day 7 of the regimen compared to the initial weighing.  There is a 
statistically significant difference between the two groups (*p ≤ 0.05). 
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Two days after DSS administration, (day 7 of the assay), Ing4-/- mice began to display 
morbidity, and 60% of the Ing4-/- mice died within 1 week (day 12 of the assay).  In 
contrast, none of the wt mice died during the course of this experiment (Figure 4.14).   
 
 
 
Figure 4.14: Kaplan-Meier survival curve for Ing4 -/- (n=8) and Wt (n=8) mice during 
DSS treatment.  Mice were given 4% DSS in their drinking water for 5 days followed by 
10 days of untreated water. 
 
The colons were harvested from all mice, either at their time of death or on day 16 of the 
experiment, and processed for histology.  Ing4-/- colons were shrunken in length relative 
to wt mouse colons (Figure 4.15A) and histology revealed that Ing4-/- mice exhibited 
complete loss of the intestinal mucosal layer (Figure 4.15B).  This data indicate that Ing4-
null mice exhibited a massive inflammatory response that destroyed the mucosal lining of 
the intestine.  These findings are consistent with the elevated serum and macrophage 
cytokine levels observed in Ing4-/- mice following LPS treatment.   
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The similarity in the inflammatory response of IkBNS-/- mice and Ing4-/- mice to DSS 
further supports our proposal that Ing4 acts as a negative regulator of NF-κB activity by 
upregulating expression of IκB genes. 
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Figure 4.15:  Ing4 null mice treated with DSS show a reduction of colon length and 
complete removal of the intestinal mucosa.  A) The graph shows the average plus 
standard deviation of the colon length for each group of 8 mice upon necropsy.  There is 
a statistically significant difference between the two groups (**p ≤ 0.02).  B) Colons 
were also fixed in 10% phosphate buffered formalin, stained with hemotoxylin and eosin, 
and subsequently analyzed by a pathologist.  Pictures were taken at the 20X 
magnification.  Arrows point to the different layers of the intestine which are abbreviated 
as: serosa (S), mucosa (M), and lumen (L). 
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Discussion 
In this study, we generated Ing4 deficient mice and primary cells in order to 
explore the role of Ing4 in development, in cell growth, and in tumorigenesis.  Our results 
reveal that Ing4 is not required during embryogenesis, yet is necessary to promote the 
proliferation of MEFs.  This finding is consistent with previous reports that the Ing4-
HB01 complex regulates a majority of histone H4 acetylation in cells and is required for 
proper progression of cells through S phase of the cell cycle (48, 209).  Interestingly, 
histone H4 acetylation can be readily detected in ChIP analysis on the active IL-6 
promoter in Ing4-/- macrophages, indicating that other HAT complexes are sufficient to 
induce chromatin remodeling in cells lacking Ing4.  One mechanism proposed for Ing4 
regulation of cell growth involves regulation of the p53 tumor suppressor. However, p53 
functions appear to be unaltered by deletion of Ing4, as wt cells and Ing4-null cells 
responded similarly to DNA damage-induced growth arrest and apoptosis mediated by 
p53. These findings suggest that the p53 pathway is not compromised in Ing4-null mice. 
 
ING4 has also been recently proposed to complex with the large subunit of NF-
κB and to inhibit NF-κB-mediated transactivation of gene expression (63).  As NF-κB 
plays a role in multiple biological processes, including angiogenesis, apoptosis, and the 
innate and adaptive immune response (3, 105), regulation of NF-κB by Ing4 could also 
impact tumorigenesis.  To examine the ability of Ing4 to regulate NF-κB activity in vivo, 
we examined the innate immune response of Ing4-/- mice.   
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LPS treatment of Ing4-null mice were highly sensitive to LPS treatment, and contained 
elevated levels of IL-6 protein in serum and in various organs, indicating that Ing4 
suppresses NF-κB signaling in mice.  Peritoneal-derived, Ing4-/-macrophages displayed 
elevated levels of nuclear RelA/p65, increased binding of RelA/p65 to relevant NF-κB 
promoters, and increased cytokine gene expression following LPS treatment.  
Upregulation of NF-κB activity in mice deleted for Ing4 was likely due to decreased 
expression of the RelA inhibitors IκBα, IκBβ, and IκBNS.  Furthermore, mice deficient 
for Ing4 displayed a similar colorectal hyperinflammatory response to DSS as reported 
for IkBNS-deficient mice (117), offering further genetic evidence that deletion of Ing4 
results in inhibition of IκB activity in vivo. 
 
Collectively, these results reveal that physiologic levels of Ing4 inhibit NF-κB 
activity by facilitating IκB gene expression in mice, and establish a role for Ing4 in 
regulating NF-κB-mediated innate immunity.  Interestingly, Ing4 deficient mice failed to 
develop spontaneous tumors, in contrast to what we and others have reported previously 
for mice deficient for Ing1 proteins (21, 28). Several reports have previously linked 
aberrant NF-κB expression to the onset of various human cancers (3, 100, 102, 104, 105, 
134, 169).  However, the role of NF-κB in tumorigenesis is uncertain, and NF-κB may 
exert oncogenic and anti-tumorigenic effects in a cell context-dependent manner.   
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Although NF-κB activity is clearly altered in Ing4-null mice, further research is needed to 
establish Ing4 as a bone fide tumor suppressor and to determine if Ing4 regulates 
tumorigenesis in mice when cancer is induced by activated oncogene expression and/or 
by DNA damage. 
 
Materials and Methods 
Generation of Ing4 knockout mice 
Mouse (129 strain) embryonic stem cells (BayGenomics clone XG370) 
containing a retroviral promoter gene trap inserted into one allele of Ing4 were used to 
generate chimeric mice, which were bred to generate Ing4-heterozygous mice and 
subsequent Ing4-homozygous mice. Mice were genotyped by PCR analysis of genomic 
DNA using the following primer sequences: ING4g1439F: 5'- 
CGGGCGGATTTCTAAGTTCG -3', ING4g2118R: 5'- 
AAAAGACAAAACAAGAGGGGGC -3', ING4c8015F: 5’ – 
AAGGGAATAAGGGCGACACG – 3’.  All mice were maintained and used in 
accordance with federal guidelines and those established by the University of 
Massachusetts Animal Care and Use Committee. 
 
Cell culture 
Mouse embryonic fibroblasts (MEFs) were generated from E13.5 day embryos as 
described previously (39).  Macrophages were generated as previously described (116).  
In brief, mice were injected i.p. with 4% thioglycolate and cells were harvested 4 days 
later.  HBSS was used to flush the peritoneal cavities.   
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Peritoneal exudates cells were plated in RPMI1640 with 10% heat-inactivated FCS.  
Thymocytes were generated by grinding thymi between frosted glass slides and cells 
were assayed for viability by trypan blue exclusion.  Approximately 106 cells were plated 
per well of a 60-mm plate in RPMI1640 with 5% FCS prior to each experiment.  All cells 
were incubated at 37oC and 5% CO2. 
 
MEF experiments 
To determine the rates of cell proliferation, multiple lines of Wt, Ing4-
heterozygous, or Ing4-null MEFs were seeded at 1 x 105 per well of a six-well plate.  
Triplicate plates of each line were harvested and counted every 24 h using a Z1 Coulter 
Particle Counter (Beckman Coulter, Miami, FL).  Duplicate gelatinized 10-cm plates with 
10,000 cells per plate were seeded in MEF medium to assay for cell survival and growth 
at low plating density.  At 8 to 12 days postplating, cells were fixed with methanol and 
stained with 0.1% crystal violet to visualize colony formation.  MEFs from three 
independent lines of each genotype were seeded onto 10-cm plates at a density of 8 x 105 
per plate in 0.1% fetal bovine serum for 3 days.  Cells were then fed with medium 
supplemented with 10% serum for 4 h, and the cultures left untreated or exposed to 8 Gy 
of γ-radiation in a cesium irradiator or 0.3 µg/mL doxirubicin (Sigma-Aldrich, St. Louis, 
MO).   At 15 h post-treatment, MEFs were pulse labeled with 60 µmol/L 
bromodeoxyuridine (BrdUrd) for 3 h, harvested by trypsinization into PBS, and fixed in 
70% ethanol overnight at 4oC.   
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Flow cytometric analysis of DNA synthesis and total DNA content was done using an 
anti-BrdUrd antibody, propidium iodide staining, and Flowjo software.  Data are 
presented as a ratio of percentage of cells in S phase for treated versus untreated cells. 
 
Thymocyte apoptosis 
Ex vivo thymocyte apoptosis experiments were done by plating 106 thymocytes 
onto 60-mm plates in RPMI medium with 5% FCS and either mock treating or irradiating 
the plates with 2.5, or 5-Gy ionizing radiation. After 4 h, cells were harvested and stained 
with annexin V and 7-AAD (BD Pharmingen, San Jose, CA) according to the 
manufacturer’s instructions, then analyzed by FACS. 
 
LPS challenge and ELISAs 
 Mice were injected i.p. with either 0.25mg or 0.75 mg LPS from Escherichia coli 
serotype O111:B4 (Sigma-Aldrich, St. Louis, MO) and monitored for one week.  In order 
to determine cytokine levels, 0.5mg LPS was injected i.p and organs or serum were 
harvested at 0, 6, or 24 hrs.  ELISAs were performed according to the manufacturer’s 
instructions (BD Pharmingen, San Jose, CA). 
 
Quantitative real-time RT-PCR (qRT-PCR) 
 Relative levels of mRNA expression were analyzed by quantitative reverse 
transcription-PCR (RT-PCR) as previously described (136).  
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cDNA was generated using Invitrogen SuperScript first-strand synthesis system for RT-
PCR. The following primer sequences (shown 5’-3’) were used in the PCR reactions:  
IκBα: TTCCTGCACTTGGCAATCATCCAC and 
TCAGGATCACAGCCAGCTTTCAGA,   
Ip10: TATCGATGACGGGCCAGTGAGAAT and 
TGATCTCAACACGTGGGCAGGATA,   
Ifnβ: TCCTGGAGCAGCTGAATGGAAAGA and 
TCTGGAGCATCTCTTGGATGGCAA, 
Ing4: GACAGCTCTTCCAGCAAAGGCAAA and 
TGCGATCCACAGGCATATCCAACA, 
Il-6: AGTCACAGAAGGAGTGGCTAAGGA and 
TCTGACCACAGTGAGGAATGTCCA, IκBβ: TGATTCATCAGCATGAGCCCTTCC 
and TTTGGCCTAGGTCATTCTGCAGGT, IκBNS: 
TTTCCCTGCCTTCCAAGAGACTGT and AGCCTTCAGAAGCAGAGAATGGGA. 
Samples were normalized to EF1α levels present in each tissue as previously described 
(136). 
 
Luciferase assay 
 HEK293FT cells were plated at a density of 5 x 10^4 cells per well of a 96-well 
plate.  The following day they were transfected with a consensus NF-κB luciferase 
reporter construct, a RelA plasmid, the Renilla expression plasmid, and either a plasmid 
containing the Ing4 cDNA or plasmid backbone using Gene Juice transfection reagent.  
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One day post transfection the cells were stimulated with 1ug/mL LPS for 4-6 hours.  Both 
firefly and Renilla luciferase were assayed using the dual luciferase reporter assay system 
(Promega Madison WI).  Samples were read on a 96-microplate Glomax Luminometer 
(Promega Madison WI). 
 
Antibodies, protein extracts, western blots, EMSAs 
 Antibodies used for western blots were IκBα (1:1000, Cell signaling) and 
p65/RelA (1:4000, Santa Cruz).  Cytoplasmic and nuclear protein extracts were made as 
previously described (232).  In brief, cells were washed with phosphate-buffered saline 
(PBS) and pellets were resuspended in 100µL of hypotonic buffer A (10 mM Tris-Cl pH 
7.8, 5 mM MgCl2, 10 mM KCl, 0.1 mM EDTA [ethylenediaminetetraacetic acid], 300 
mM sucrose, 5mM β-glycerol phosphate, 0.5 mM dithiothreitol, 0.1% NP-40, plus 
protease inhibitors) and incubated on ice for 10 minutes.  Nuclei were pelleted and the 
supernatant was collected as the cytoplasmic fraction.  The resulting pellet was then 
resuspended in 50µL of buffer B (20mMTris-Cl pH 7.8, 5 mM MgCl2, 320mM KCl, 0.2 
mM EDTA, 25% glycerol, 0.5 mM dithiothreitol, 5 mM β-glycerol phosphate, plus 
protease inhibitors) and incubated on ice for 15 minutes.  Debris was then removed by 
centrifugation and the supernatant was collected as the nuclear fraction.  For western blot, 
50ug of wt or Ing4 null macrophage cytoplasmic or nuclear extracts were run on a 10% 
polyacrylamide gel.  The cytoplasmic fraction was probed with anti-IkBα and the nuclear 
fraction was probed with anti-p65/RelA.   
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EMSAs were performed according to the manufacturer's instructions (Promega Madison 
WI) using 10ug wt or Ing4 null macrophage nuclear extracts.  The antibody to p65/RelA 
was used for the gel shift experiments. 
 
ChIPs 
 ChIPs were performed according to the manufacturer’s instructions (USB 
Cleveland OH).  All PCRs were performed using SYBR Green (Qiagen Valencia CA) in 
an ABI real-time PCR machine.  The antibodies used were acetylated-H4 (Upstate Lake 
Placid NY), p65/RelA (Abcam Cambridge MA), and IgG (Abcam Cambridge MA).  The 
primer sequences for the NF-κB binding site in the Il-6 promoter were: 
AGCTACAGACATCCCCAGTCTC and TGTGTGTCGTCTGTCATGCG. 
 
DSS colitis  
 Wt and Ing4-/- mice were provided ad lib drinking water containing 4% dextran 
sodium sulfate (DSS) (Miltenyi) for 5 days, followed by 11 days of non-treated water.  
During this experiment, mice were weighed daily and observed for rectal bleeding.   
Mice exhibiting any symptoms of illness or morbidity were euthanized, and colons were 
removed, measured, flayed and fixed in formalin.  The remaining mice were euthanized 
and similarly processed at the end of the 16-day experiment. Colon sections were stained 
with hemotoxylin and eosin before being analyzed by a pathologist. 
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CHAPTER V: 
GENERAL DISCUSSION 
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Forward 
Research presented in this thesis details the generation and characterization of 
genetically engineered mouse models deleted for two ING family genes, Ing1 and Ing4 .  
These genes are of interest as they have been proposed to be involved in p53 and NF-κB 
signaling and to have tumor suppressing capabilities. Additionally, data is present in the 
literature indicating that these genes are involved in several biological processes, 
including DNA repair, cell growth regulation, and chromatin remodeling.  Chapter 2 
described the characterization of a mouse deficient for p37Ing1b, the longer of two splice 
variants.  We found that Ing1 can suppress the development of follicular lymphoma (FL), 
providing an in vivo confirmation that an ING protein can function as a tumor suppressor.  
However, our results also indicate that Ing1 is not required for p53 function.  Chapter 3 
described the characterization of mice deficient for both the p37Ing1b and p53 tumor 
suppressor.  This report extended the observations from Chapter 2 by studying purified 
follicular B-cells and confirmed that Ing1 has p53-independent anti-oncogenic functions.  
We also observed the development of diffuse large B-cell lymphoma in these mice.  
Chapter 4 described the characterization of mice deficient for Ing4.  Similar to Ing1, Ing4 
is not required for proper development or regulation of p53 function.  Instead, our data 
reveals that Ing4 serves as a negative regulator of the NF-κB pathway.  In this chapter we 
will summarize these findings, explore their implications, and propose some unanswered 
questions resulting from these results. 
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Current understanding of the ING gene family 
The Inhibitor of Growth (ING) family was discovered using a subtractive 
hybridization of normal versus transformed human epithelial tissue.  Subsequent database 
searches identified four additional members of this gene family, that are well-conserved 
from yeast to humans.  Studies using overexpression or knockdown experiments in 
transformed cell lines indicated that the ING genes have roles in DNA repair, chromatin 
remodeling, and the regulation of cell growth.  These studies also determined that most 
ING proteins interact with p53 and may be required for p53 function.  Additionally, in 
vitro studies suggest that some ING proteins are also involved in the NF-κB pathway.  
Retrospective epidemiological studies revealed that ING genes are either lost or 
underexpressed in human primary tumors and in some cases the reduced ING gene 
expression is predictive of a poor prognosis.  Thus, ING genes also appear to play a 
significant role in the development and progression of human cancers.  However, the in 
vivo function of these genes had not been explored and the ever-increasing number and 
often conflicting results of in vitro studies warranted the development of genetically 
modified mice bearing alterations in ING genes.  These mouse models were used to 
explore further the role of the ING proteins in development and in the regulation of 
normal and neoplastic cell growth.  Two different Ing-deficient mouse models are 
described in this dissertation. 
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What we have learned from Ing1 knockout mice. 
Initial studies of mouse Ing1 determined that it was ubiquitiously expressed and 
has three splice variants generated from different promoters which are translated into two 
distinct protein products (239).  Ectopically expressing each variant in transformed cell 
lines suggested that the proteins have opposing effects on p53 function.  The long form, 
p37Ing1b, might act as a negative regulator of p53 function and the shorter forms, p31Ing1a 
or p31Ing1c, might act in conjunction with p53.  However, it was determined that only the 
p37Ing1b isoform can be co-immunoprecipated with p53, making it an open question as to 
how p31Ing1a or p31Ing1c might be regulating p53.  Concomitant with our studies of Ing1 
function in mice, Kichina et al. generated a mouse deficient for all Ing1 isoforms.  These 
mice were viable with no obvious abnormalities (108).  Mouse embryonic fibroblasts 
(MEFs) derived from Ing1-deficient mice display little or no changes in cell cycling after 
treatment with taxol or other DNA damaging agents.  Surprisingly, Ing1 deficient mice 
were more susceptible to whole body gamma irradiation than wt littermates. A subset of 
these mice also developed cancer, the most prevalent being classified as follicular center 
B-cell lymphoma.  This tumor specificity is in contrast to the various types of different 
tumors that spontenaously develop in p53-deficient mice. There exists the possibility that 
loss of Ing1 is a secondary event needed for transformation in other tumor types such as 
those observed in humans that have altered ING1 expression.  It would be interesting and 
important to explore this possibility in future experiments. 
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One caveat of the report by Kichina et al. is that the mice were deficient for all 
Ing1 splice variants.  Previous observations in mouse and human cells suggested that 
each splice variant might have different and possibility opposing functions, which could 
complicate the interpretation of the results.  In contrast, we have generated a mouse 
deficient for only the long predominant Ing1 isoform, p37Ing1b (see chapter 2) (39).  Our 
study also noted the involvement of Ing1 in the development of follicular lymphoma and 
further revealed that the p37Ing1b variant is responsible for tumor suppression in vivo.  We 
also studied the effects of DNA damaging agents to induce apoptosis in both MEFs and 
thymocytes.  Loss of p37Ing1b increased the susceptibility of MEFs and double positive 
thymocytes to both ionizing radiation (IR) and doxorubicin induced cell death.  This 
might explain why Kitchina et al observed an increase in lethality when Ing1 null mice 
were treated with whole body ionizing radiation.  We further noted that Ing1b-deficient 
MEFs grew faster but had no alteration in their ability to undergo cell cycle arrest due to 
DNA damage. 
 
These observations using p37Ing1b deficient MEFs and thymocytes made us 
question the prevailing literature that Ing1 functions in tumor suppression by altering p53 
activity. To address this question, we utilized genetic approach by crossing p37Ing1b 
deficient mice to both Mdm2+/- and p53 null mice.  We expected that p37Ing1b deficiency 
would rescue the embryonic lethality of Mdm2 loss and that the enhanced apoptosis seen 
in primary cells deficient for p37Ing1b would be rescued on a p53 null background.   
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After intercrossing p37Ing1b -/-, Mdm2+/- mice we discovered that p37Ing1b deficiency did 
not rescue the embryonic lethality induced by Mdm2 deficiency.  Additionally, mice 
deficient for both p37Ing1b and p53 (p37/53-/-) showed a greater amount of apoptosis 
compared to p53-null mice.  We also observed that p37/53-/- MEFs grew even faster than 
p53-/- MEFs.  This data clearly indicates that there are p53-independent functions for 
Ing1.  Additionally, we observed that ectopic expression of activated Ras caused p37Ing1b 
null MEFs to undergo premature senescence.  This result also supports the conclusion 
that there was an intact Arf/Mdm2/p53 pathway present in these cells. From these 
observations, we conclude that p37Ing1b is not required for p53 function, and Ing1 may 
work entirely independentl of p53.  We can also conclude from these findings that Ing1 is 
indeed a tumor suppressor that can regulate primary cell growth.   
 
One question that arises from the development of follicular B-cell lymphoma in 
the p37Ing1b knockout mice oncerns how loss of a pro-survival gene can cause mice to 
develop lymphoma?  This was answered by analyzing the ability of purified wt or 
p37Ing1b null total (B220+) and follicular (IgDHi) B-cells to undergo apoptosis or to 
proliferate .  We found that the p37Ing1b null B-cells did not have compromised apoptosis 
following treatment with several different agents.  Additionally, p53 loss did not have 
any significant effect on the ability of p37Ing1b deficient B-cells to undergo apoptosis.  
Interestingly, proliferation following IgM or LPS treatment was increased in p37Ing1b null 
B-cells and was even higher in p37/p53 double null B-cells confirming the results in the 
MEFs.   
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The p37/53 double null mice also developed thymomas at a slightly decreased rate 
compared to p53 null mice. This delay in tumor development could be due to the 
increased apoptosis and Bax expression present in the p37/53 null double positive 
thymocytes.  In order to determine a possible mechanism for the development of DLBL 
in the p37/53 null mice we did quantitative real-time PCR on tumor samples from these 
animals for the expression of IκBα (Figure 5.1).  The expression of the NF-κB inhibitor 
was dramatically lower in most tumor samples tested.  This observation coupled with the 
increased p65/RelA and IL-6 expression and hyperproliferation following LPS treatment 
of the p37/53 null tumors and FO B-cells suggests that the NF-κB pathway may be 
elevated in these mice.   
 
In summary, these findings suggest that p37Ing1b regulates proliferation in both B-
cells and MEFs, but has tissue specific effects such as differential induction of apoptosis.  
The cooperativity we observed between Ing1b and p53 in suppressing tumorigenesis also 
confirms that p37Ing1b has p53-independent functions.  Additionally, our data suggests 
that Ing1 may be involved in the NF-κB pathway. 
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Figure 5.1:  Expression of IκBα in p37/53 null purified FO (IgDHi) B-cells and tumor 
samples.  Quantitative real-time PCR using primers to IκBα was done on FO (IgDHi) B-
cells and tumor samples from mice deficient for both p37Ing1b and p53.  Experiment was 
done in triplicate and the graph shows average and standard deviation. 
 
 
 
Currently no extensive epidemiological study has been performed on ING1 
expression in human FL or DLBCL, which is required before these findings can be 
applied to the clinic.  However, it is possible that new diagnostic tests could be designed 
around the ING1 gene for predisposition to FL or DLBCL.  Certyainly loss of p53 in an 
Ing1-deficient background strongly shifts the tumor spectrum to a more aggressive DLBL 
in mice, and loss of p53 would be a key prognostic indicator of long-term outcomes in FL 
patients.  In addition, ING1 levels might be used as a marker to determine what therapy 
regimen may work optimally.   
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In support of this possibility, ING1 has been found to greatly sensitize glioblastoma cells 
to DNA damaging agents (208) and we found that Ing1 loss sensitized thymocytes and 
MEFs to ionizing radiation and doxorubicin induced apoptosis (39).  Additionally, the 
Ing1 knockout mice could be used to test novel chemotherapeutic regimens to treat FL 
and DLBCL patients, following further validation of these models.  Current treatment for 
FL has not improved much in the past 8 to 10 years and there has been little impact on 
patient survival (19, 90, 91).  Yet its incidence is increasing in the western world, making 
models of this disease very important (90).  Mice are becoming more prevalent as tools 
for preclinical testing of novel therapies, but require additional steps to valid them so that 
the data obtained can inform future clinical trials (25, 80, 201, 229).  It would be useful to 
determine how close the Ing1 knockout mice recapitulate human FL and if the mice can 
be treated with current therapies successfully.  One caveat that is apparent is that the Ing1 
deficient mice develop FL rather late, which is not overly conducive for preclinical 
modeling.  But, this may be closer to the human disease since FL usually arises much 
later in life.  The p37/53 knockout mice could be useful in development of treatments for 
DLBCL and the study of de novo and transformed DLBCL development.  Treatment for 
DLBCL with current anthracycline based therapy is potentially curable; however, 
variability in response is sometimes observed (5, 93).  Development of more effective 
treatments and diagnostic tests are needed and the p37/53 knockout mice may assist in 
this endeavor. 
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What we have learned from Ing4 knockout mice 
Similar to ING1, ING4 was also found via in vitro experiments to interact with 
p53 and to have potential roles in several biological processes.  Additionally, ING4 was 
found to interact with RelA and act as a negative regulator of the NF-κB pathway.  
However, the precise in vivo function of ING4 is not known.  Therefore, we generated 
mice deficient for Ing4.  These mice failed to develop spontaneous tumors, but did show 
a hypersensitivity to lipopolysaccharide (LPS).  A greater number of Ing4 null mice 
treated with LPS died within 24 hours and showed elevated levels of Il-6, Rantes, and 
Mcp-1.  These elevated cytokine levels were also seen at the transcript level in 
macrophages and included IFNβ and IP-10.  Interestingly, IκBα, IκBβ, and IκBNS 
transcript levels were decreased in Ing4 null macrophages.  Using a dextran sodium 
sulfate (DSS) colitis model, we found that Ing4 null mice were more susceptible to 
inflammation and death following this treatment.  Histological analysis following DSS 
treatment showed that the mucosal layer of the intestine of Ing4 null mice was completely 
lost.  These findings support previous transfection work in glioblastoma cell lines 
indicating a role for Ing4 as a negative regulator of NF-κB.  Several well-established p53 
responses were also tested in the Ing4 null cells.  Ing4 null MEFs grew slower and did not 
have defects in cell cycle arrest following treatment with doxorubicin and ionizing 
radiation.  Thymocytes from Ing4 null mice were not compromised in their ability to 
undergo apoptosis following treatment with ionizing radiation.  These observations 
suggest that the p53 pathway is not perturbed in Ing4 deficient mice.  
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The NF-κB complex is important in innate immunity and inflammation, which are 
important responses that protect the host from pathogens (3).  In addition, alterations of 
NF-κB function have been found to lead to the development of cancer (105) and other 
diseases; such as inflammatory bowel disease (75), various diabetic complications (74), 
and atherosclerosis (120).  Identifying modifiers of this important pathway could lead to 
better ways to manipulate deregulated NF-κB function during pathological conditions.  
We did not observed the development of tumors in the Ing4 null mice.  This observation 
does not rule out the possibility that Ing4 suppresses tumorigenesis, as Ing4 might have a 
role in inhibiting induced tumors.  NF-κB has been found to act as a tumor promoter 
under certain conditions (104, 169), and given the function of Ing4 to negatively regulate 
NF-κB, it is possible that loss of Ing4 could promote tumors via this mechanism.  The 
involvement of Ing4 in the NF-κB pathway also suggests that it may have functions in 
other processes, such as atherosclerosis and autoimmunity.  Further epidemiological 
studies are needed to explore these possibilities. 
 
In summary, our data confirms that ING4 can act as a negative regulator of the 
NF-κB pathway in vivo, that Ing4 has a key role in regulating innate immune functions 
such as inflammation, and further reveals that this negative regulation of NF-κB activity 
is due to the upregulation of IκB gene expression by Ing4.  However, the precise 
mechanism for the regulation of the IκB genes requires further study.  Additionally, our 
data clearly indicates that Ing4 does not appear to be a major participant in the p53 
pathway. 
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Unanswered questions  
 There remain several additional questions arising from our research into the 
functions of the Ing genes.  Given that the phenotypes of both the Ing1 and Ing4 
knockout mice are relatively subtle, it would stand to reason that the other members of 
the Ing family may be compensating for loss of Ing1 or Ing4.  The Ing genes can be 
grouped based on which chromatin remodeling complex they can be found as 
components.  Ing1 and Ing2 are part of the Sin3 HDAC complex and one Ing gene might 
compensate for loss of the other.  Ing4 and Ing5 are part of the HBO1 complex and may 
compensate in the functioning of this complex.  As Ing3 is in a separate complex a 
knockout mouse of this gene might give the most pronounced phenotype.  Crossing Ing1 
and Ing2 deficient mice may give a phenotype that more closely resembles what was 
observed  in the tissue culture-based experiments, although both Ing genes  were present 
and in these cells.  Similarly, an Ing4 x Ing5 double knockout mouse may be needed 
before the expected tumor suppressing effects of these genes are apparent in the tumor 
assays.  To that end, we have generated Ing5 heterozygous mice, but characterization of 
their phenotype is beyond the scope of this thesis.  Subsequent studies should also 
generate and characterize development and tumorigenesis in the Ing4xIng5 mice as well.  
Additional questions that could be addressed would include a study to determine the 
extent to which the Ing4 null mice are tumor prone.  Several chemical carcinogens are 
known to induce tumors in specific tissue types.  Some of those chemicals appear to have 
an inflammatory requirement and therefore should be first employed in these studies.   
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They include treatment with diethylnitrosamine (DEN) and dimethylnitrosamine (DMN) 
to induce liver cancer and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) to 
induce lung cancer (134, 230).  Ing4 null could also be crossed to the APCMin mice or p53 
null mice, as both models of mice are tumor prone.  Additionally, the Ing4 null mice 
should be treated with a lower dose of DSS to induce IBD and colon cancer.  Another 
experiment that could be performed is to cross the p37Ing1b null mice to Eµ-myc mice in 
order to further explore the involvement of this gene in B-cell derived lymphomas, B-cell 
function, and development. 
 
Conclusions 
 In conclusion, Ing1 and Ing4 null mice have revealed that these genes have p53-
independent roles in tumorigenesis but that both may regulate the NF-κB signaling 
pathway.  Ing1 is a tumor suppressor gene and loss of this gene leads to the development 
of FL and DLBL.  Additionally, Ing1 loss sensitizes DP T-cells and MEFs to apoptosis 
induced by DNA damaging agents.  Ing4 null mice have revealed that this gene has a 
significant role in the regulation of the NF-κB pathway due to its ability to regulate the 
expression of IκB genes.  This finding also suggests that Ing4 may have a role in several 
diseases processes, including infection and cancer.  Thus, further functional studies of the 
role of Ing1 and Ing4 in development and in disease are warranted. 
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Additional work on Ing genes: 
 
I. Generation of Ing5 knockout mice: 
We obtained a mouse ES cell line (RRC086) from Baygenomics bearing a 
retroviral promoter trap inserted into one allele of the Ing5 gene was used in standard 
blastocyst injection experiments to generate chimeric mice.  DNA sequence analysis of 
the gene-trapped locus revealed that the retrovirus inserted between exon 1 and exon 2 
thereby possibly interrupting the entire coding region for Ing5 (Figure S1A).  Several 
high-degree chimeric mice were bred with C57Bl/6 mice to generate agouti offspring, 
and genomic DNA was harvested from tail biopsies and analyzed by PCR (Figure S1B) 
for the presence of the βGeo cassette to identify mice that inherited the Ing5-targeted 
allele.  This allowed for the identification of heterozygous animals, but did not 
differentiate het from null mice.  Circular PCR or sequencing the product from primers 
between either exon 1 and the 5’ region of the genetrap or exon 2 and the 3’ region of the 
genetrap will be needed in order to design a better genotyping strategy.  No further work 
was done on these mice, which were subsequently cryopreserved. 
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Figure S1: Generation of Ing5-deficient mice. A) Schematic of the gene-trapped locus 
showing the gene-trap inserted between exon 1 and exon 2.  B) PCR genotyping of the 
mouse tail biopsies showing the presence of the βGeo cassette.  An approximately 700bp 
fragment is generated from the βGeo primers (5’-GGTCAATCCGCCGTTTGTTC-3’ and 
5’-CAGTTCAACCACCGCACGATAG-3’). 
 
 
II. Generation of Ing1/Ing4 double null mice: 
In order to explore the possibility that Ing genes compensate for each other, we 
crossed p37Ing1b null mice to Ing4 null mice.  These Ing1/Ing4 heterozygous animals were 
intercrossed until they were null for both alleles.  We also derived Ing1/Ing4 null mouse 
embryonic fibroblasts (MEFs).  The resulting Ing1/Ing4 double null animals were found 
to be viable, but appeared to be more prone to develop seizures than wt controls.  This 
behavior needs further investigation.  Additionally, these mice could have an even more 
exacerbated inflammatory response given the elevated NF-κB activity in Ing1 (see 
Chapter 3) and Ing4 null (see Chapter 4) animals. 
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Generation of Foxo3a knockout mice: 
 
FOXO3a was suggested to function at the G2/M checkpoint and to participate in 
DNA repair pathways (5).  These findings suggested that FOXO3A may be acting as a 
tumor suppressor.  In order to explore this possibility we obtained a mouse ES cell line 
(XA026) from Baygenomics bearing a retroviral promoter trap inserted into one allele of 
the Foxo3A gene.  This ES cell line was used in standard blastocyst injection experiments 
to generate chimeric mice.  DNA sequence analysis of the gene-trapped locus revealed 
that the retrovirus inserted between exon 1 and exon 2 thereby possibly interrupting the 
entire coding region for Foxo3A (Figure S2A).  Several high-degree chimeric mice were 
bred with C57Bl/6 mice to generate agouti offspring, and genomic DNA was harvested 
from tail biopsies and analyzed by PCR (Figure S2B).  PCR genotyping indicated that 
Foxo3a null mice were viable and appeared similar to wt littermates.  During the course 
of this work the DePinho group published the characterization of Foxo3a deficient mice 
in Science (1).  They discovered that female mice deficient for Foxo3a showed global 
follicular activation resulting in oocyte death and depletion of functional ovarian follicles.  
The functional assays that were conducted on MEFs from these animals did not show any 
significant defects.  Also, Foxo3a null mice were not tumor prone.  They did, however, 
show some physiologic defects, such as a mild compensated anemia and decreased rate of 
glucose uptake following an overnight fast (1).  No subsequent work was conducted on 
these animals which were cropreserved.   
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Subsequent literature searches did find papers suggesting an interaction between p53 and 
Foxo3a (6).  Also, a paper by Lin et al. using the same Baygenomics ES cell line that we 
have found that Foxo3a can regulate NF-κB activity and also thymocyte activation (4).  
This group also determined by western blot that the XA026 ES cell contains a complete 
knockout of Foxo3a. 
 
 
 
Figure S2: Generation of Foxo3a-deficient mice. A) Schematic of the gene-trapped locus 
showing the gene-trap insertion site at position 15948.  B) PCR genotyping of the mouse 
tail biopsies.  Primers 1 (5’-CCTCCTAAAAATAAGCGTGCTACG-3’) and 2 (5’-
CCTACTGTGTGACAACCTCTGCTG-3’) produced a 603bp Wt product.  The 363bp 
mutant product was generated using primers 2 and 3 (5’-
GCACAGATGCGTAAGGAGAAAATACC-3’). 
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Work on Wnt5a null mice: 
 
Work in collaboration with Huiling Liang on Wnt5a deficient mice resulted in 
two publications.  These papers found that Wnt5a null mice develop B-cell lymphomas 
due to its ability to negatively regulate B-cell proliferation.  Wnt5a was found to signal 
through the non-canonical Wnt/Ca2+ pathway to suppression Cyclin D1 expression (2).  
Therefore, Wnt5a is acting as a tumor suppressor gene in B-cell lymphomas.  Wnt5a was 
also found to alter survival of αβ-T-cells by regulating Bax and Bcl-2 expression (3).  
These results suggest that Wnt5a signals through the non-canonical Wnt/Ca2+ pathway, 
but can alter the canonical Wnt pathway.  They also suggest that Wnt5a is critical for 
normal T cell development.  My efforts contributed to these studies by assisting Huiling 
with several experiments including Southern blots, in vitro kinase assays, and fetal 
thymic organ culture experiments. 
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